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Abstract 
Neglected tropical diseases (NTDs) are a group of conditions that exert disability and 
poverty on populations that comprise the world’s poorest billion people. These 
conditions, although caused by different organisms and cause distinct disease, they 
share geographical distribution within tropical regions, occur during similar 
ecological conditions and most importantly have similar biological mechanisms that 
are utilized to facilitate the pathology of these diseases. Proteolytic enzymes like 
proteases are used in many biological mechanisms such as, migration through tissue 
and cellular compartments; haemoglobin digestion, evasion of immune system 
responses and cause necrosis and fibrosis to vital tissues and organs. Genomic, 
transcriptomic, and proteomic studies on parasites (S. mansoni and F. hepatica), 
parasitic vector (An. gambiae) salivary glands and snake venom show that these 
diverse pathogens appear to be utilizing similar molecules to perform similar 
biological mechanisms. Therefore, it is of interest to ascertain whether a cross-
cutting approach in research could facilitate a better understanding of these diseases. 
Therefore, the initial aim of this work was to investigate molecular parallels of the 
mechanisms used by these tropical disease pathogens, including parasites, snake 
venom toxins, and haematophagic parasite vectors, to access their host’s blood 
stream. Using a bioinformatics-led approach, in combination with immunological 
and proteomic analyses, this study demonstrated the presence of similar compounds 
between shared molecular molecules (serine proteases and other proteins) causing 
pathology in parasites, parasitic vectors and snake venom. This similarity was not 
only at the bioinformatics level, but presence of cross-reactivity toward parasite 
proteins was detected using antivenoms and toxin-specific antibodies. In addition, 
sera collected from patients infected with S.mansoni exhibited an immune response 
to snake venom. One of this study aims was to investigate possibilities of using 
homologous proteins in parasitic vectors and snake venom as therapeutic 
applications. For this purpose, chimeric epitopes of homologous snake venom (Echis 
ocellatus) and mosquito salivary proteins were designed as primary vaccine that 
could be boosted by mosquito bites. If succeeded, this method would prevent, or at 
least reduce, the devastating pathology and death caused by snake venom at a low 
cost, with limited logistical complications.   
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1.1 Introduction 
Neglected tropical diseases (NTDs) are a group of disfiguring and disabling 
conditions that are among the most widespread infections affecting the world’s most 
impoverished regions (Daumerie et al. 2010). These diseases are caused by variety of 
organisms such as viruses, bacteria, parasitic protozoa and worms, and other 
conditions such as Buruli ulcer and snakebites (Herrera et al., 2011; Kasturiratne et 
al., 2008; WHO 2012). Despite the fact that NTDs are clinically diverse, they are 
grouped as poverty-related diseases since they flourish in settings of extreme poverty 
in tropical regions, where they tend to coexist. NTDs are ancient diseases that have 
plagued humanity for centuries; they now primarily affect low-income countries 
throughout sub-Saharan Africa, Asia, and Latin America. The fact that they affect 
low-income countries, mainly the poorest populations, living in remote, rural areas, 
urban slums or conflict zones, lower the global attention to these diseases and thus 
make them neglected. 
 
The majority of these diseases are transmitted through insect (mosquitoes, 
black flies, sand flies, and tsetse flies) and snail vectors.  While others, spread via 
contaminated water or worm infested soil. While NTDs can be fatal, their primary 
importance is that they typically result in chronic disabilities, disfigurements, 
complications in pregnancy, impaired physical and cognitive development, that 
eventually limit adult productivity in the workforce (Herrera et al., 2011). In fact, 
NTDs rank closely with diarrheal diseases and malaria in the number of years lost to 
disability and premature death, or disability adjusted life-years (DALYs) (Hotez et 
al., 2007). Thus, NTDs enhance poverty by placing huge burdens on both the health 
and economic development of low-income countries.  
Treatments for some NTDs are available, however, many have significant 
adverse side effects and are not well tolerated by patients (Daumerie et al. 2010). 
Given the limited access to existing treatments, rapid reinfection following 
treatment, and drug resistance (Daumerie et al. 2010; Health & Diseases 2007; Hotez 
et al. 2007) NTDs, and the billions of people affected by them, 
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increased attention regarding the need for novel interventions to eliminate and treat 
these diseases. 
 
 
Figure 0.1 NTDs distribution: Map showing geographic overlap and distribution of the seven most 
common neglected tropical diseases (the soil-transmitted helminth infections (hookworm, ascariasis, and 
trichuriasis); lymphatic filariasis; schistosomiasis; and diseases that cause blindness—trachoma and 
onchocerciasis (river blindness) (figure from; Hotez et al. 2009). 
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1.2 Geographical  
1.2.1 Epidemiological burden of NTDs 
Until the last decade, NTDs were low on national and international health 
agendas as priority was given to the “big three”: HIV/AIDS, malaria, and 
tuberculosis (TB) (Molyneux et al., 2005). NTDs are considered as one of the most 
potent reinforcements of the poverty trap and the world’s poorest billion people have 
at least one of these diseases because NTDs tend to coexist in 56 of 58 endemic 
countries as illustrated in figure 1.1 (Hotez et al., 2009). Multiple NTDs frequently 
coexist not just in the same populations, but also within the same individuals 
(Solomon et al., 2012). Poverty and NTDs fed upon another; as access to disease 
control intervention and therapeutic services are typically low in the communities 
vulnerable to NTDs. As described in the following sections, this large population of 
the world’s population becomes anchored into poverty by NTDs. 
Trachoma and onchocerciasis, which cause blindness, are prevalent 
worldwide in about 84 million and 37 million people, respectively (Fenwick 2012, 
Hotez et al., 2009). A further 120 million people have lymphatic filariasis, and 
180,000 cases of leprosy hamper productivity and eliminate normal social life 
opportunities as a result of their deformability (Fenwick, 2012; WHO 2012). Other 
NTDs can lead to permanent disfigurement or disability, especially when limbs have 
to be amputated as a life-saving procedure; for example, over 400,000 amputations 
are performed annually as a result of snakebite envenoming (Williams et al. 2010). 
Further examples include 5,000–6,000 cases of buruli ulcer reported annually, out of 
which 33% of reported cases in Africa reach category III (patient has single > 15 cm 
in diameter, multiple lesions or lesion(s) at a critical site (eye, breast, genitalia) and 
osteomyelitis) (WHO, 2012). Human African trypanosomiasis (sleeping sickness) 
affects 42,000 individuals who are at risk of being severely debilitated and mortality 
reaches 100% in untreated cases (Simarro et al., 2010). Without post-exposure 
prophylaxis, rabies causes acute encephalitis and is always fatal, with an estimated 
24,000 deaths occuring annually in Africa (Both et al., 2012). Leishmaniasis has a 
global incidence of 1–1.5 million cases of cutaneous leishmaniasis and 500,000 of 
visceral leishmaniasis (Bhargava and Sing, 2012), leaving deep and permanent scars 
or even destroying the mucous membranes of the nose, mouth, and throat. In its 
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visceral form, it infects vital organs and is fatal without treatment (Bhargava and 
Sing, 2012). In the Americas 8 million people are infected with Chagas disease 
(Bern et al., 2011); acute disease can cause young adults to develop myocarditis, 
pericardial effusion, and/or meningoencephalitis, leaving them out of the labour 
force (Bern et al., 2011). Among 207 million people with schistosomiasis, children 
and adolescents tend to have the highest disease intensity (Steinmann et al., 2006); it 
disrupts their school attendance, causes anaemia and malnutrition, and impairs 
cognitive development (Hotez et al., 2009). Although nearly eradicated, Guinea-
worm disease causes agonizing, severe pain, which can last for extended periods 
coinciding with the peak agricultural season (Rinaldi, 2009). More than 2.5 billion 
people – over 40% of the world's population – are now at risk from Dengue as it has 
emerged as a rapidly spreading vector-borne disease affecting mostly poor, urban 
populations (Racloz et al., 2012). Over 90% of the global burden of these NTDs is 
believed to occur in Africa (Molyneux et al., 2005). 
 
1.2.2 NTDs in sub-Saharan Africa 
In sub-Saharan Africa (SSA), NTDs are the most common health issues 
affecting the 500 million impoverished people (Hotez and Kamath, 2009) (Table 2). 
The collective burden of these diseases may be up to one-half of SSA’s malaria 
disease burden and more than twice that of TB (Hotez and Kamath, 2009).  
Almost 50% of SSA’s poorest people have hookworm infection (Hotez and 
Kamath, 2009); of them, 40–50 million school aged children may have impaired 
physical and intellectual development, and reduce their school performance and 
attendance as a consequence of the infection. In addition, 7 million pregnant women 
are threatened by anaemia and, therefore, low foetal birth weight, impaired milk 
production, and increased risk of death for both mother and infant (Hotez and 
Kamath, 2009). Schistosomiasis has become the second most prevalent parasitic 
infection in SSA; around 192 million infected individuals account for 93% of the 
total global burden of schistosomiasis. Other NTDs such as lymphatic filariasis and 
onchocerciasis, affect around 46–51 million and 37 million people, respectively 
(Hotez and Kamath, 2009). Moreover, human African trypanosomiasis and visceral 
leishmaniasis occur at a prevalence of around 10,000 cases annually. Snakebite 
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envenoming kills around 7,500-32,000 individuals annually in SSA alone with a 
devastating impact on the population (Kasturiratne et al. 2008; Harrison et al., 2011). 
Each one of these NTDs exert a significant disability and reduction on SSA’s 
economy, especially in agricultural productivity that coincide with rainfall and 
monsoon seasons, as most of the rural poor population depends on agriculture as a 
source of income and food (Hotez and Kamath, 2009).  
 
Table 0.1Ranking of Neglected Tropical Diseases (NTDs) in SSA by Prevalence and Distribution 
(Hotez & Kamath 2009). 
1.3 Ecological  
1.3.1 Influence of rainfall on some tropical diseases  
NTDs have major impacts on the economic status of the poorest sector of the 
population worldwide, who depend mainly on agricultural activity and grazing 
livestock. Therefore, the rainy and monsoon season coincides with an increase in 
these activities. This coincidence is exemplified by the increase in hospital 
admissions due to snakebites (Kasturiratne et al., 2008; Molesworth et al., 2003; 
Mohapatra et al., 2011). In West Africa, the probability of snakebite incidence is 
increased in the period between March and July at the beginning of the rainy season 
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and during the harvest period after the peak rains; both periods have intense 
agricultural activity (figure 2) (Molesworth et al., 2003). Snake irritability, 
concomitant with the breeding season, is also coincident with the start of the rainy 
season (Warrell and Arnett, 1976). This is coherent with the hypothesis that heavier 
rains force snakes to drier areas thus increasing human-snake contact (Molesworth et 
al., 2003). 
 
Figure 0.2 Comparison of the distribution of monthly-normalized difference vegetation index (NDVI) 
and snakebite incidence (with permission from; Molesworth et al. 2003) 
Different species of mosquitoes play critical roles in transmission of many 
tropical diseases (e.g., malaria and many NTDs such as dengue fever and yellow 
fever). The literature demonstrates a relation between rainfall seasons and mosquito 
burden. Rainfall facilitates the growth of mosquito populations (Chaves et al., 2012; 
Chaves et al., 2011). On one hand, continuous rainfall can inhibit mosquito activity 
and therefore have negative effects on oviposition. On the other, it can lead to 
increased mosquito abundance via a phase locking i.e. rainfall facilitates the growth 
of mosquito populations (figure 3) (Chaves and Kitron, 2011). 
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Considering the above information, one might conclude that there can be an 
overlapping period where both snakebite incidence and number of mosquitoes 
increase during the rainy season. 
 
Figure 0.3 Associations between rainfall and mosquito oviposition: Time series (a), (b) and (c) 
show the average number of egg rafts (thick lines) and individual replicates (thin lines) for observation periods A, 
B and C, respectively. (d), (e) and (f) show the daily rainfall during the observation periods A, B and C, 
respectively (with permission from; Chaves & Kitron 2011). 
 
1.4 Biological 
1.4.1 NTDs, is there a shared focus?  
Most NTD-causing pathogens (parasite, bacteria, virus, or even venom) share 
a common biological challenge; they must all be able to invade their host. Once on 
or inside their host, they must rapidly find ingress to their final habitat or pathogenic 
site – a specific cell type, organ, or vessel. In parasite NTDs this involves migration 
through host tissue, extracellular matrix, basement membranes, and/or blood or 
lymph vessel walls and the pathogen must overcome host defence mechanisms, i.e., 
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physiochemical, immunological, and behavioural barriers. Given that NTDs share 
the same geographical distribution and cause high morbidity and mortality on the 
suffering population, a cross-cutting approach in research may facilitate a better 
understanding of the co-morbidity of the disperate NTD pathogens.  
The next section of this introduction explore similarities between 
schistosomes, fasciola and snake venom proteins in the context of accessing the 
intravascular and tissue compartments.  
 
1.4.2 Schistosomiasis  
Schistosomes are blood-dwelling parasites that cause schistosomiasis or 
bilharzia. The main species causing the disease in humans are Schistosoma mansoni, 
S. haematobium, and S. japonicum. Schistosomiasis is, after malaria, the most 
prevalent serious parasitic disease. Recent epidemiological studies indicate that 200 
million people are infected in underdeveloped and developing regions; further, the 
disease is a growing concern for travellers worldwide (Figure 4.1) (Gryseels et al. 
2006). The latest WHO report states that the annual mortality rate due to 
schistosomiasis could be as high as 200,000 and estimates that 600 million people 
live in high-risk areas. The loss in DALYs caused by the disease is about 1.53 
million (Gryseels et al. 2006). 
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Figure 0.4 Global distribution of schistosomiasis (Gryseels et al. 2006). 
1.4.2.1 Schistosome life cycle  
Schistosomes have a multi-stage life cycle (Figure 5). Adult worms are 7–20 
mm white or greyish in colour. They have a cylindrical body with two terminal 
suckers (oral and ventral), a complex structured tegument, a digestive tube, and a 
reproductive system. Schistosomes are distinctive from other trematodes; they are 
not hermaphrodites as they have separate sexes. The long thin female resides in a 
groove in the male body called the gynaecophoric channel. After mating, the 
permanently embraced couple migrates to either the perivesical (S. haematobium) or 
the mesenteric (other species) venous plexus. Schistosomes are blood-dwelling 
parasites so their residence in blood vessels guarantees a rich source of blood and 
globulins that they digest through anaerobic glycolysis.  
The adult lifespan averages three to five years; however, some may live as 
long as 30 years. During this time the female may produce as many as 600 billion 
eggs. The eggs bear ciliated miracidium larvae, which help the egg during migration 
to the lumen of the bladder (S. haematobium) or the intestine (other species) through 
its proteolytic enzyme secretion. Once in the lumen, the eggs can be excreted by 
urine or faeces to the outer environment. The embryonated eggs are viable for up to 
seven days. When the eggs are released into fresh water, the miracidium swims from 
the hatched egg searching for an intermediate host (fresh water snail). Guided by 
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light and chemical stimuli, the free-swimming miracidium penetrates the snail and 
multiplies asexually into multicellular sporocysts. Germ cells within sporocysts 
continue multiplying and growing, producing thousands of the bifurcated tail 
cercariae. After four to six weeks of infection the young cercariae emerge from the 
snail and swim around in water for up to 72 hours seeking for a definitive host. 
Stimulated by water turbulence, shadow, and chemicals released from human skin, 
the cercariae attach to the skin of its definitive host in order to initiate infection. 
After attachment to human skin, cercariae secrete proteolytic enzymes that 
breakdown the skin’s proteins to facilitate penetration of the cercarial head through 
the skin layers. As cercariae penetrate the skin they lose the bifurcated tail and 
transform into migrating schistosomula. The juvenile schistosomulum may remain 
within the skin for about two days until it locates a post-capillary venule. Upon 
reaching the capillaries, schistosomula migrate to the lungs where they further 
develop in order to continue migration to liver sinusoids, approximately within eight 
to ten days of penetration. After arrival at the liver, the parasite develops an oral 
sucker through which it feeds on red blood cells. Parasites reach maturity in six to 
eight weeks from the origin of infection, after which the mature male and female 
worms pair, the female resides in the gynaecophoric channel to produce eggs, and 
the life cycle starts again.  
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Figure  0.5  Schistosome  life  cycle.  (figure  from; 
http://www.cdc.gov/parasites/schistosomiasis/biology.html)  
 
1.4.2.2 Pathology  
1.4.2.2.1 Acute pathology 
Skin penetration by schistosome cercariae can provoke a local urticarial rash 
that may last for a few days. That occurs particularly after primary infection in non-
indigenous who visited or migrated to endemic areas as it often goes unrecognized in 
endemic populations (Gryseels et al., 2006). 
Acute schistosomiasis, otherwise known as Katayama fever, is a systemic 
hypersensitivity, serum sickness-like illness, which develops against released 
antigens during migration of the schistosomula and early oviposition (Bottieau et al., 
2006). Clinical onsets occur after several weeks of initial infection in some, but not 
most, newly infected patients. The disease is associated with marked peripheral 
eosinophilia, fever, fatigue, myalgia, malaise, non-productive cough, 
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hepatosplenomegaly, and patchy infiltrates on chest radiography (Gryseels et al., 
2006). Later, migration and positioning of the mature worm provoke abdominal 
symptoms. Although the syndrome can be fatal, most patients show spontaneous 
recovery over several weeks. Katayama fever is most common with S. mansoni and 
S. japonicum, and is most likely to appear in primary infected individuals with heavy 
infection (Gryseels et al., 2006). It is common in tourists, travellers, and people 
accidentally exposed to transmission foci (Bottieau et al., 2006).  
1.4.2.2.2 Chronic pathology  
Chronic schistosomiasis occurs through pathogenic reaction to eggs trapped 
in the patient’s tissue rather than to adult worms. Disease manifestation appears a 
number of years after initial infection. The pathogenic reaction is characterized as a 
cellular, granulomatous inflammation around trapped eggs in the intestine, liver (S. 
mansoni and S. japonicum) or urinary bladder (S. haematobium), which is 
progressively replaced by fibrotic deposits. Eggs are trapped in tissues during 
perivesical or peri-intestinal migration, or after embolization in the liver, spleen, 
lungs, or cerebrospinal system. Proteolytic enzymes secreted by the eggs during this 
process provoke an eosinophilic inflammatory reaction that establishes the 
granuloma. The severity of symptoms varies according to the intensity of the 
infection and the immune status of the infected patient. 
1.4.2.3 Schistosomiasis diagnosis (table 2) 
Schistosomiasis can be diagnosed through direct or indirect methods. Direct 
methods depend on the detection of parasite eggs in excreta or tissue of infected 
individuals or detection of parasite-derived material in the patient’s circulation or 
excreta. Indirect methods rely on the detection of schistosome-specific antibodies in 
patient blood samples (Doenhoff et al., 2004). 
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Category Method Detection of 
Applicable for infection with 
S. haem. S. mans. S.jap. 
Direct: 
Parasitological 
Examination of 
urine, stool, 
rectal mucosa 
Eggs + + + 
Indirect:  
Assessment of 
specific pathology 
through clinical, 
biochemical and 
immunological 
disease markers 
Looking/asking for 
symptoms and signs 
Gross haematouria, 
bloody diarrhoea, 
microhaematuria, 
proteinuria,  
leukocyturia, 
 occult blood in stool 
+ 
 
+ 
+ 
+ 
 
+ 
 
(+) 
 
+ 
 
(+) 
 
 
 
(+) 
Looking for organ 
involvement 
 
Assessment of 
altered immune 
function 
Sonographical alteration* 
 
Altered liver 
haemodynamics and 
collagen synthesis 
 
Altered cell-mediated 
immunity 
+ 
 
 
 
 
 
 
+ 
+ 
 
 
+ 
 
 
 
+ 
+ 
 
 
(+) 
 
 
 
+ 
Indirect, Direct: 
Immunological 
 
Serology  
 
In vivo immediate 
and delayed-type 
hypersensitivity 
Specific antibodies  
 
Schistosome-derived 
antigens 
 
Previous sensitization 
+ 
 
 
+ 
 
 
+ 
+ 
 
 
+ 
 
 
+ 
+ 
 
 
+ 
 
 
+ 
*Of liver and spleen, and lower and upper urinary tract, respectively. 
Table 0.2 Categories of diagnostic methods, (+) only inconclusive data exist (table from; Feldmeier et 
al., 1993). 
1.4.2.4 Brief summary of treatment and control 
Over the past few decades, schistosomiasis control strategies have shifted 
fundamentally due to production of schistosomicides like praziquantel (PZQ) 
(Gryseels et al., 2006). The focus on transmission control through the intermediate 
host has been altered by controlling morbidity using population-based chemotherapy 
(Liu et al., 2011). Although this strategy has the advantage of quick results, it needs 
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careful and long-term planning to ensure sustainability and progression to face the 
challenging stages of infection and control of transmission (Gryseels et al., 2006). 
Three main drugs have been used to treat schistosomiasis; metrifonate 
(targeting S. haematobium), oxamniquine (targeting S. mansoni), and PZQ (for all 
human species) (Liu et al., 2011). Because of its broader spectrum, schistosomiasis 
is readily treated by a single annual oral dose of PZQ, an acylated quinoline-
pyrazine. However, potential resistance of schistosomiasis to PZQ has recently 
become a concern, thereby increasing the focus on the need for alternatives. As with 
other major parasitic diseases, vaccine development research is ongoing and 
extensive. Researchers are trying to develop a schistosomiasis vaccine that will 
prevent the parasite from completing its life cycle in humans.  
1.4.2.5 The saga of schistosome migration 
Invasion of skin is the initial event in infection of the vertebrate host by 
schistosome larvae. Skin is a formidable barrier made by connected cells of the 
epidermis, the dermal-epidermal basement membrane, and the extracellular matrix of 
the dermis. Cercariae are stimulated to penetrate the skin by interaction with 
medium-chain fatty acids on the skin surface (Stirewalt et al., 1965; McKerrow et 
al., 1985; Haeberlein and Haas, 2008). After host identification, ventral suckers of 
the cercariae aid their attachment to the epidermis. Schistosome cercariae have a 
specialized head organ that has the ability to stretch and retract, and is used to find a 
suitable place for invasion (He et al., 2005). The external opening of the acetabular 
gland ducts is present on the disc-like apex of the head. The acetabular gland 
secretions are sticky and released into the microenvironment in large quantities after 
stimulation (He et al., 2005). 
 
Proteases released from the acetabular glands initially degrade keratin at the 
skin surface (McKerrow et al., 1985). Once on the skin, cercariae (transforming into 
schistosomula) may cross the epidermis directly or first migrate down a hair shaft. 
The active component in acetabular gland secretions, cercarial elastase, is 
responsible for the subsequent proteolytic activity of invading larvae (McKerrow and 
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Salter, 2002); it diffuses widely ahead of the invading larvae (Stirewalt and Walters, 
1973). Nevertheless, other surface-associated proteases, namely serine proteases and 
metalloproteases (e.g., SmPepM8), of the schistosomula in coordination with the 
cercarial enzyme may facilitate subsequent vascular invasion (Silva et al., 2011; 
McKerrow et al., 1985; Curwen et al., 2006). 3-day-old schistosomulea, which now 
lack preacetabular-gland contents, are as effective as cercariae at degrading the 
basement-membrane-like extracellular matrix of endothelial cells (Curwen and 
Wilson 2003; McKerrow, Jones, et al. 1985). 
Finally, whilst migrating to the blood venules, schistosomula have to degrade 
the basement membrane that is the final barrier to dermal entry. In the basement 
membrane, the lamina densa contains two forms of collagen IV and collagen VII 
(McKerrow et al., 1985; Curwen and Wilson, 2003; Ruppel et al., 2004). The major 
obstacles in the dermis itself are collagen, elastin, and reticulin fibres. Basement-
membrane degradation would enable parasite invasion not only of the epidermal 
basement membrane, but of small dermal vessels as well. During this phase serine 
proteinases correspond to cleavage of a globular heparin-binding region from the 
'arms' of the laminin molecule (McKerrow et al., 1985). Following entry to the 
dermis, parasite invasion would be facilitated by degradation of elastin (McKerrow 
et al., 1983, 1985). Furthermore, metalloprotease activity has already been 
demonstrated in secretions from maturing schistosomula after the first 24 hours 
(Curwen and Wilson, 2003). 
 
 
1.4.3 Fascioliasis  
Food-borne trematodiasis account for over 665,000 DALYs worldwide; 
fascioliasis accounting for 35,000 of these (Fürst et al., 2012). Fascioliasis is a 
zoonotic disease that infects humans through consumption of water plants (e.g., 
watercress) contaminated by F. hepatica or F. gigantica metacercaria (Cabada and 
White, 2012). Globally, fascioliasis is the most widespread food-borne trematode 
infection (Fürst et al., 2012). Reports have shown significant numbers of disease 
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cases from Southeast Asia, Northern Africa, the Middle East, and South America 
(Cabada and White, 2012). Several factors are likely to explain the expanding 
endemic territories of fascioliasis, namely human migration, poverty and poor living 
conditions, animal trade, and environmental changes (Cabada and White, 2012). 
 
1.4.3.1 Fasciola life cycle (Figure 6) 
Embryonated ova hatch in fresh water, where newly emerged meracidia 
infect lymnaeid snails, the obligatory intermediate host (Cabada and White, 2012). 
After a period of development, cercariae emerge from the snails to form the encysted 
metacercariae in water or on aquatic plants. Mammals, including humans, are 
infected when they ingest infected aquatic plants or water (Cabada and White, 2012). 
After ingestion, the newly excysted juveniles actively penetrate and transverse the 
gut wall into the peritoneal cavity within two or three hours (Cancela et al., 2010). 
Four or five days post-infection, the parasites reach the liver, penetrate the 
parenchyma and continue burrowing for several weeks. The parasites mature and 
start to release eggs within the major bile ducts. Eggs can be found in the bile and 
faeces eight weeks post-infection (Cancela et al., 2010). 
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Figure 0.6 Fasciola life cycle. (figure from; http://www.cdc.gov/parasites/fasciola/biology.html) 
 
 
The primary roles for stage specific proteases and antioxidant enzymes in the 
early infection have been elucidated (Tkalcevic et al., 1995) who identified proteases 
in newly excysted juvenile stage of fasciola. Proteomic studies were able to reveal 
important proteases in different F. hepatica stages. Of the recognized proteases, 
cysteine and asparaginyl proteases were detected (Kasný et al., 2009). Similar to 
other trematodes, these proteases are believed to be involved in tissue invasion, 
immune system evasion, and haemoglobin digestion. 
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1.4.3.2 Pathology 
Food-borne trematodes do not have the ability to replicate in the human host. 
This makes them different from protozoan parasite infection, such as the malaria 
parasite Plasmodium spp., which can replicate within infected individuals (Keiser 
and Utzinger, 2009). Thus, morbidity due to food-borne trematodiasis and other 
trematode-borne diseases is related to infection intensity and worm burden (Keiser & 
Utzinger 2009). In addition, worm burden has a direct effect on inflammatory lesions 
and damage of tissue and target organs. Common symptoms of fascioliasis includes 
dyspepsia, fever, right upper quadrant pain, anorexia, hepatomegaly, splenomegaly, 
ascites, urticaria, respiratory symptoms, and jaundice, which might be seen in the 
acute stage of fascioliasis (Keiser and Utzinger, 2009). In the chronic stage, when the 
parasites enter into the biliary tree, symptoms such as biliary colic, intermittent 
jaundice, epigastric pain, nausea, fatty food intolerance, cholangitis, acute 
pancreatitis, and cholecystitis may present (Keiser and Utzinger, 2009). 
 
1.4.3.3 Diagnosis 
Diagnosis of fascioliasis is performed through three main approaches: direct 
parasitological diagnosis, immunodiagnosis, and molecular diagnostic tests (Cabada 
and White, 2012). Direct parasitological diagnosis depends on detection of parasite 
eggs in stool, sputum, or other biofluids (Fürst et al., 2012). Indirect 
immunodiagnosis detects parasite antigens or antibodies in patient blood. 
Complementary tools are available for the diagnosis of the hepatobiliary parasitic 
infections, for example, ultrasound, computer tomography, magnetic resonance 
imaging, and tissue harmonic imaging (Keiser and Utzinger, 2009).  
 
1.4.3.4 Brief summary of treatment and control 
Public health interventions are playing a major role in the control of 
fascioliasis. To reduce the prevalence and intensity of infections, and as a result 
morbidity and mortality, chemotherapy (mainly by triclabendazole), improved access 
to adequate sanitation, the use of chemical fertilizers and food inspections, 
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information, education, and communication campaigns have been employed. The 
consumption of raw or undercooked aquatic products increases the risk of acquiring 
fascioliasis; therefore, changing this behaviour and raising public awareness to its 
risks is a key factor in controlling the disease. No vaccines are available yet for the 
prevention of fascioliasis, however, progressing gene discovery and proteome 
research may decrease the gap to develop effective vaccines and the next generation 
trematocidal drugs. 
 
1.4.4 Snake envenoming 
Mortality due snakebite is a neglected health issue affecting the rural poor in 
low-income tropical countries (Harrison et al., 2011). It kills over 50,000 individuals 
in Asia (Mohapatra et al., 2011) and 7,500 in SSA (Chippaux, 2011) annually; 
globally, it is estimated that as many as 95,000 people die every year as a result of 
snakebite envenoming (Kasturiratne et al., 2008) (Figure 7). The catastrophic effects 
behind snakebites are due to the fact that the majority of the affected population are 
the least able to access or afford effective treatment (Harrison et al., 2011). Recently, 
snakebite envenoming has been designated by WHO as a NTD (WHO, 2013). 
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Figure 0.7 The global regional estimate of snakebite-induced deaths, the grouping of the countries was 
according to the Global Burden of Disease (GBD) (figure from; Kasturiratne et al., 2008). 
 
1.4.4.1 Clinical features of snakebite envenoming 
Mortality due to envenoming by venomous snakes is estimated to be 94,000–
125,000 cases per year worldwide (Kasturiratne et al., 2008). Further, snakebites can 
cause long-term morbidity as limb necrosis may develop as a result of envenoming 
(Chippaux, 1998). The complexity of snake venom and the variation in its 
composition cause a wide range of post-envenomation symptoms. Clinically 
significant effects can be observed in envenomed patients that may cause potential 
morbidity and mortality. Venomous snakes that contain neurotoxins (Elapidae) can 
cause flaccid paralysis and systemic myolysis; others components (Viperidae) can 
act on the coagulation cascade and may lead to coagulopathy, haemorrhage, renal 
damage and failure, cardiotoxicity, and local tissue injury (White, 2005). These 
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symptoms are triggered by the action of venom toxins that have varying molecular 
targets and enzymatic activities (McCue, 2005).  
 
 
1.4.4.2 Antivenom as treatment of envenoming 
The only available specific treatment of snakebite envenoming is intravenous 
administration of animal-derived (mostly horse or sheep) antivenom (Gutiérrez et al., 
2006). Many laboratories in different countries produce antivenoms using various 
methodologies. The production yields three different types of products depending on 
the nature of the active principle; antivenoms that consist of whole IgG molecules, 
antivenoms composed of F(ab′)2 fragments obtained by pepsin digestion of IgG, and 
a few laboratories produce Fab fragments after papain digestion of IgG (Gutiérrez et 
al., 2006). The restriction of antivenom efficacy to limited geographical and 
biological spectrum is explained by the large immunochemical diversity of snake 
venoms (Lalloo and Theakston, 2003). They are highly effective in the neutralisation 
of toxins responsible for systemic effects such as haemorrhage, coagulopathy, and 
haemodynamic disturbances. Likewise, neurotoxicity caused by postsynaptic 
neurotoxins in elapid envenomings can be reversed if treated early (Lalloo and 
Theakston, 2003). On the other hand, observations suggest that antivenoms are not 
very effective in the reversal of presynaptic induced neurotoxicity (Gutiérrez et al., 
2006). The main problem associated with antivenom efficacy related to local tissue 
damage that is due to the extremely rapid development of local pathology rather than 
the lack of neutralizing antibodies in antivenoms (Gutiérrez et al., 1998). Antivenom 
safety is also of current concern since it often coincides with early and late adverse 
reactions (Theakston et al., 2003; Lalloo and Theakston, 2003). 
As proteins (proteases and others) considered playing a major role in 
pathology initiation and progression, in both parasites and snake venom, the next 
few sections will briefly discuss some of the major proteins shared between parasites 
and snake venom.  
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1.4.5 Proteases and their role in parasitemia and envenoming 
1.4.5.1 Proteases and trematodes (S. mansoni and F. hepatica) 
S. mansoni and F. hepatica are trematodes that belong to the same phylum, 
Platyhelminthes. These digenetic trematodes have complex life strategies, involving 
changes between asexually and sexually reproducing life stages within different 
hosts; intermediate (mostly snails) and definitive (vertebrate species), respectively. 
To successfully complete this complex life cycle, these parasites produce molecules 
that play distinct and pivotal roles. For example, eicosanoids trigger local 
immunosuppression and vasodilatation and carbohydrates serve for molecular 
mimicry within infected hosts (Kasný et al., 2009). In addition, proteins in general 
and peptidases in particular, play a number of crucial roles during parasitism (Kasný 
et al., 2009). Peptidases produced by trematodes have been identified as essential 
enzymes in the immature (larval) and mature (adult) stages (Figure 8.1) (Cesari et 
al., 2000; Dvorak et al., 2005; Sajid et al., 2003). They are critical elements in many 
host-parasite interactions such as invasion, migration through tissue compartments, 
degradation of nutritional proteins (e.g., haemoglobin), immune evasion, and 
activation and modulation of inflammation (Caffrey et al., 2004; Delcroix et al., 
2007; Donnelly et al., 2006; He et al., 2005; Koehler et al., 2007; McKerrow et al., 
2006). For example, cercarial elastase a serine proteases is the key enzyme in 
infection establishment, metalloprotease in trematodes are essential for host immune 
system evasion and aspartic protease is used in hemoglobin digestion during feeding 
processes (Kasný et al. 2009; Ingram et al. 2003; Ingram et al. 2012; Caffrey et al. 
2004; Silva et al. 2011; Koehler et al. 2007). The vital role of peptidases for 
trematode survival places these molecules as primary targets for the development of 
new drugs (e.g., cysteine peptidase inhibitor K11777) (Abdulla et al., 2007; 
McKerrow et al., 2006) or as constituents of molecular vaccines (e.g., cathepsins L1 
and L2 of F. hepatica) (McManus and Dalton, 2006). 
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Figure 0.8 Comparison of protease release by larval versus adult helminth parasites. In larvae, 
proteases function primarily in tissue invasion or immune evasion. In adults, they function in gut degradation of 
host proteins, anticoagulation, and immune evasion (figure from; McKerrow et al. 2006). 
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1.4.5.2 Proteases and snake venom 
Snake venoms are probably the most highly concentrated biological secretion 
found in vertebrates, and are complex mixtures of enzymatic and non-enzymatic 
proteins, peptidases and carbohydrates (Aird 2002). Venomous snake families 
produce pharmacologically active proteins: enzymes (phospholipase A2 [PLA2], l-
amino acid oxidases [LAAOs], metallo- and serine proteases, 
phosphomonoesterases, phosphodiesterases, acetylcholinesterases, 5´nucleotidases, 
and hyaluronidases); nerve growth factors; compounds affecting blood coagulation 
by disturbing heamostatasis and induce bleeding; C-type lectins; activators and 
inhibitors of inflammation, septic shock, and tumour growth; myotoxins causing 
extensive damage to skeletal muscles, cardiotoxins; cytotoxins; platelet 
glycoproteins; natriuretic peptides; disintegrins; and three-finger toxins (Georgieva 
et al. 2008; Montecucco et al. 2008). 
Despite the important role of snake venom proteases in immobilization and 
digestion of prey, they are responsible for various effects on biological functions 
after envenomation (e.g., haemorrhage, shock, or disorder of blood coagulation and 
nervous or muscular impulse transmission) (White, 2005; Lalloo et al., 1996).  
The function and the role some of these shared proteins between parasites 
and snake venom will be described in the following sections. 
 
1.4.5.3 Proteases shared between parasites and snake venom 
1.4.5.3.1 Serine peptidases (SP) 
1.4.5.3.1.1 Parasites (S. mansoni and F. hepatica) serine peptidases 
Three main activity types of S1 family of peptidases have been described: i) 
chymotrypsin-like: peptidases expressing this activity prefer one of the hydrophobic 
amino acids at P1 position, phenylalanine over alanine by around 50,000 times; ii) 
trypsin-like: preference arginine or lysine at P1 position of the cleaved substrates; 
and iii) elastase-like: they generally prefer small aliphatic amino acids such as 
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alanine at P1 position (Kasný et al., 2009). 
Schistosome cercarial elastase (CE) has a characteristic serine peptidase 
catalytic triad in the active site (His68/Asp126/ Ser218; numbering for SmCE) 
(Rawlings et al., 2008). It facilitates the degradation of various skin macromolecules 
including collagen, gelatin, keratin, fibronectin, laminin, and peptide backbone of 
proteoglycans or cell-cell contacts in the epidermis. The main interesting fact in CE 
is its ability to cleave another fundamental skin component, dermal elastin (Salter et 
al., 2000). Therefore, it is believed that elastases from cercarial acetabular glands 
play pivotal roles during cercarial host skin penetration. Additionally, schistosome 
CE may also help the cercariae evade the host immune response (Kasný et al., 2009). 
The activity of another type of SP; kallikrein-like peptidase was purified 
from S. mansoni adults. The (66 kDa) peptidase was detected with d-Pro-Phe-Arg-p-
nitroanilide substrate. The inhibition profile of S. mansoni kallikrein-like peptidase is 
characterized by common serine peptidase inhibitors, such as 
phenylmethylsulphonyl fluoride (PMSF), aprotinin, or soybean trypsin inhibitor 
(Carvalho et al., 1998). In addition it has shown the ability to cleave bradykinin and 
induce reduction of the arterial blood pressure of experimental animals (rats), 
possibly due to a peripheral vasodilatation effect which might reflect a similar effect 
in the natural host (Carvalho et al., 1998). Studies have demonstrated a variety of 
physiological functions for the enzyme such as processing of bioactive peptides, 
blood coagulation, and enhancement of glycosylation of IgE (Kasný et al., 2009). 
1.4.5.3.1.2 Snake venom serine peptidases 
Snake venom serine proteinases (SVSPs) are among the best-characterized 
venom enzymes affecting the haemostatic system. They belong to the trypsin family 
S1 of clan SA, the largest family of peptidases (Halfon and Craik, 1998). SVSPs can 
be classified into thrombin-like or kallikrein-like proteases. They affect various 
components in the blood coagulation cascade, on the fibrinolytic and kallikrein-kinin 
systems and on cells that in combination cause a major imbalance in the haemostatic 
system of their prey (Seegers and Ouyang, 1979; Markland, 1998; Pirkle, 1998). 
They are present in venoms of the families Viperidae, Crotalidae, Elapidae, and 
Colubridae. Snake venom enzymes characterized as serine proteinases are defined by 
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a common catalytic mechanism that includes a highly reactive serine residue that 
plays a key role in the formation of a transient acyl-enzyme complex, which is 
stabilized by the presence of histidine and aspartic acid residues within the active site 
(Barrett and Rawlings 1995). 
The thrombin-like SVSPs are recognized by their ability to cleave fibrinogen 
at the arginine-lysine bonds on the α- and β-chain of fibrinogen releasing 
fibrinopeptides and consequently transforming fibrinogen into fibrin (Pirkle, 1998). 
On the other hand, kallikrein-like SVSPs share similarity with mammalian kallikrein 
enzymes in initiating the release of bradykinin by cleaving of kininogen 
proteolytically (Matusi et al., 2000). The release of bradykinin, known for its 
vasodilator nature, causes an increase in vascular permeability and hypotensive 
symptoms (Warrell 2010). Notwithstanding the high degree of mutual sequence 
identity, SVSPs show specificity toward a given macromolecular substrate 
(Markland, 1998).  
1.4.5.3.2 Metalloproteases (MP) 
1.4.5.3.2.1 Parasites (S. mansoni and F. hepatica) metalloproteases 
In 2009, MEROPS the peptidases and peptidase inhibitors database 8.2 
(http://merops.sanger.ac.uk) included 511 different metallopeptidase sequences of 15 
clans and 54 families. Of these, ten various sequences of five trematode species were 
classified in seven clans and nine families (Rawlings et al., 2008). 
1.4.5.3.2.2 Leucyl aminopeptidase (LAP) 
Studies show that sequence identity of S. mansoni, S. japonicum, and F. 
hepatica LAPs is greater than 34% in multiple alignments. The highly conserved C-
terminal domain, which is the active site motif ‘NTDAEGR’, was identified in all 
three amino acid sequences of S. mansoni LAP (SmLAP), S. japonicum LAP 
(SjLAP), and F. hepatica LAP (FhLAP) (Kim & Lipscomb 1993). 
LAPs are broadly distributed cytosolic exopeptidases that possess six sub-
units with 12 Zn+2 cations of around 56 kDa for SmLAP/SjLAP, and FhLAP 
(McCarthy et al. 2004; Rawlings et al. 2008). They cleave the leucine amino acid at 
P1 of the substrates, and not those with aspartate and glycine at P1 position. 
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Schistosome LAP is immunolocalized predominantly in the gastro-dermis and sub-
tegument of adult parasites (McCarthy et al., 2004). Additionally, LAP activity was 
localized in S. mansoni eggs (Kasný et al. 2009). This suggests that schistosome 
LAP may participate in haemoglobin digestion and surface membrane re-modelling 
(McCarthy et al., 2004). LAP activities were also detected in the S. mansoni cercarial 
and schistosomular protein extracts. Furthermore, transcription analyses revealed 
significant expression of these peptidases by all developmental stages (Jolly et al. 
2007; Auriault et al. 1982; Liu et al. 2006; McCarthy et al. 2004). Recombinant F. 
hepatica LAP (FhLAP) immunisation showed significant protection in immunized 
sheep (>89%) against metacercariae infection (Piacenza et al., 1999). It is also 
recognised as a potential immunodominant diagnostic marker, reacting with sera 
from fascioliasis patients. 
 
1.4.5.3.2.3 Surface peptidase (Leishmanolysin) 
Leishmanolysin (also called invadolysin), is a surface peptidase of the 
metallopeptidase M8 family found in S. mansoni proteome data (Silva et al., 2011). 
The conserved glutamate residue in the catalytic site acts in conjunction with a zinc 
ion to deprotonate and activate a water molecule. In turn, the activated water 
molecule acts as a nucleophile to attack the carbonyl of the peptide bond in a variety 
of substrates. These proteins are involved in different types of processes in 
Leishmania parasites, for example the inhibition or perturbations of host cell 
interactions and the degradation of the extracellular matrix (Fitzpatrick et al., 2009). 
These proteins may have similar activities in schistosomes. SmPepM8 
(Smp_090100) is the second most abundant component of cercarial secretions (Silva 
et al., 2011). Other studies showed that SmPepM8 was also secreted from skin 
schistosomula, which provides insight on how it may contribute to tissue invasion by 
schistosomes and suggest this protein as a potential anti-parasitic target (Curwen et 
al., 2006; Fitzpatrick et al., 2009). Homology of this protein with a surface protease 
of Leishmania GP63 that contributes in surface remodelling of transforming larva 
against host complement may suggest a similar function in schistosomes (Dvorák et 
al. 2008). The presence of metalloprotease activity in early schistosomula may 
reflect the re-ordering of parasite surface as an adaptation process to intravascular 
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residence (Dvorák et al. 2008). 
 
1.4.5.3.2.4 Snake venom metalloproteases 
SVMPs are enzymes with multiple domains whose main toxic effects are due 
to disruption of the haemostatic system. SVMPs are classified within the M12 
reprolysin family of metalloproteases and categorized according to their 
multidomain organization in classes PI to PIV (Bjarnason and Fox, 1994; Fox and 
Serrano, 2005). These enzymes are synthesized in vivo as multimodular proteins that 
comprise a signal peptide, a pro-domain, and a metalloprotease domain (class PI). 
Certain SVMPs also exhibit subsequent C-terminal domains, i.e., the disintegrin 
(class PII) or disintegrin-like domain (class PIII), the cysteine-rich domain (class 
PIII), and the C-type lectin-like domain (class PIV) or sub-unit. A recent update of 
the originally proposed SVMP classification scheme includes the following 
precursor classes: PIIa-PII precursors that in their mature form do not release the 
disintegrin domain; PIIb-PII precursors whose mature form comprises dimeric 
SVMPs; D-I-precursors that do not contain a metalloprotease domain; PIIIa-PIII 
precursors that release their disintegrin and cysteine-rich domains; PIIIb-PIII 
precursors that form dimeric SVMPs (Ramos and Selistre-de-Araujo, 2006; Fox and 
Serrano, 2005). 
The zinc-binding motif, HEX box, is shared with ADAMs (for A Disintegrin 
And Metalloprotease) homologous proteins described in some organisms including 
mammalians. SVMPs and ADAMs belong to the reprolysin protein family and 
together with other protein families (astacins, serralysins, matrixins or matrix 
metalloproteases, snapalysins and leishmanolysins), form the clan of metzincins 
(Gomis-Rüth, 2003). The name metzincins is related to a conserved methionine 
residue in a β-turn downstream from the zinc-binding motif. 
SVMP activity is associated with haemorrhage or the disruption of the 
haemostatic system, which are mainly mediated by the M domain proteolytic activity 
(Escalante et al., 2011). Haemorrhage is induced by SVMP interruption of the 
interactions between endothelial cells and the basement membrane through the 
degradation of endothelial cell membrane proteins (e.g., integrin, cadherin) and 
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basement membrane components (e.g., fibronectin, laminin, nidogen, type IV 
collagen) (Takeda et al., 2012; Gutiérrez and Rucavado, 2000). Furthermore, blood 
coagulation proteins (e.g., fibrinogen, factor X, prothrombin) are also targets of their 
proteolytic activities (figure 9.1). 
 
Figure 0.9 Key events in microvascular damage induced by snake venom hemorrhagic 
metalloproteinases. Non-hemorrhagic P-I SVMPs (A) hydrolyze some BM components, such as laminin, nidogen 
and some FACITs, whereas P-I or P-III hemorrhagic SVMPs (B) are capable of hydrolyzing, in addition to these 
substrates, other components which are likely to play a more critical role in capillary mechanical stability, i.e. 
types IV, VI and XV collagens, and perlecan. (figure from; Escalante et al. 2011). 
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1.4.5.3.3 Aspartic protease 
1.4.5.3.3.1 Parasites (S. mansoni and F. hepatica) aspartic protease 
In aspartic protease, an activated water molecule via the side chain of 
aspartate initiates the nucleophilic attack (Morales et al., 2004). Aspartic protease 
(cathepsin D, CD) sequences have been found in many trematodes. In schistosome, it 
has been localized in the gastrodermis of adult worms using immunohistochemical 
or molecular techniques (Schulmeister et al., 2005; Brindley et al., 2001). In addition 
to this, schistosome CD activity has been detected in eggs and miracidium of S. 
japonicum (Verity et al., 1999). CD is intimately involved in worm nutrition by 
facilitating degradation of host haemoglobin (Brindley et al., 2001; Delcroix et al., 
2007; Caffrey et al., 2004). Moreover, schistosome CD may have a role in 
schistosome immune invasion as they can effectively cleave human IgG by 
removing Fc fragments, or degrade C3 factor of the complement (Verity et al., 
2001). 
 
1.4.5.3.3.2 Snake venom aspartic protease 
Aspartic protease has been discovered in E. ocellatus venom gland 
transcriptome. Wagstaff and Harrison (2006) have provided evidence indicating that 
aspartic protease might be a secreted component of snake venom and therefore 
propose it as a new class of venom toxins. Sequence similarity has been 
demonstrated between venom aspartic protease and the sequence of mammalian CD, 
which is similar to renin and exhibits renin-like activity. The renin-angiotensin 
system is characterized by enzymatic activation of angiotensinogen to angiotensin I 
(ang-I), which is then hydrolysed by angiotensin-converting enzyme producing the 
vasoconstrictor ang-II (Pagliaro and Penna 2005; Lee et al. 1996). This might 
suggest a local hypertension induction by renin-like activity of E. ocellatus venom 
aspartic proteases in envenomed patients (Wagstaff and Harrison, 2006), as a 
consequence serving to exacerbate SVMP-induced tissue distraction; entry of venom 
aspartic proteins into the vascular system would also be expected to induce systemic 
hypertension (Wagstaff and Harrison, 2006). 
 
 
32 
1.4.5.4 Phospholipase A2 
1.4.5.4.1 Parasites (S. mansoni and F. hepatica) phospholipase A2 
Phospholipases are important enzymes that facilitate lipid metabolism; 
phospholipase A2 (PLA2) catalyses the specific hydrolysis of ester bonds linking the 
acyl chain to the C-2 position of 1,2-diacyl-3-sn-glycerophospholipids (Rogers et al., 
1991). They include several unrelated protein families with common enzymatic 
activity. Two most important families are secreted and cytosolic phospholipases A2. 
Other families include Ca2+ independent PLA2 (iPLA2) and lipoprotein-associated 
PLA2s (lp-PLA2), also known as platelet activating factor acetylhydrolase (PAF-AH) 
(Dennis 1994). PLA2 is one of the most well studied phospholipid-degrading 
enzymes, partly because it is a major and important component of snake and bee 
venoms and of pancreatic digestive secretions. In parasites, the enzyme plays a 
potential role in lipid metabolism, membrane synthesis, remodelling, and/or 
separation and migration (e.g., tissue migration of L4 larva of nematodes) (Grieve et 
al., 2000; Hawn and Strand 1993). Previous studies have shown considerable 
homology between these enzymes from different organisms at both the amino acid 
and nucleotide levels, although they show little conformity in terms of their 
molecular size and their substrate and pH requirements (Rogers et al., 1991). 
Membrane-bound forms of PLA2 are believed to be involved in membrane lipid 
homeostasis and are particularly active against highly cytotoxic phospholipid 
hydroperoxides that can be generated in membranes as a result of superoxide radical 
release from activated leukocytes (Rogers et al., 1991). Many studies have 
demonstrated that PLA2 (Smp_166530.1) (lysosomal phospholipase A2 or LCAT-
like lysophospholipase), is present in trace amounts in S. japonicum and S. mansoni 
gut lumen, although it appears to be antigenic (Rogers et al., 1991; Nawaratna et al., 
2011; Berriman et al., 2010). 
 
1.4.5.4.2 Snake venom phospholipase A2 
Snake venoms classified in the Colubridae, Elapidae and Viperidae families 
comprise rich sources of PLA2s (Gutiérrez and Lomonte, 2013). Structurally, snake 
venom PLA2s are classified within groups I (elapid enzymes), found in mammalian 
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pancreas, and II (viperid enzymes) (Fry et al., 2008). The amino acid sequences and 
crystal structure of many snake venom PLA2s have been reported, over 280 PLA2 
enzymes have been determined. Despite the differences in their pharmacological 
properties, structural characterization has revealed a relatively high identity (40–
99%) in many of their sequences and a conserved structural scaffold (Kini, 2003). 
Nevertheless, these enzymes display an impressive array of 
pharmacological/toxicological activity effects including, in addition to pry digestion, 
pre- and post-synaptic neurotoxicity, myotoxicity, cardiotoxicity, coagulopathy, 
hypotension, haemolysis, and proinflammation (Kini, 2003; Montecucco et al., 
2008). PLA2 group I exhibit pre- or post-synaptic neurotoxicity. The pre-synaptic 
PLA2 are responsible for the irreversible disruption of neurotransmitter release at the 
neuromuscular junction. On the other hand, post-synaptic neurotoxins competitively 
block acetylcholine receptors in the neuromuscular junction. This type of 
neurotoxicity can be reversed by rapid antivenom treatment (Lalloo and Theakston, 
2003). PLA2 myotoxins (group II) are more potent and fast-acting than non-
enzymatic components of snake venom (Kini, 2003). They can induce myonecrosis 
or system myotoxicity. PLA2-induced inflammatory reactions have been 
demonstrated; inflammatory cell infiltration promoted by PLA2 isolated from Naja 
naja atra and phagocytic activity of macrophages stimulated by Asp49 and Lys 49 
PLA2s from Bothrops asper venom (Zuliani et al., 2005; Zhang and 
Gopalakrishnakone, 1999). 
Shared proteins other than proteases like c-type lectin are found in parasites 
and snake venom and play a role in pathology caused by these pathogens. The next 
section is briefly summarises the function of some of these proteins in both parasites 
and snake venom. 
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1.4.5.5  Non-enzymatic proteins shared between parasites and 
snake venom 
1.4.5.5.1 C-type lectin 
1.4.5.5.1.1 Parasites (S. mansoni and F. hepatica) c-type lectin 
C-type lectins (C-TLs) are a family of carbohydrate-binding proteins. They 
enable diverse biological processes including immune cell signalling and trafficking, 
activation of innate immunity, and venom-induced haemostasis (Weis et al., 1998). 
In helminth C-TLs share sequence and structural homology with mammalian 
immune cell lectins (Loukas and Maizels, 2000). Recently, they have been identified 
from nematode parasites, proposing clear roles for these proteins at the host–parasite 
interface, particularly in immune evasion. 
Among the parasitic Platyhelminthes, no C-TL genes have yet been identified 
despite around 10,000 schistosome expressed sequence tags (ESTs) in the EST 
database. However, there is biochemical evidence for lectin expression in trematodes 
(Loukas and Maizels, 2000). There is positive evidence for the presence of 
surface/secreted lectins at most life cycle stages of the schistosome. Immune 
recognition of schistosome larvae by mollusc intermediate hosts is mediated by 
haemocyte surface lectins. Furthermore, a cDNA encoding a haemocyte C-TL 
homologous to selectins has been cloned from B. glabrata (Loukas and Maizels, 
2000). In addition, acetabular glands of cercariae of the avian schistosome 
Trichobilharzia has been found to express activity of lectin on its surface. Lectin has 
been found to have specificity for tissue glycosaminoglycans, suggesting a role in 
recognition and/or penetration of host connective tissues. 
Lectin-like activity in trematodes is not limited to larvae. Binding of a 
monoclonal antibody to human E-selectin to the surface of S. mansoni schistosomula 
was found to be inhibited in the presence of appropriate ligands for E-selectin 
(Loukas and Maizels, 2000). This finding may explain the ability of schistosomes to 
adsorb host molecules, for example antibodies, complement components, and major 
histocompatibility complex (MHC) class I antigens, on to their surface avoiding 
immune recognition (Loukas and Maizels, 2000).  
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1.4.5.5.1.2 Snake venom c-type lectin 
In snake venom there are two types of C-TLs; the classic sugar binding C-
TLs found in many animals and C-type lectin-like proteins (CLPs) found only in 
snake venom (Ogawa et al., 2005). Sugar binding C-TLs comprise a less toxic 
component of the venom and their role in venom is not fully understood (Weis et al., 
1998). In contrast, CLPs of snake venom have a variety of biological properties, 
acting for example as anticoagulants, pro-coagulants, and agonists/antagonists of 
platelet activation. The structural and functional studies of the first identified CLP, 
factor IX/factor X-binding protein, show the ability of this protein to bind to the γ-
carboxyglutamic acid domain of factors IX and X in Ca2+ (Atoda et al., 1994). Other 
unique CLPs have been also identified. The later show the ability to agonists and 
antagonists platelet receptors, platelet glycoprotein Ib and glycoproteins Ia/IIa and 
VI, collagen receptors and the following CLPs that modulate platelet function 
(Morita 2004; Huang et al. 1995). 
 
 
As described in previous sections of this chapter, vectors like mosquitoes 
transmit many NTDs. Mosquitoes saliva contain a mixture of vasodilatory, 
antiplatelet, and anticlotting molecules to assists the process of taking blood meal 
(Calvo et al. 2006). Of these components, proteases and proteins that share nature 
with some snake venom proteins like serine proteases and C-TL have been 
identified. The next section describe briefly role of these proteins in mosquito saliva.  
1.4.5.6 Mosquito sialome  
Mosquito sialome is the set of mRNA and proteins expressed in the salivary 
glands, especially of mosquitoes. Salivary glands of mosquito contain hundreds of 
compounds that work as anti-haemostatic and immunomodulatory components 
aiding the finding and blood feeding from the vertebrate host. Only adult female 
mosquitoes are haematophagic, while both sexes take sugar meals. 
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Proteases have been identified from mosquito salivary glands. Of them, many 
serine proteases could be involved in specific host proteolytic events that could 
affect clotting or the complement cascade (Ribeiro et al. 2004; Francischetti et al. 
2002). Other serine proteases are possibly involved in immunity, as they share a 
similarity with prophenoloxidase-activating enzymes responsible for the melanotic 
immune reactions of arthropods. In addition to serine protease, metalloprotease 
homologous to a Drosophila enzyme involved in remodelling of the salivary glands 
was also discovered in the salivary transcriptome of An. gambiae (Arcà et al. 2005).   
The C-TL protein family is expressed in most mosquito sialotranscriptomes 
(Ribeiro et al. 2004; Arcà et al. 2005). This protein family is involved in immune 
recognition and in Plasmodium development in Anopheles mosquitoes (Ribeiro et al. 
2007). The role of C-TLs in salivary immunity has not yet been demonstrated; 
nevertheless it is interesting that in snake venom this protein family has been 
employed in performing various unrelated functions such as an anticlotting, toxin, 
and platelet aggregation inducer (Morita 2004). Lectins may also play a role in the 
lectin pathway of complement activation (Ribeiro et al. 2007). 
 
1.4.6 Aims  
The vast literature discussing NTDs highlights the role of these diseases in 
the exacerbation of living conditions of the world’s poorest populations. 
Epidemiological studies illustrate how populations suffer the burden of NTDs, where 
single individuals may be suffering from more than one NTD. Despite their variety, 
biological studies of NTD pathogens and factors show that several NTDs may use 
similar mechanisms in their pathology such as migration through tissue and cellular 
compartments; haemoglobin digestion and use of the vascular system as a carrier; the 
use of vectors as an infection-spreading tool; and inoculation in tissue or blood. They 
all evade immune system responses and cause necrosis and fibrosis to vital tissues 
and organs. 
Looking at genomes, transcriptomes, and proteomes, these diverse pathogens 
appear to be utilizing similar molecules to perform similar biological mechanisms. 
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Therefore, it is of interest to ascertain whether a cross-cutting approach in research 
could facilitate a better understanding of these illnesses. Thus, the initial aim of this 
work was to examine molecular parallels of the mechanisms used by a variety of 
tropical disease pathogens, including parasites, snake venom toxins, and 
haematophagic parasite vectors, to access their host’s blood stream. 
To fulfil this target, S. mansoni and F. hepatica parasites and An. gambiae 
salivary glands were compared to major toxin (proteases and other proteins) in snake 
venom. Both S. mansoni and F. hepatica parasites have a migratory phase in which 
the parasite secretes proteolytic enzymes to break through tissue layers. In addition, 
adult S. mansoni live within the vascular system grazing on digested haemoglobin, 
avoiding haemostatic and immunological attack from blood components. Both 
parasites destroy the tissue surrounding the eggs of schistosomes and adult fasciola, 
and change the nature of the surrounding tissue structure causing necrosis and/or 
fibrosis. To do so, they use proteases that perform a similar function to their 
analogues in snake venom. Further, mosquito saliva has a wide range of proteins that 
help the insect to suck blood avoiding the danger of death by the bitten individual; 
these components have been found to share a similarity with snake venom. 
In order to identify the molecular parallels between the proteases described 
above we designed a bioinformatics-led approach to investigate the transcriptomes of 
distinct S. mansoni life stages, F. hepatica adult, and mosquito sialome using 
publicly available data. This was followed by an investigation of the identified 
proteins expressed by these parasites, mosquitoes, and venom. After determining the 
shared molecules and their function in each pathogen, we subsequently aimed to 
examine the ability of antivenoms, used to prevent toxic effects of venom toxins, to 
neutralize homologous proteins in parasites and mosquito saliva using 
immunological tests.  
The secondary aim of this research was to investigate opportunities of using 
homologous proteins in parasites, parasitic vectors, and snake venom as therapeutic 
applications. Molecules secreted and produced by these different pathogens have 
complex effects on human physiology, thus as an added benefit, these products may 
serve as the basis for novel therapeutic strategies. Consequently, we aimed to 
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construct chimeric epitopes of homologous snake venom (E. ocellatus) and mosquito 
salivary proteins as the primary vaccine and test whether boosting with proteins 
delivered by mosquito bites induces protective immunity against snakebites. This 
unique approach utilizes and exploits natural immunogens to stimulate sustained 
levels of protective immunity against vaccine-preventable diseases, with a particular 
focus on snakebite envenoming. 
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1.5 Materials 
1.5.1 Parasites  
1.5.1.1 Schistosoma mansoni life cycle stages and preparation 
All S.mansoni life cycle stages were homogenised samples (cercaria, 
cercarial transformation fluid (CTF), schistosomula, adult worm and soluble egg 
antigens (SEA)) and generously provided by Prof. Mike Doenhoff, University of 
Nottingham. 
 
1.5.1.1.1 Reduced samples 
50 µl of parasite homogenate (or 2.3µg/µl of total protein) per sample were 
solubilised in 250 µl of 0.02 M phosphate buffered saline (PBS) pH 7.2, incubated 
on ice for 30 minutes then centrifuged for 1 hour at 4 °C, 13,000 rpm. The 
supernatant was collected and aliquot to 50 µl in each tube. 2X protein loading 
buffer (PLOB), containing the reducing agent, β-mercaptoethanol, which act to 
further denature proteins by disrupting intra and inter molecular disulphide bridges, 
was added at volume of 12.5 µl for each aliquot, boiled for 5 minutes followed by 
quick cool down and re-centrifuged for 1min.  
 
1.5.1.1.2 Non-reduced samples 
The same protocol described above (reduced samples) was used to prepare 
non-reduced sample proteins. However, the loading buffer was prepared without 
reducing agent (5% β-mercaptoethanol). 
 
1.5.1.1.3 Native proteins 
  50 µl of pre-prepared parasite homogenate were added to 12.5 µl of 
native protein loading buffer, boiled for 2 minutes followed by quick cool down and 
quick centrifugation at 4 °C, 13,000 rpm.  
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1.5.2 Fasciola hepatica 
Fasciola hepatica parasites were a gift from Dr. James Lacourse. Flukes 
were stored at – 80 °C until prepared. The whole worm was homogenised in 
homogenisation buffer as described in Appendix I. The homogenates were prepared 
using the same preparation protocols used for S.mansoni. 
 
1.5.3 Anopheles gambiae salivary glands 
Females An. gambiae were raised and kept in Liverpool School of Tropical 
Medicine insectary. Salivary glands were dissected in 0.02 M PBS pH 7.2 and stored 
at – 80 °C. The pooled salivary glands were homogenised using tissue homogenizer 
on ice, vortex for 30 seconds then centrifuged for 30 minutes at 4°C, 13,000 rpm. 
The resulting supernatant was aliquoted and stored at – 20 °C. The preparation of the 
sample for electrophoresis and immunoblotting was as described above for the 
Schistosoma life cycle stages.  
1.5.4 Snake venom 
All venoms used in this study were extracted from snakes maintained in 
herpetarium at the Alistair Reid Venom Research Unit in Liverpool School of 
Tropical Medicine under special dietary and climatic conditions. Paul Rowley and 
Dr Rob Harrison conducted the venom extractions.   
The following snake venoms were used in this study: Echis ocellatus, Echis 
pyramidum leakey, Bitis arietans, Naja haje, Naja nigricollis, Naja pallida, 
Dendroaspis angusticeps, Acanthophis antarcticus. Lyophilized venom samples 
were reconstituted at a concentration of 10mg/ml in 1X phosphate-buffer (1XPBS) 
and stored at -80oC. Before venom protein analysis on SDS-PAGE gel, samples were 
diluted to a final concentration of 1mg/ml in 2X PLOB. For non-reduced samples, 
non-reduced 2X PLOB was added and both (reduced and non-reduced samples) 
prepared as described above. 
All buffers and stock solutions used throughout the course of this 
experimental work can be found in Appendix 1. 
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1.5.5 Human sera and immunoglobulins 
In chapter 5 of this study we tested immune-cross reactivity between snake 
venom and purified human immunoglobulins; Malawian malaria patients IgGs, IgGs 
and IgM purified for therapeutic reasons, GAMMAGARDS and PENTAGARDS 
respectively, and whole serum collected from patients with schistosomiasis and 
filariasis infection. 
Purified immunoglobulins; Malawian malaria patients IgGs, 
GAMMAGARDS (IVIgG) and PENTAGARDS (IVIgM), were gifted by Dr Richard 
Pleass. 
IVIgG purified from malaria infected Malawians was obtained from blood 
donated for erythrocyte transfusions by 834 Malawian adults who were seronegative 
for anti-HIV antibodies (ELISA. Wellcome).  Plasma was air-freighted on dry ice to 
the Central Laboratory of the Swiss Red Cross Blood Transfusion Service in Berne, 
Switzerland. Samples negative for both HBsAg (Ausria II,Abbott) and anti-H IV 
antibodies (anti H IV- 1, EIA, Abbott; anti HIV- I + 2, EIA, Abbott) were pooled 
and submitted to the commercial process of immunoglobulin extraction. The process 
includes cold ethanol fractionation and pH4 treatment, both procedures shown to 
remove and or inactivate viruses (Taylor et al. 1992) 
GAMMAGARDS (IVIgG) was processed from the pooled plasma of 3000 
healthy donors and provided as freeze-dried preparation (Baxter Healthcare 
Corporation, USA) (Mekhaiel, Czajkowsky, et al. 2011). Similar, PENTAGARDS 
(IVIgM) prepared as pooled polyreactive normal IgM that contains >90% i.v. IgM 
(IVIgM) from plasma of >2500 healthy donors and provided as freez-dried 
preparation (Hurez et al. 1997; Kaveri et al. 2012). Prior experiments, the IVIgs were 
reconstituted in PBS to the desired dilution according to the experiment and kept 
sterile at 4°C. 
Schistosomiasis patients’ sera collected by Dr Russell Stothard group. 
Schistosomiasis patients’ sera were collected from two villages in Uganda; one has a 
high prevalence of infection (Bugoto) and the other with low prevalence (Lawanika) 
on two separate collections. The first was baseline collection before treatment and 
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the other one-year after treatment. These samples were a part of ongoing monitoring 
and evaluations of the Schistosomiasis Control Initiative (SCI) program in Uganda 
that started on 2003(Koukounari et al. 2006; Zhang et al. 2007; Balen et al. 2006).  
 
Dr Mark Taylor’s group in Liverpool School of Tropical Medicine 
generously provided filariasis patients’ sera, symptomatic and asymptomatic 
(Hoerauf et al. 2003). The samples were collected during a study held in Ghana. In 
an endemic area for lymphatic filariasis in the Western Region of Ghana at which 
mass treatment with drugs had not started, 78 men and 15 women aged 18–55 years 
with a minimum microfilaremia of 40 mf/ml were selected in six villages. The 
selected villages have no other human filarial species endemic. Exclusion criteria 
were applied as follow; abnormal hepatic and renal profiles (alanine 
aminotransferase >30 U/l; c-glutamyl-transpeptidase >28 U/l; creatinine >1.2 mg/ 
100 ml) measured by dip-stick chemistry (Reflotron, Roche Diagnostics, Mannheim, 
Germany), body weight <40 kg, alcohol or drug abuse, chronic medication, 
pregnancy or breast feeding in females, and the mental inability to understand the 
explanations of the study design. All participants gave informed consent (Hoerauf et 
al. 2003). 
1.6 Methods  
1.6.1 SDS-PAGE gel preparation and electrophoresis  
Samples homogenates were size-separated by SDS-PAGE (15%) according 
to manufacturer’s recommendations (BioRad, UK). 1mm glass plates were 
assembled using the mini-Protean electrophoresis system (BioRad, UK). 1mm 15% 
polyacrylamide resolving gels (for 4 gels: 7.5 ml dH2O, 5ml 1.5M Tris pH 8.8, 7.5ml 
40% Bis Acrylamide, 200µl 10% SDS, 120µl 10% ammonium persulphate (APS) 
and 14µl TEMED) were prepared, poured into the glass plates and overlaid with 
dH2O in order to remove any bubbles and prevent drying. The gels were allowed to 
polymerize for 45 min. Following polymerization, dH2O was removed and stacking 
gel mixture (for 4 gels: 5ml dH2O, 2ml 0.5M Tris pH 6.8, 350µl 40% Bis 
Acrylamide, 30µl 10% APS and 5µl TEMED) was loaded on top of polymerized 
resolving gel and a 15-well 1mm comb was inserted between the plates. Again, the 
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stacking gel was allowed to polymerise for an additional 45 min. Electrophoresis 
was carried out using a mini-Protean cell (BioRad, UK) at 200V for 45 min to 1 hour 
in 1X Tris-glycine-SDS (TGS) running buffer. A standard broad range molecular 
weight protein marker ranging between 10 to 225kDa (Promega, UK) (5µl) was run 
alongside 5µl of samples used in this work in order to give an indication of the 
molecular weight of the proteins in the samples. Separated samples on 15 % gels 
were stained with Coomassie Blue R-250 overnight and destained with Coomassie 
destain solution until clear. 
 
1.6.2 Immunoblotting 
After protein concentration optimization was done, new SDS-PAGE gels 
prepared loaded with 5µl of each sample and electro-blotted to 0.45µm nitrocellulose 
membranes as described in the manufacturer’s protocols (BioRad, UK).  
Immunoblotting was used to detect specific proteins in parasites, mosquitoes’ 
salivary glands and venom that were immunoreactive to antivenoms, toxin-specific 
antibodies and human sera and immunoglobulins. Following separation of proteins 
on 1D SDS-PAGE (conducted as described in the previous section), the 
polyacrylamide gel was sandwiched together with a 0.45 µm nitrocellulose 
membrane (BioRad, UK) between two double layers of filter paper and foam 
padding. Then the sandwich was inserted into a cassette and placed into an 
immunobloting transfer tank (BioRad, UK) filled with immunotransfer buffer (2.03g 
Tris, 14.26g glycine, 800ml H2O and 200ml methanol). After one hour of electro-
transfer at 100V with continuous mixing by a magnetic stirrer, the transfer of 
proteins from the SDS-PAGE gel onto the nitrocellulose membrane was complete. 
During electo-transfer an ice block was inserted into the transfer tank to prevent the 
buffer from overheating during the process. 
Bands on the nitrocellulose membrane were visualized using 1X Ponceau S 
dye to check the efficiency of electro-transfer and to enable labeling of markers and 
sample well lanes. After that, membranes were thoroughly rinsed in 1X Tris-
buffered saline Tween-20 (TBST) to remove the Ponceau S dye. Following washing 
steps, the membranes were blocked by overnight incubation in blocking buffer (5 % 
non-fat milk in TBST) to reduce non-specific protein binding. The following day the 
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strips were washed 3 times in TBST over 60 minutes and incubated with Blocking 
buffer (details in Appendix I) for 3 hours and then incubated overnight with the test 
antibodies (variety of polyclonal and monoclonal snake antivenoms, toxin specific 
IgGs and human sera and immunoglobulins) (table 4.1) at concentration ranging 
from 1:1000 and 1:5000 for antivenoms and 1:100 to 1:200 for the rest in blocking 
buffer. Blots were washed with TBST as described above and incubated for 1 hour 
with secondary antibodies (rabbit anti-horse, donkey anti-sheep, goat anti-mouse and 
anti-human IgG) (1:1000 dilution) coupled to horseradish peroxidase (HPR). 
Visualization of the results was performed using a 3,3’-Diaminobenzidine 
peroxidase (DAB) peroxidase substrate (Sigma, UK) after washing with TBST. 
1.6.3 Mass spectrometry 
1.6.3.1 In-gel trypsin digestion 
Protein bands from the immunocross-reacteive proteins from the parasites 
and mosquito samples were excised from one-dimensional SDS-PAGE gels. The 
bands were destained and in-gel trypsin-digested as described by Hayter et al 
(Hayter et al. 2003).  The protein plug was excised from 1D SDS-PAGE gel using 
fine scalpel and transferred to a 1.5 ml microcentrifuge tube. To destain the plug and 
remove all traces of Coomassie stain, 20-50µl of distaining solution containing 50 
mM Ammonium bicarbonate/ 50% (v/v) acetonitrile (AmBic/ACN) was added and 
incubated for 10 minutes at 37°C. This step was repeated by replacing the solution 
with a fresh one until no stain remains in the plug and the gel is transparent. Once 
destained, 20µl of 10mM dithiotheritol (DTT) reducing agent was added to each tube 
and incubated at 37 °C. After 30 minutes, DTT was removed and the samples were 
alkylated by incubating them in 20µl of 55mM iodoacetamide (IAN) at 37 °C for 30 
minutes in the dark. Following that, the plugs were dehydrated using 10µl of 100% 
ACN, and the incubation continued for 15 minutes. After dehydration, the 
supernatant was removed from the plug (should turn white) and the remaining 
solvent was allowed to air dry at 37°C. Once dry, 10µl of 1:10 trypsin (stock 
prepared by re-suspending 25µg proteomics grade trypsin (Sigma, UK) in 50mM 
acetic acid) in 50mM ammonium bicarbonate/ 50% ACN (giving a final 
concentration of 0.1µg/µl) was added and incubated for 1 hour at 37°C. The 
digestion was allowed to continue overnight after the addition of 10µl of the trypsin 
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solution. The next day, the reaction was halted by the addition of 2µl of 2.6M formic 
acid. The digested bands were then dried in a SpeedVac centrifuge and stored at -
20°C. Prior to analysis, the bands were rehydrated in 50µl HPLC-grade water, 
sonicated for 15 minutes and centrifuged for 20 minutes at 13,000 rpm. 
1.6.3.2 HPLC- tandem mass spectrometry (HPLC-
MS/MS) and protein identification using bioinformatics tools 
In order to identify parasite and mosquito salivary gland proteins that showed 
immunocross-reactivity to anti-venom, homogenated samples (5mg/ml solution in 
0.1% formic acid mobile phase buffer) were centrifuged for 20 minutes at 13,000 
rpm. The LC-MS/MS analysis was performed as described by Currier et al (Currier 
et al. 2010). Using Ultimate 3000 system (Dionex, UK), the samples were fractioned 
in the first diminution using ion exchange 2mm x 50mm ProPac ® SCX-10G 
column over a gradient (600-900mM NaCl in 0.1% formic acid, pH 2.3) at a flow 
rate of 60µl/min. The generated fractions (20 per sample) were subjected to second 
dimension fractionation using a 300µm I.D> x 15 cm capillary LC ion-exchange 
column packed with 3µm PepMap™ C18 stationary phase. The gradient used for 
this stage was 2-90% acetonitrile in 0.1% formic acid over 50 min at a flow rate of 
300nl/min. Peptides eluted from the above process were analysed on an LCQ Deca 
XP Plus Mass spectrometer (ThermoFisher, UK), operating on a ‘triple play’ mode 
(zoom scan followed by MS/MS). 
The identification of proteins was performed using Proteome Discoverer 
1.0.0 (ThermoScientific) software, by screening LC-MS sequence data against Uni-
prot database incorporating both Sequest (ThermoScientific (Yates III et al. 1996)  
and Mascot (Matrix Science Ltd, UK (Perkins et al. 1999) search algorithms.  For 
the analysis, 1.5Da parent mass tolerance was used, allowing for 1 missed cleavage. 
For modifications, carbamidomethylation of cysteine was fixed and oxidation of 
methionine was variable. The degree of confident was optimized as follow, high 
confidence peptide matches for Sequest were filtered with an XCorr cut-off (+1 > 
1.5, +2 > 2 and +3 > 2.5) and for Mascot, an Exp value of less than 0.01 specified a 
confident peptide match (Currier et al. 2010). 
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1.6.4 Enzyme-Linked Immunosorbent Assay (ELISA) 
1.6.4.1 End-point ELISA titration 
Assays were prepared using 100ng of venom from Echis pyramidum leakey 
per well. 30µl diluted venom (1mg/ml in PBS) was added to 30ml of coating buffer 
(1.59g Sodium carbonate Na2CO3, 2.93g Sodium bicarbonate NaHCO3, 0.2g Sodium 
azide NaN3, 1L H2O at pH 9.6) to give a final concentration of 1ng/µl then loaded to 
a 96 well ELISA plate. The plate was then wrapped in cling film and incubated 
overnight at 4°C. The following day, the plate was washed with TBST six times then 
non-specific protein binding blocked with 100 µl 5% non-fat milk (blotto) (diluted 
with TBST – 0.01M Tris- HCl, pH 8.5; 0.15M NaCl; 1% Tween 20) for 3h at room 
temperature (RT) wrapped in cling film. After 3h the plate washed six times in 
TBST and incubated with the test antibodies (human immunoglobulins and parasitic 
patients sera (purified human immunoglobulins; Malawian malaria patients IgGs, 
IgGs and IgM purified for therapeutic reasons, GAMMAGARDS and 
PENTAGARDS respectively, and serum collected from patients with 
schistosomiasis and filariasis infection) prepared as follows: each well of the the 
plate was loaded with 100µl blotto except for the first wells (first column). The first 
column was loaded with 150µl of 1:10 diluted primary antibody followed by 1:2 
serial dilutions the method was repeated across the wells of the plate until the one 
before the last, where 50µl is removed and discarded. The last row of the plate was 
left with blotto only as a control. Then the plate was wrapped in cling film and 
incubated overnight at 4°C. The next day the plate was washed again in TBST as 
described previously and incubated in horseradish peroxidise-conjugated goat anti-
human IgG (1:1000; Sigma, UK) for 3 h at RT. Results were visualized by addition 
of substrate (0.2% 2,2/-azino-bis (2-ethylbenzthiazoline-6-sulphonic acid) in citrate 
buffer, pH 4.0 containing 0.015% hydrogen peroxide; Sigma, UK) and measurement 
of optical density (OD) at 405nm. End point titres were determined by the 
immunoglobulin/ sera titre that exhibited OD readings greater than three standard 
deviations of the control reading. 
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1.6.4.2 Relative avidity ELISA 
Plates were coated with E. p.leakeyi venom as described above and incubated 
overnight at 4°C with 1:10 for immunoglobulins and 1:50 for sera (the avidity titres 
were optimized according to end-point titres and amount of sera available). After 
washing with TBST, 0.1ml of the chaotrope, ammonium thiocyanate (that disrupts 
protein-protein bonds and therefore used here a measure of the strength of antibody-
antigen binding) was added to the wells in a range of concentrations (0–8 M) for 
15min followed by washing in TBST prior to the addition of the secondary antibody. 
Plates were washed, and all subsequent steps were the same as the end-point ELISA. 
Relative avidity was expressed as the avidity-index of ammonium thiocyanate 
concentration at which 50% of the bound antibodies are eluted off.  
 
1.6.5 PNGase F enzyme Deglycosylated venom blots 
In eukaryotic cells glycosylation is a major post-translational modification 
(Bekri, 2006). There are several pathways for protein modification with sugars 
(glycans), the most common being the addition of glycans to an asparagine (N-
linked) or to a serine or threonine (O-linked) residue in the secretory compartment 
(ER and Golgi). 
This protocol describes the enzymatic removal of glycans from venom 
protein using PNGase F (BioLabs, UK). This experiment was done to determine if 
post-translation modification of venoms (Echis ocellatus, Echis pyramidum leakey, 
Bitis arietans, Naja haje, Naja nigricollis, Naja pallida, Dendroaspis angusticeps, 
Acanthophis antarcticus) is affecting the cross reactivity with human sera and 
immunoglobulin. PNGase F is able to remove most N-glycans, while the enzymes in 
the Protein Deglycosylation Mix [PNGase F, O-Glycosidase (Endo-α-N-
Acetylgalactosaminidase) and other enzymes] remove N-glycans, short O-glycans, 
and certain long chain O-glycans. 
The venom-deglycosylation enzyme mixture was prepared as described by 
manufacturer (BioLabs, UK). The following components were mixed in 0.5ml 
eppendorf tube: 14µl venom (140µg) was mixed with 2µl 10X denaturing buffer and 
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4µl dH
2
0. The mixture was prepared and the entire solution components were kept 
on ice. The mixture was then boiled at 100°C for 10min. After that 4µl 10X G7 
buffer, 4µl 10% NP-40, 1µl PNGase F and 1µl dH
2
0 were added to the mixture. Then 
the mixture was incubated for 1hr at 37°C. At the end of incubation time 100µl of 
reduced 2X PLOB (40µl 2X PLOB and 60µl PBS) was add to the 30µl 
deglycosylated venom sample and boiled for 2mins. 10µl of each sample were 
loaded on a 15% SDS-PAGE gel were the first lane was loaded with 10µl of protein 
marker.  
 
1.6.6  Ethical declaration 
All animal experimentation conducted during the course of this work was 
undertaken using standard protocols approved by the Liverpool School of Tropical 
Medicine and University of Liverpool Animal Welfare Committee and performed 
with the approval of the UK Home Office under project license #40/3216. 
For filariasis patients’ sera, the Ethical Committee of the School of Medical 
Sciences of the University of Science and Technology, Kumasi, Ghana approved the 
study. Study procedures were in accordance with the Helsinki Declaration of 1975 
(as revised 1983 and 2000). Pfizer Inc. (Karlsruhe, Germany) provided VibramycinÒ 
tabs (Hoerauf et al. 2003). 
For schistosomiasis patients, ethical clearance was obtained from the 
Ugandan National Council of Science and Technology and Imperial College 
London. For ethical reasons, it was not appropriate to include any untreated control 
groups in the study design. 
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Chapter 3   Bioinformatics analysis to identify shared molecules in 
Schistosoma mansoni, Fasciola hepatica and snake venom 
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3.1 Introduction 
  Understanding the molecular functions used by microorganisms and 
identifying new therapeutic targets has been increasingly accomplished and 
rationalized using genomic and bioinformatics tools. In this study, we focus on 
identifying similarities between two kinds of proteases—those that are used by 
parasites to migrate through host tissue compartments, evade the immune system, 
digest host blood and disturb the infected individual’s haemostatic mechanism, and 
those present in snake venom that lead to the victim’s local and systemic pathology.  
Schistosome parasites use several serine proteases to facilitate vital biological 
function. They use cercarial elastase, a chymotrypsin serine protease, as a major 
invasive larval protease during host skin penetration (Ingram et al. 2012; Salter et al. 
2002). Another type of serine protease was identified in schistosome cercaria and 
adult stage, the SmSp1, a kallikrein-like serine peptidase (Cocude et al. 1997; El-
Ansary 2003; Kasný et al. 2009). Kallikrein-like peptidases participate in a variety of 
physiological functions such as processing of bioactive peptides or blood 
coagulation (Kasný et al. 2009). In schistosome SmSp1 was localized on the surface 
of male worms and in parenchyma of both sexes suggesting a role of SmSP1 is in 
modulation/evasion of the host immune response (Cocude et al. 1997; Kasný et al. 
2009). In parallel, snake venom serine proteases (SVSP) play a pivotal role in 
affecting the haemostatic system (Serrano and Maroun, 2005). They act on a 
variation of coagulation cascade components, on the fibrinolytic and kallikrein–kinin 
systems and on cells to cause an imbalance of the haemostatic system of the prey 
(Serrano et al. 1998). 
Metalloprotease is another protease utilized in several vital processes in 
parasitism and envenomation. In trematode parasites (schistosome and fasciola) 
metalloprotease (leucyl aminopeptidase and dipeptidyl peptidase III) have potentially 
crucial roles in parasite nutrition (hemoglobin digestion) and maintenance of 
tegumental structure (dismantling, degradation and turnover of the protein 
components of the membrane) (Day and Chen, 1998; Kasný et al., 2009; McCarthy 
et al., 2004). It’s expressed in the early invasive stages of the parasite as well as adult 
stages and egg (McCarthy et al. 2004; Kasný et al. 2009). On the other hand, snake 
venom metalloproteases (SVMP) induce hemorrhage or disruption of the hemostatic 
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system, which are primarily mediated by the proteolytic activity of the M domain 
(Takeda et al. 2012). Hemorrhage is induced by disturbing the interactions between 
endothelial cells and the basement membrane through the degradation of endothelial 
cell membrane proteins and basement membrane components (Markland and 
Swenson 2013). While targeting blood coagulation proteins disturbs the hemostatic 
system (Takeda et al. 2012; Morita and Iwanaga 1981). 
Other peptidases and enzymes like aspartic protease (Koehler et al. 2007; 
Schulmeister et al. 2005; Wagstaff & Harrison 2006) and phoshpholipase A2 (Rogers 
et al. 1991; Kini 2003) also found to have a pivotal role in essential and ingenious 
mechanisms that insure sustainability and succession of infection/envenomation. 
Given the potential similarities between proteases found in parasites and 
those comprise major toxin proteins in snake venom and to improved understanding 
of molecules that are critical to success of parasitism/envenomation, the 
transcriptomic data of S. mansoni, F. hepatica and snake venom (Echis ocellatus) 
was bioinformatically investigated. The assembled contig library of each life stage of 
S. mansoni (cercaria (SCAP), 7-day schistosomula (SLAP-7), lung-stage 
schistosomula (SLAP), 21- and 28-day adult (SWAP-21, SWAP-28), and egg stages 
(SEA)) and of F.hepatica adult stage (FAP) that involved in migrating or causing 
pathological damage to the host was selected for this study. These stages were 
selected as they use at least one type of protease in their biological functions such as 
migration for cercaria and schistosomula and blood digestion for adults. 
Transcriptomic data has provided opportunities for a more rational approach to 
expanding our perspective of parasite biology and gaining a better understanding of 
processes such as host-parasite interaction in order to propose drug targets and 
vaccine candidates for parasitic diseases and to study evolution and comparative 
genomics, transcriptomics and proteomics (DeMarco & Verjovski-Almeida 2009; 
Protasio et al. 2012; Nahum et al. 2012; Wilson et al. 2007). In silico and 
bioinformatics studies have revealed the possibility of identifying important novel 
proteins and proteases. Recent technological improvements in cDNA sequencing 
using next generation sequencing (NGS) platforms have permitted the development 
of various new strategies for high-throughput automated sampling of DNA and 
cDNA. These developments have supported an exponential increase in the number of 
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sequences available in public databases, thus increasing the yield of biological 
information that facilitates the identification of molecules playing a key role in 
biological pathways or processes that could become targets for new parasitological 
therapy (Young et al. 2010).  
Briefly, expressed sequence tags (ESTs) assembled as contigs for the 
different S. mansoni life stages and F. hepatica (SCAP, SLAP-7, SLAP, SWAP-21, 
SWAP-28, SEA and FAP) were downloaded from schistodb website 
(ftp://ftp.sanger.ac.uk/pub/pathogens/maa/S.mansoni/ESTs/) and adult-stage F. 
hepatica (FAP) from 
(ftp://ftp.sanger.ac.uk/pub4/pathogens/Fasciola/hepatica/ESTs/) and compared the to  
available transcriptomic data for E. ocellatus (Eo-db), developed at the Alistair Reid 
Venom Research Unit (Wagstaff and Harrison 2006). First, the databases were 
blastp-searched against the Echis ocellatus venom database (Eo-db) to explore the 
presence of similarity and conservation between transcriptome of parasites and snake 
venom. Next, ESTs encoding parasite proteins that shared similarity with snake 
venom were analysed using the multiple alignment program Constraint-based 
Multiple Protein Alignment Tool (COBALT) available at 
(http://www.ncbi.nlm.nih.gov/tools/cobalt/). Then, functional annotations of the 
parasites and snake venom databases were compared to gain more information for 
understanding the functions of transcriptomic data of the parasites and venom using 
molecular function Gene Ontology (GO) terms. Gene Ontology (GO) is a controlled 
vocabulary of terms for describing behavior of genes and their products (Harris et al. 
2004), which is valuable to measure gene functional similarity. The data were 
analyzed using Blast2GO software.  The Blast2GO suite is a comprehensive 
bioinformatics tool for functional annotation of sequences and data mining on the 
resulting annotations, mainly based on the gene ontology (GO) vocabulary (Conesa 
& Götz 2008). 
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1.7 Methods 
 
1.7.1 Data 
A total of 15,240 S. mansoni contigs assembled in FASTA format sequence 
data. The data was separated according to life stage (cercaria (SCAP), 7-day 
schistosomula (SLAP-7), SLAP, 21- and 28-day adult (SWAP-21, SWAP-28) and 
soluble egg antigen (SEA)). These assembled contiguous sequences are available on 
the schistodb website (ftp://ftp.sanger.ac.uk/pub/pathogens/maa/S.mansoni/ESTs/). 
Further, to identify putative homologues between trematodes (S. mansoni and F. 
hepatica) and snake venom proteases, 3332 EST sequences from adult-stage F. 
hepatica (FAP) (ftp://ftp.sanger.ac.uk/pub4/pathogens/Fasciola/hepatica/ESTs/) 
were also downloaded as FASTA file. The parasites databases were pairwise blasted 
against E. ocellatus (Eo-db), developed at the Alistair Reid Venom Research Unit 
(Wagstaff and Harrison 2006). BLAST search of parasites contiguous sequences 
were undertaken using an Intel, dual 2.8GHz RedHat Enterprise Linux 9.0 
workstation running Biolinux 6.0 (available at http://envgen.nox.ac.uk) gainst E. 
ocellatus (Eo-db) data. BLASTp was performed using the command: (blastall –i 
schistosma_proteases.fasta –d echis_ocellatus_data.fasta –p blastp –o 
schistosoma_vs_echis.txt –v 10 –b 10) at e-value of 1e-05. Retrieved parasites 
sequences were aligned to parallels from snake venom databases using the 
CLUSTAL alignment tool in Jalview a free program for multiple sequence 
alignment editing, visualization and analysis (available at; http://www.jalview.org) 
(Waterhouse et al. 2009). 
1.7.2 Blast2GO software  
The functional annotation of the parasites and snake venom transcriptome 
were compared using Blast2GO software. Blast2GO software suite is a 
comprehensive and integrated bioinformatics tool for the automatic, high-
throughput, functional annotation of DNA or protein sequences and data mining for 
the resulting annotation, on the basis of GO vocabulary (Götz et al. 2008). GO 
annotation in this software proceeds through BLAST searches against sequence 
databases, mapping of homologue sequences to GO terms and final GO term 
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assignment using the Blast2GO annotation rule (Conesa and Götz, 2008; Götz et al., 
2008). Annotation algorithm used by this software took multiple parameters into 
account such as sequence similarity, BLAST HSP (highest scoring pair) length and 
e-values, the GO hierarchical structure and GO term evidence codes (Götz et al. 
2008). The parameters and the steps used by the program in this analysis are 
described in Figure 3.1. 
 
Figure 0.1 a. Blast2GO project phases; b. parameters used in B2GO analysis. 
1.8 Results  
1.8.1 BLAST and the alignment of S. mansoni and F. hepatica 
ESTs with snake venom ESTs 
To initiate our investigation on the shared molecules between parasites, 
proteases and snake venom and to detect similarities in sequences representing these 
proteases, we carefully searched the literature for the types of proteases present in 
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parasites and their functions. We were mainly considering parasites proteases that 
are belong to the same protein family that major snake venom toxin proteases belong 
to. Several proteases found to be vital for the initiation of parasitism and the 
sustainability of parasite infection were identified. Of these, serine proteinases like; 
cercarial elastase (Newport et al. 1988; Salter et al. 2002), SmSP1, a kallikrein-like 
serine peptidase (Rawlings et al. 2008; Cocude et al. 1997) and SmDPP IV (Curwen 
et al. 2006). Metalloprotinases like; leucyl aminopeptidase (LAP) (Burley et al. 
1990) and dipeptidyl peptidase III (DPP III) (Verjovski-Almeida et al. 2003) have 
been extensively characterized. Other trematode proteases have been annotated in 
EST databases, for example, cysteine peptidases (Robinson et al. 2008) and aspartic 
peptidases (Wong et al. 1997).  
Next, to determine whether there were regions of similarity that may be a 
consequence of functional relationships between protein sequences of trematode (S. 
mansoni and F. hepatica) proteases and snake venom proteases, the constructed 
databases populated from publicly available assembled contigs of schistosome 
proteases and the available fasciola adult-stage data were blasted against the protease 
data of snake venom (Echis ocellatus) (Wagstaff and Harrison 2006). The present 
dataset was subjected to blastp analysis using an Intel, dual 2.8GHz RedHat 
Enterprise Linux 9.0 workstation running Biolinux 6.0 (available at 
http://envgen.nox.ac.uk) to identify putative orthologous between trematodes (S. 
mansoni and F. hepatica) and snake venom proteases. 
Several schistosome proteases were showed to be orthologous to major toxic 
proteases sequences in snake venom (Figures 3.2-3.3). Interestingly, cercarial 
elastase—the serine protease critical for the initiation of schistosomiasis infection 
(Salter et al. 2000)—bore sequence similarities to snake venom serine protease using 
permissive (E-value <1E−05). Cercarial elastase is a clan SA trypsin family serine 
protease able to cleave insoluble elastin, a major component of the dermis of skin 
(Salter et al. 2002). Although the maximum identity per cent between parasite 
protease and venom protease was found to be 25%, which is low in term of 
homology, however, it contains local regions that represent homology. Moreover, 
these homologues regions contain two motifs that are known to surround serine 
proteinase evolutionary markers and active site residues for the S1 family of clan 
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SA, TAAHC around His57, DIAL around Asp 102, GDSGGP around Ser195 and 
GIVSW for Ser214 (the residues’ numbers are according to chymotrypsinogen 
numbering) (Krem and Di Cera 2001) (Figure 3.2). 
          
 
Description Max score Max score Query cover E value Max ident Accession 
gi|205275149| serine 
protease Echis ocellatus 
57.8 57.8 97% 2e-14 25% CAQ72889.1 
gi| 293491172 | serine 
protease Echis ocellatus 
53.1 53.1 97% 5e-10 25% ADE45140.1 
gi| 297593738 | serine 
protease Echis ocellatus 
52.4 52.4 96% 8e-10 24% ADI47552.1 
Figure 0.2 Multiple sequence alignment of S. mansoni cercarial elastase with Echis ocellatus serine 
protease isoforms. Comparative CLUSTAL (Jalview) sequence alignment of cercarial elastase (gi|256048737| 
with Echis ocellatus (gi|205275149|), (gi|293491172|) and (gi| 297593738 |) serine protease. Identities are 
higlighted in blue. Red shades highlight motifs known to surround serine proteinase evolutionary markers and 
active site residues for the S1 family of clan SA.        
 
 
Similarly, metalloprotease from parasites, specifically A Disintegrin And 
Metalloproteinase 17 (ADAM17) peptidase, displayed similarities with group III 
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snake venom metalloproteinase (SVMPs). The maximum identity per cent between 
the two proteins was 53% (Figure 3.3). Several motifs showed conservation between 
the two proteins; AHEMxGHSxGxxHD, the two-histidine motif, which embedded in 
an active-site α-helix. In SVMP this motif lay within the metalloproteinase domain 
(Takeda et al. 2012). In this motif the glutamic acid or glu (E) is the catalytic residue 
(Gomis-Rüth 2003).  In addition, another motif the GEECDxG that lay within the 
disintegrin domain in SVMP showed to be conserved between parasites and snake 
venom. The GEECDxG exhibited conservation between SVMPs and have high 
potential immunogenicity (Wagstaff et al. 2006). In general, SVMPs are grouped 
with the ADAMs protein family (Casewell 2012). However, ADAMs contain 
domains that are absent in SVMPs and they are widely recognised as highly diverse 
proteins with functional roles involving the shedding of membrane-bound protein 
domains and acting as molecular switches that activate other proteins by proteolysis 
(White 2003; Casewell 2012). 
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Description Max score Max 
score 
Query cover E value Max ident Accession 
gi|83523646| Group III snake 
venom metalloproteinase 
Echis ocellatus 
62.8 132 73% 2e-14 53% CAJ01689.1 
gi|297593844| Snake venom 
metalloproteinase Echis 
ocellatus 
56.6  
 
56.6  
 
22% 4e-
10 
 
 
30% ADI47605.1 
gi|297593932| Snake venom 
metalloproteinase Echis 
ocellatus 
56.2 56.2 22% 5e-10 30% ADI47649.1 
Figure 0.3 Multiple sequence alignment of S. mansoni, ADAM17 peptidase, with Echis ocellatus, 
Group III snake venom, metalloproteinase. Comparative CLUSTAL (Jalview) sequence alignment of 
schistosome ADAM17 peptidase (gi|256088937| with Echis ocellatus (gi|83523646|) Group III snake venom 
metalloproteinase, (gi|297593844|) and (gi|297593932|) snake venom metalloproteinase. Identities are 
highlighted in blue. Red shades highlight conserved motifs within the metalloproteinase domain of the protein. 
1.8.2 Blast2GO Gene Ontology (GO) terms prediction 
To gain a basic understanding of the protein functions in which they are 
involved and to better understand parallel functions between parasites and snake 
venom, molecular function GO terms were assigned to the constructed databases. 
Gene ontology provides structured, controlled vocabularies and classifications 
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covering different domains of molecular and cellular biology (Harris et al. 2004). 
The GO of parasites’ peptidases was compared to the ontology of snake venom (E. 
ocellatus) peptidases. A total of 15,240 S. mansoni assembled EST contigs (average 
sequences length of 666 ± 194 bp) and 737 F. hepatica ESTs (average sequences 
length of 572± 143 bp) were subjected to GO annotation. The details of parameters 
used in this investigation are demonstrated in Figure 3.1. The successive annotation 
of the inferred proteins revealed a total of 3446 molecular function GO terms for the 
six different life stages of S. mansoni and 345 for the F. hepatica adult worm; details 
of each life stage are shown in Table 1. The predominant terms for the S. mansoni 
life cycle stages were binding (GO: 0005488), followed by catalytic activity (GO: 
0003824) (Table 2). Similarly, binding (GO: 0005488) was the most abundant term 
for the F. hepatica adult worm, followed by protein binding (GO: 0005515) (Table 
5). 
Life stage Number of 
assembled 
contigs 
Average sequence 
length ± standard 
deviation 
Returning IP 
results 
Gene Ontology (molecular 
function) 
Cercaria  3967 438 ±  
6.44 
358 590 
Day 7 
schistosomula 
3101 723 ±  
246.72 
951 953 
Lung-stage 
schistosomula 
1364 633 ± 
9.22 
411 55 
21-day adult 371 904 ± 
164.60 
113 346 
28-day adult 450 845 ±  
220.40 
332 384 
Egg  5987 454 ±  
8.23 
608 1118 
Fasciola adult 737 572 ±  
143 
- 354 
Table 0.1 Summary of the assembled contig data for the different life stages of S. mansoni and F. 
hepatica following a detailed bioinformatics annotation analysis. 
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From 3967 contigs of S.mansoni infective stage, the cercaria, that initiate the 
infection by penetration of host skin, a total of 590 molecular function GO terms 
were inferred. For proteases, metallopeptidase activity (GO: 0008237) was the 
predominant term with 0.18%, followed by cysteine-type peptidase activity (GO: 
0008234) with 0.10%. The frequency of serine-type peptidase activity (GO: 
0008236) was 0.08% and 0.03% for threonine-type peptidase activity (GO: 
0070003); however, no function was inferred for aspartic-type peptidase activity 
(GO: 0070001) (Table 3.2). A total of 358 proteins were predicted from cercaria 
contigs in InterProScan; 162 proteins were predicted as domain, 62 as conserved site 
and 93 as family, as well as others such as active site and binding site (Table 3.3). 
In 7-day schistosomula, which travel through skin layers to enter the host’s 
circulation from the dermal lymphatics and venules, 3101 assembled contigs were 
bioinformatically studied. A total of 953 GO molecular function terms were 
detected. However, unlike cercaria, all five types of proteases were identified in 7-
day schistosomula. Cysteine-type peptidases (GO: 0008234) were first, with 0.48%, 
followed by 0.26% for metallopeptidase activity (GO: 0008237) (Table 3.2).  
 
Of the total identified molecular function GO terms, aspartic-type peptidase 
activity (GO: 0070001) was highest with 0.16%, followed by serine-type peptidase 
activity (GO: 0008236) with 0.13% and threonine-type peptidase activity (GO: 
0070003) with 0.10% (Table 3.2). An InterProScan study revealed 951 different 
proteins, 416 of which were domain, 308 family and 96 conserved sites (Table 3.3). 
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GO code GO term Cercaria % 
Day 7 
schistosomula 
% 
Lung-stage 
schistosomula 
% 
Day 21 
adult % 
Day 28 
adult % 
Egg 
% 
GO:0003674 Molecular function 13.03 28.31 35.92 33.96 37.78 22.10 
GO:0005488 Binding 11.19 24.96 32.04 31.54 34.22 19.86 
GO:0003824 Catalytic activity 8.24 15.09 18.99 16.71 16.67 11.63 
GO:0016787 Hydrolase activity 5.14 7.32 10.12 7.55 7.33 6.10 
GO:0008233 Peptidase activity 0.45 1.32 1.91 1.89 1.11 0.68 
GO:0004175 Endopeptidase activity 0.33 1.06 - 1.08 0.44 0.45 
GO:0008238 Exopeptidase activity 0.05 0.10 - 0.27 0.22 0.13 
GO:0070001 Aspartic-type peptidase 
activity 
- 0.16 - 0.27 - - 
GO:0004190 Aspartic-type 
endopeptidase activity 
- 0.16 - 0.27 - - 
GO:0008234 Cysteine-type peptidase 
activity 
0.10 0.48 - 0.27 0.44 0.13 
GO:0004197 Cysteine-type 
endopeptidase activity 
0.08 0.39 - 0.27 0.44 0.08 
GO:0008237 Metallopeptidase activity 0.18 0.26 - 0.27 0.22 0.17 
GO:0004222 Metalloendopeptidase 
activity 
0.13 0.16 - 0.27  0.05 
GO:0008235 Metalloexopeptidase 
activity 
- 0.06 - - - 0.13 
GO:0004181 Metallocarboxypeptidase 
activity 
- - - - - 0.05 
GO:0008236 Serine-type peptidase 
activity 
0.08 0.13 - 0.27 0.44 0.12 
GO:0004252 Serine-type endopeptidase 
activity 
0.08 0.06 - - - 0.12 
GO:0070003 Threonine-type peptidase 
activity 
0.03 0.10 - 0.27 - 0.08 
GO:0004298 Threonine-type 
endopeptidase activity 
0.03 0.10 - 0.27 - 0.08 
GO:0070011 Peptidase activity, acting 
on L-amino acid peptides 
0.43 1.29 - 1.62 1.11 0.65 
GO:0004177 Amino-peptidase activity - 0.03 - - - 0.08 
GO:0016805 Dipeptidase activity - 0.03 - -  0.02 
GO:0004180 Carboxypeptidase activity 0.03 - - - 0.22 0.05 
GO:0004623 Phospholipase A2 activity 0.05 0.03 - 0.27 - 0.03 
Table 0.2 The three most abundant GO terms and a detailed description of the protease family’s GO 
terms. The percentage indicates the number of sequences with the described GO term out of the total number of 
sequences uploaded to the software.  
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Only 55 molecular function GO terms from 1364 assembled contigs of SLAP 
were characterised (Table 3.2). Although the parent term peptidase activity was 
inferred from the GO term analysis with 1.91%, not one of the five types of 
proteases appeared in the results. In the InterProScan study, 411 proteins were 
detected, with 144 domain, 153 family and 63 conserved sites.    
Similarly, in the 21-day adult worm, which resides in the hepatic portal 
system, 346 molecular function GO terms were inferred from 371 assembled contigs. 
All five peptidase types (cysteine-type peptidases (GO: 0008234), metallopeptidase 
activity (GO: 0008237), aspartic-type peptidase activity (GO: 0070001), serine-type 
peptidase activity (GO: 0008236) and threonine-type peptidase activity (GO: 
00703)) occurred with the same percentage of 0.27% (Table 3.2). The InterProScan 
results showed 113 proteins differentiated in 73 domains, 21 families and 8 
conserved sites as well as 9 PTM and 2 repeats (Table 3.3). 
InterProScan 
domain Cercaria 
Day 7 
schistosomula 
Lung-stage 
schistosomula 
21-day 
adult 
28-day 
adult Egg 
Domain 163 417 145 73 115 257 
Family 94 309 154 21 155 146 
Conserved 
site 69 97 64 8 38 113 
Binding site 2 20 2   17 
Active site 6 34 8  12 29 
Region 13 38 30 9 10 22 
PTM 7 4    13 
Repeat 4 32 8 2 2 11 
Table 0.3 Protein domains inferred using the InterProScan analysis from B2GO software from peptides 
inferred from schistosoma life cycle stages. 
In the 28-day adult, aspartic-type peptidases activity (GO: 0070001) and 
threonine-type peptidase activity (GO: 0070003) were not detected in the 384 GO 
terms retrieved from the 450 assembled contigs. Cysteine-type peptidases (GO: 
0008234) and serine-type peptidase activity (GO: 0008236) were similar at 0.44%, 
while the metallopeptidase activity (GO: 0008237) percentage was 0.22% (Table 
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3.2). InterProScan analysis revealed 332 proteins; 155 were families and 115 were 
domains (Table 3.3). 
Finally, the egg stage that is laid intravascularly and many are carried away 
from the site of deposition by blood flow, to become lodged in the nearest capillary 
bed down-stream or excreted with faeces. 5987 assembled contigs were subjected to 
Blast2GO GO analysis, which resulted in 1118 molecular function GO terms. 
Metallopeptidase activity (GO: 0008237) was the most abundant protease result with 
0.17%. Cysteine-type peptidases (GO: 0008234) came next with 0.13%, followed by 
0.12% for serine-type peptidase activity (GO: 0008236) and finally 0.8% for 
threonine-type peptidase activity (GO: 0070003). No results were detected for 
aspartic-type peptidase activity (GO: 0070001) (Table 3.2). After screening the 
assembled contigs using InterProScan, 608 proteins were detected—257 were 
domains, 146 were families and 113 were conserved sites. Others such as binding 
sites, active site regions and repeats were identified as well (Table 3.3). 
 
This analysis demonstrates that GO categories with an interesting enrichment 
of Schistosome life stages over all schistosome proteins are “binding function” 
(including calcium- and lipid binding proteins) and “enzymatic activity” (including 
the hydrolytic and catalytic enzymes). Proteases of all classes are expressed in 
different stages of the parasite. In addition, we can notice the differences among 
different proteases expressions at the different stages, especially those that consider 
being consecutive, like cercaria and schistosomula. This may be related to the tissue 
compartment or body part the parasite resides in and the different adaptations it 
undergoes to ensure the success of parasitism. 
 
F. hepatica adult worm inferred a total of 354 molecular function GO terms, 
of which binding (GO: 0005488) was the predominant one, with 22.7% of the total 
number of loaded sequences. Protein binding (GO: 0005515) was the second with 
20.7%. Peptidase activity was inferred from 8.0% of the loaded ESTs (Tables 3.1, 
3.4). Notably, peptidases of the cysteine and serine types were the only types of 
peptidases detected by this analysis. Unlike schistosomes, there were no inferred 
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catalytic or hydrolytic GO terms. In addition, from the proteases point of view, no 
metalloproteases, aspartic proteases or threonine proteases were detected, although 
the percentage of the GO term-detected peptidases was higher in fasciola than in the 
schistosome lifecycle stages. The InterProScan result was negative, which could be 
because the fasciola database was released recently and has not yet been annotated or 
analysed in detail. 
 
 
GO Code GO term F. hepatica adult worm 
GO:0003674 Molecular_function 24.0% 
GO:0005488 Binding 22.7% 
GO:0005515 Protein binding 20.6% 
GO:0070011 Peptidase activity, acting on L-amino acid peptides 8.0% 
GO:0008233 Peptidase activity 8.0% 
GO:0004175 Endopeptidase activity 7.7% 
GO:0004197 Cysteine-type endopeptidase activity 7.2% 
GO:0008234 Cysteine-type peptidase activity 7.2% 
GO:0008236 Serine-type peptidase activity 0.8% 
GO:0004252 Serine-type endopeptidase activity 0.5% 
GO:0008238 Exopeptidase activity 0.3% 
GO:0004869 Cysteine-type endopeptidase inhibitor activity 0.3% 
GO:0008239 Dipeptidyl-peptidase activity 0.3% 
Table 0.4 The three most abundant GO terms and a detailed description of the protease family   GO 
terms. The percentage indicates the number of sequences with the described GO term out of the total number of 
sequences uploaded to the software.  
 
For comparative analyses, E. ocellatus EST data generated at the Alistair 
Reid Venom Research Unit was also included. For this dataset, the same 
bioinformatic analyses described in the Methods section were conducted. From 113 
contigs, a total of 101 molecular function GO terms were inferred, with most of them 
matching those encoded by schistosome and fasciola. However, several inferred 
molecular function GO terms from E. ocellatus were not detected in parasites—
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peptidyl-dipeptidase inhibitor activity (GO:0060422), L-amino-acid oxidase activity 
(GO:0001716), cytokine binding (GO:0019955), metalloenzyme regulator activity 
(GO:0010576), hyalurononglucosaminidase activity (GO:0004415) and 
prostaglandin-endoperoxide synthase activity (GO:0004666). It is noteworthy that all 
of the snake venom proteases were under endopeptidase molecular function, whereas 
the parasite proteases were divided between endo- and exopeptidases. 
 
 
GO code  GO term  
Schistosoma mansoni 
Fasciola 
hepatica 
adult %  
Echis 
ocellatus 
% Cercaria %  
Schistosomula 
%  
Day 
21 
adult 
%  
Day 
28 
adult 
%  
Egg 
%  
Day 7  Lung stage  
Go:0003674  Molecular function  13.03 28.31 35.92 33.96 37.78 22.1 24 77.1 
Go:0005488  Binding   11.19 24.96 32.04 31.54 34.22 19.86 22.7 58 
Go:0003824  Catalytic activity  8.24 15.09 18.99 16.71 16.67 11.63   75.6 
Go:0016787  Hydrolase activity  5.14 7.32 10.12 7.55 7.33 6.1 0 51.1 
Go:0008233  Peptidase activity  0.45 1.32 1.91 1.89 1.11 0.68 8 47.3 
Go:0004175  Endopeptidase activity  0.33 1.06 0 1.08 0.44 0.45 7.7 47.3 
Go:0008238  Exopeptidase activity  0.05 0.1 0 0.27 0.22 0.13 0.3 0 
Go:0070001  Aspartic-type peptidase activity  0 0.16 0 0.27 0 0 0 1.5 
Go:0008234  Cysteine-type peptidase activity  0.1 0.48 0 0.27 0.44 0.13 7.2 0 
Go:0008237  Metallopeptidase activity  0.18 0.26 0 0.27 0.22 0.17 0 38.2 
Go:0008236  Serine-type peptidase activity  0.08 0.13 0 0.27 0.44 0.12 0.8 7.6 
Go:0070003  Threonine-type peptidase activity  0.03 0.1 0 0.27 0 0.08 0 0 
Table 0.5 Comparison of protease molecular function GO terms between parasites (S. mansoni and F. 
hepatica) and snake venom (E. ocellatus) proteases. 
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1.9 Discussion 
In this chapter, the in silico approach was employed to elucidate fundamental 
molecules that are critical to success of parasitism/envenomation and share parallel 
nature in parasites and snake venom. The transcriptome of these pathogens’ data was 
bioinformatically investigated and compared. Comparative analyses between 
transcriptome of different organisms using GO comparison have been used to gain 
understanding of molecular and biological aspects (Cantacessi et al. 2010; Conesa & 
Götz 2008). The assembled contig library of each life stage of S. mansoni (cercaria, 
7-day schistosomula, SLAP, 21- and 28-day adult and soluble egg antigen) and adult 
F. hepatica involved migration or caused pathological damage to the host, was 
surveyed for orthologous in protein sequences and molecular function GOs 
comparison with snake venom database. These parasites stages use different proteins 
and proteases, like cercarial elastase, metalloprotease and aspartic protease, to 
facilitate the destruction of tissue compartments laying the parasite way to the final 
habitat, digest blood meal obtained from host or evade the immune system of the 
host. In comparison, snake venom use similar proteases to destroy systemic integrity 
of envenomed patient and cause profound coagulopathy and myotoxicity as well as 
neurotoxicity.  
The BLASTp and alignment of S. mansoni and F. hepatica protease ESTs 
against snake venom ESTs revealed orthologues among essential enzymes in the 
pathology of schistosoma and fasciola and major toxins in snake venom. The serine 
protease cercarial elastase (chymotrypsine family) showed 25% identity with snake 
venom serine protease (SVSP) (accession numbers CAQ72889.1 and ADI47555.1), 
as shown in Figure 3.1 in the Results section. Although this identity is considered to 
be low, it includes serine proteinase evolutionary markers and active site residues for 
the S1 family of clan SA. Further, TAAHC, DIAL, GDSGGP and GIVSW with their 
development and maintenance played an important role in the evolution of these 
proteolytic enzymes as variation in active site structure permit the enzyme to fulfill 
new roles (Krem & Di Cera 2001). The homology between serine proteases from the 
two different organisms was represented in other serine protease isoforms from 
schistosome that had an identity of 32% with SVSP (accession numbers ADI47559.1 
and ADI47560.1). Similar to cercarial elastase, SmSP1, another serine protease 
 
 
69 
found in schistosomes,  shared motifs with snake serine proteases that surround the 
active sites of clan A S1 serine protease family similar to that showed in cercarial 
elastase.  
Functionally, cercarial elastase is a predominant secreted protease that is 
essential for host skin invasion due to its ability to digest insoluble elastin (Ingram et 
al. 2012). Furthermore, an isoform to cercarial elastase localised on the surface of 
schistosomula has been implicated in immunomodulatory roles, including the 
cleavage of host complement components and of host IgG and IgE bound via Fc 
receptors to their surface (Tort et al. 1999; Kasný et al. 2009).  
On the other hand, SmSP1 of adults was shown to cleave bradykinin and 
provoke a reduction of the arterial blood pressure of experimental animals (rats), 
possibly due to a peripheral vasodilatation effect. Thus, parasite enzymes might have 
a similar influence on the visceral vasculature and capillary permeability of their 
natural hosts (Carvalho et al. 1998; Kasný et al. 2009). In comparison, SVSPs affect 
the pathways of the coagulation cascade by activating blood components utilised in 
the coagulation cascade, fibrinolysis and platelet aggregation or by proteolytic 
degradation (Serrano and Maroun 2005). This is in addition to characterised SVSPs 
that are able to lower the blood pressure and bring about disturbances of the 
hemostatic function (Serrano et al. 1998). This correlates SVSPs with SmSP1 more 
than cercarial elastase as SmSP1 is known, as described above, to induce the 
reduction of blood pressure.  
 
Other important proteases such as metalloprotease shared some identity 
(53%, accession number CAJ01689.1) with snake venom metalloprotease (SVMP) 
(Figure 3.2). In human active schistosomal periovular granulomas, 
metalloproteinases are key enzymes in the metabolism of collagen and in the 
physiopathology of fibrosis (Gomez et al. 1999). Similarly, in snake envenomation, 
SVMPs are responsible for haemorrhage and multiple tissue-damaging activities, 
including myonecrosis, dermonecrosis, blistering and oedema (Takeda et al. 2012; 
Watanabe et al. 2003).The schistosome metalloprotease belongs to the ADAM 
family of metalloprotease. Snake venom metalloprotease found to be closely related 
to the ADAM family of metalloproteases (Takeda et al. 2012) this may explain the 
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expressed identity between schistosome metalloproteases and SVMP. 
In GO analysis performed using B2GO, comparing the inferred terms of S. 
mansoni and F. hepatica with the snake venom protease database indicated shared 
molecular functions in their proteases, which were represented in the organisms 
(Table 3.5). These proteases included cysteine, aspartic and metalloproteases, which 
are known to function in multi-enzyme cascades to perform different biological 
functions. Several observations were made. All of the snake venom proteases 
inferred in our study were under endopeptidase molecular function, whereas the 
parasite proteases were divided between endo- and exopeptidases. In this regard, 
snake venom proteins are synthesised in secretory epithelial cells lining the tubules 
of the venom gland (Mackessy & Baxter 2006). The most commonly quantified 
classes of snake venom enzymes include phospholipase A2 (PLA2), 
phosphodiesterase, phosphomonoesterase, L-amino acid oxidase, specific 
endopeptidases and nonspecific endopeptidases (McCue 2005). More than 150 
different endoproteases have been isolated and about one third of these have been 
structurally characterised (Ogawa et al. 2007; Vaiyapuri et al. 2010). In contrast, 
little information is available about the functions of exopeptidases (aminopeptidases 
and dipeptidyl peptidases), which are capable of hydrolysing the N-terminal 
residue(s) of peptides in venom (Ogawa et al. 2007). Several studies demonstrated 
the presence of aminopeptidase in snake venom, for example, Aminopeptidase A 
(APA), Aminopeptidase B (APB), Aminopeptidase N (APN) and Dipeptidyl 
peptidase (DPP); however, the roles of these aminopeptidases in snake venom have 
not yet been fully understood (Ogawa et al. 2007; Vaiyapuri et al. 2010; Aird et al. 
2013). This may in a way explain why parent GO terms related to exopeptidases 
were not inferred in our analysis for E. ocellatus venom, and metalloenzyme 
inhibitor activity (GO:0048551) and metalloenzyme regulator activity (GO:0010576) 
were the only GO terms related to exopeptidases inferred through this analysis.   
On the other hand, exopeptidases have been closely studied in Schistosome. 
Exopeptidases in Schistosomes likely play a role in haemoglobin digestion following 
endopeptidases activity (Merrick et al. 2003). Several schistosome exopeptidases 
have been reported, including cathepsin C, cathepsin B, aminopeptidase and 
dipeptidyl peptidase (Sajid 2003; Kasný et al. 2009; Rawlings et al. 2008; Myers et 
al. 2008).  
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When comparing the different life stages of S. mansoni, the variations in the 
percentage of proteases at each stage inferred in our study were obvious. This might 
reflect the different biological functions of the parasite at each stage according to the 
nature of the site of that stage inside the host. This starts with cercaria, which 
initiates the infection by penetrating the host skin using acetabular gland contents in 
which cercarial elastase (serine protease) plays a vital role (El-Ansary 2003; Bahgat 
et al. 2002). At this stage, the parasite needs to stimulate blood clotting, which can 
seal ruptured capillaries during parasite migration, in which serine protease and 
metalloprotease may participate (Dvorák et al. 2008; Ingram et al. 2003). This 
demonstrate the presence of serine protease and metalloprotease GO term in the 
inferred molecular functions (Table 3.2) Obviously, no aspartic protease GO term 
was inferred from this stage, which might correlate with the fact that the parasite at 
this stage is not digesting blood from the host. In schistosomula, the consecutive 
stage, we notice an increase in the level of proteases GO terms as this stage actively 
migrates through tissue compartments, may reach the lung alveoli and start to 
contact host blood. Hence, it may start feeding on blood and digestion facilitated by 
aspartic proteases (Miller and Wilson 1978; Harrop et al. 1999). On the other hand, 
the absence of some of these fundamental proteases at some stages of S. mansoni 
may be related to the yet incomplete sequencing project (Table 3.2). The adult stage 
at which the parasite has reached the final habitat secretes proteases for the 
maintenance and sustainability of the infection (El-Ansary 2003; Curwen et al. 2004; 
Guerra-Sá et al. 2005). This stage utilises proteases for host blood digestion and the 
escape and evasion of the host’s immune system. Proteases like cercarial elastase, 
cathepsin B (Sm31), cathepsin L1, cathepsin L2, cathepsin D, cathepsin C and 
legumain (Sm32) are capable of modulating the host immune response and 
regulating the synthesis of specific and other IgE antibodies (El-Ansary 2003). This 
is reflected in our finding as all type of proteases GO terms was detected. On the 
other hand, eggs are deposited by the adult stage and are trapped in the tissues of the 
infected host, inducing granuloma, portal fibrosis, hepatosplenomegaly and 
gastrointestinal varices (Pearce and MacDonald 2002; Rinaldi et al. 2009). Proteases 
have also been found to play a role in this process (Ashton et al. 2001; Cesari et al. 
2000; Morales et al. 2008). Similar to Schistosome, F. hepatica utilises different 
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proteases during the route of the infection in order to ensure the success of parasitism 
(Stack et al. 2011; Boukli et al. 2011; Kasný et al. 2009). 
The preliminary data presented in this chapter provides a basic overview of 
the presence of shared functions between proteases utilized by migrating parasites 
and snake venom as both use proteases to facilitate and sustain pathology. It is 
interesting to investigate further if these trascriptomics similarities will extend to 
represent in vitro reactions on the proteomic level. Wither serine proteases, 
metalloproteases and other proteases used by parasites during tissue migration, 
immune system evasion, host blood digestion, vasodilatation and granuloma 
formation will be detected with antivenoms and antibodies raised against venom full 
of proteases utilised by snakes to deliver venom to the victim’s blood system. This 
venom’s components disturb the victim’s natural systems, affecting haemostasis and 
vasodilatation, therefore causing damage to local tissue and systematic pathology. 
This will be investigated in the next chapter.  
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Chapter 4     Immunological analysis of the cross-reactivity of 
parasite and venom proteins 
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1.10 Introduction 
Molecules shared among species of various genera, families, and phyla have 
been widely described. The expression of immune responses among different species 
of various genera, known as antigenic community, is responsible for antigenic cross-
reactivity (Boukli et al. 2011; Losada et al. 2005). Sharing molecules among 
different organisms is an expected result of the conserved function of many 
molecules, such as enzymes, hormones, and receptors, during evolution (Boukli et al. 
2011). This characteristic has special relevance for identifying molecules with 
potential for the development of drugs or vaccines that could be effective against 
different species or genera of organisms.  
In the previous chapter, we demonstrated the presence of similar enzymes 
used by the S. mansoni and F. hepatica parasites and snake venom to trigger 
pathology. For instance, cercarial elastase, which is the major larval protease in S. 
mansoni and essential for host skin invasion (Ingram et al. 2012; Knudsen et al. 
2005) has a shared molecular function with serine proteases from snake venom and 
displays a degree of sequence homology with venom serine proteases. In addition to 
cercarial elastase, both parasites and venom use other enzymes to ensure success and 
sustainability for infection/pathology, such as phospholipases, aspartic proteases, 
metalloproteases and hyaluronidase, which is a component found in snake venom 
and parasites, that is able to spread degradation of extracellular matrix that may 
contribute to the spreading of venom toxins (Gutiérrez et al. 2007; Levine et al. 
1948; Evans 1953). 
However, the literature has stated that the transcriptome of an organism does 
not necessarily correlate with the translatome and protein expression in biological 
samples (Maier et al. 2009). Post-transcriptional regulation of synthesis and the 
degradation rate of a protein have an impact on molecule differentiation, and thus, 
affect the correlation between transcriptome and proteome (Kristensen et al. 2013). 
Therefore, in this chapter, we aimed to further investigate this similarity on the 
protein level, using immunological and proteomic approaches. Knowing that 
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antivenom has the ability to bind to most venom toxin proteins, because horses/sheep 
are hyperimmunised with venom, we aimed to identify the parasite proteins bound 
by antivenom.   
Taking into account the proteases we are interested in, we selected a group of 
antivenom- and toxin-specific immunoglobulin Gs (IgGs) for the investigation. We 
compared parasite protein cross-reactivity to i) the venoms of snakes that are life 
threatening and a daily hazard in large tracts of Africa, and which share an 
epidemiological distribution with schistosome and fasciola parasites. Thus, E. 
ocellatus venom was selected as our element of comparison with parasites in our 
experiments. Serine proteases and metalloproteases are major components of this 
snake venom, and they are thought to disrupt several distinct elements of vascular 
haemostasis of envenomed victims (Wagstaff & Harrison 2006). As such, it is a 
good example for our comparison, and ii) a monospecific antivenom, EchiTAB G, 
which neutralizes the toxic effect of E. ocellatus venom (Abubakar et al. 2010), was 
selected as the primary antibody for our experiments 
 
To increase our chances of identifying additional antigenically cross-
reactivevenom and parasite proteins, we broadened our antivenom selection to 
polyspecific antivenoms produced against a mix of vipers and elapids, because of the 
precence of a wider spectrum of IgG specificities to these elapid venom  proteins 
(e.g. neurotoxins). Thus, we included the African polyspecific antivenoms EchiTAb-
PLUS-ICP and SAIMR polyvalent (Abubakar et al. 2010; Mebs et al. 1988). We 
included in this analysis polyspecific antivenom developed against non-African 
snake venom as a control and to investigate whether the shared molecules exist in 
snakes found in areas that do not encounter schistosomiasis. Mass-spectrometry 
analysis of these protein was performed to elucidate which parasite proteins 
immunoreacted to the antivenoms and to link the reactive protein of the antibodies to 
what we observed using transcriptome data.  
 
Finally, to exclude non-specific binding to other antivenom components, an 
immunoblot was performed with antibodies raised to specific E. ocellatus venom 
protein groups.  
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1.11 Materials  
The source and preparation of the samples are described in detail in Chapter 
2, Section 2.1. 
1.12 Methods  
1.12.1 Electrophoresis analysis and immunoblotting 
Sample homogenates were size-separated by SDS-PAGE (15%), then 
electroblotted to 0.45 µm nitrocellulose membranes, according to the manufacturer’s 
(Bio-Rad, UK) recommendations, as described in Chapter 2, Section 2.6. The 
membranes were incubated overnight in a variety of polyclonal and monoclonal 
snake antivenoms and toxin-specific IgGs (Table 4.1), at 1:5000 and 1:200 dilutions 
respectively, in a blocking buffer.  
We began the experiments using the E. ocellatus monospecific antivenom 
(EchiTAb G®) which has the ability to neutralize the most clinically relevant toxic 
activities (lethal, haemorrhagic, coagulant, and necrotizing) of this venom (I. S. 
Abubakar et al. 2010). Selection of this antivenom was based on our rationale of the 
presence of similar proteins between parasites that reside in the capillaries of a 
human host and have the ability to disturb tissue compartment integrity and migrate 
to the vascular system, and venoms of snakes that cause tissue necrosis and interrupt 
haemostasis in their victims. Our interest in African snakes was motivated not only 
by the shared biological mechanisms between these different organisms, but also, as 
described in Chapter 1, by the fact that these pathological organisms exert health 
issues on populations that reside in the same geographical locations. To upgrade this 
investigation, we broadened our antivenom specificity to the polyspecific EchiTAb-
Plus-ICP (S. B. Abubakar et al. 2010) and SAIMR antivenoms (Mebs et al. 1988), 
which are effective against venoms of not only E. ocellatus, but also other toxic 
snakes, such as vipers and elapids, which cause different pathologies (e.g. elapids 
cause neurotoxic pathology) in Africa (Table 4.1). The selection of these 
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polyspecific antivenoms was to cover more medically important snakes and to 
investigate whether broadening venom selection would increase the possibility of 
detecting more shared proteins. Finally, to test whether this cross-reactivity is to 
African snakes only or if it is true of other snakes distributed in non-African 
countries, we used antivenom (Polyvalent Snake Antivenom; CSL Australia) 
developed against snakes found in Australia and nearby countries (O’Leary and 
Isbister 2009). We considered the fact that the source of antibodies raised against 
venom might affect the background of the immunoblots, as sheep, for example, 
might have been infected with parasites that share biological molecules with 
parasites we used in our experiment. Therefore, we tried to select antivenom raised 
in equines as well as in ovines.    
Table 0.1 Snake antivenom used in this study. 
 
 
 
 
Snake Antivenom  Snake  IgG type Reference  
EchiTAb G®; carpet viper 
monospecific (MicroPharm, UK) 
 
E. ocellatus  Ovine  (Abubakar et al. 
2010 (a); Abubakar 
et al. 2010 (b)) 
EchiTAb-Plus-ICP, African-
polyspecific (Instituto 
Clodomiro, University of Costa 
Rica) 
 
E. ocellatus, B. arietans, N. 
nigricollis 
Equine (Gutiérrez et al. 
2005) 
SAIMR Polyvalent, African-
polyspecific (South African 
Institute for Medical 
Research (SAIMR), 
Johannesburg, South Africa) 
B. arietans, B. gabonica, N. 
annulifera, N. melanoleuca, N. 
mossambica, D. polylepis, D. 
angusticeps, D. jamesoni, H. 
haemochatus 
Equine (Mebs et al. 1998) 
Polyvalent Snake Antivenom 
(Australia–Papua New Guinea) 
Australian-polyspecific (CSL 
Limited, Australia) 
 
P. australis, N. scutatus, 
P. textilis, A. antarcticus, O. 
scutellatus 
Equine (O’leary and  Isbister 
2009) 
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1.12.2 Mass spectrometry 
The detailed description of this experiment is illustrated in Chapter 2 sections 
2.7.a-b 
 
1.13 Results  
1.13.1 Protein profiling  
To determine the protein composition of the parasite life cycle, homogenates 
were fractionated by 15% SDS-PAGE electrophoresis (Figure 4.1). The parasite 
protein profile showed a more complex protein composition compared with snake 
venom, which is logical, as the parasite samples, except cercarial transformation 
fluid and soluble egg antigen, were homogenates for the whole worm stage and not 
secretory/excretory fluids only. There were variations in the parasite protein profiles 
separated by reducing SDS-PAGE of specimens prepared from different schistosome 
stages. For instance, when comparing the cercaria (lane 1 in Figure 4.1) and 
schistosomula (lane 2 in Figure 4.1) stages, which are two consecutive stages of the 
parasite, we noticed a big difference in their profiles. This shows the complex 
morphological and physiological changes that occur in the individual life-stages of 
the parasite and displays the distinct adaptations of the parasite to both parasitic life 
and free living.    
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Figure 0.1 Analysis of parasite stages and venom proteins: 15% reduced SDS-PAGE gel stained 
with Coomassie blue of the following samples: Schistosoma mansoni life cycle stages (1 cercaria, 2 cercarial 
transformation fluid, 3 schistosomula, 4 S. mansoni adult, 5 soluble egg antigen), 6 Fasciola hepatica adult worm 
proteins, and 7 Echis ocellatus venom proteins. Samples were normalized for loading according to the best 
protein amount to have the strongest reaction to antibodies used in the blots as in the following sections. The 
molecular weight markers (kDa) are shown on the left side of the image. Note the complexity of the protein 
composition of the parasite.  
 
1.13.2 Protein immunoreactivity analysis 
An immunoblotting assay was performed to identify the S. mansoni and F. 
hepatica proteins that reacted with a variety of mono- and poly-specific snake 
antivenoms (Table 4.1). 
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Figure 0.2 Reduced (15% SDS-PAGE gel) immunoblotting against various antivenoms: African a) 
monospecific EchiTAb G, b) polyspecific EchiTAb-Plus-ICP, and c) SAIMR polyvalent; and Australian d) CSL 
polyspecific. As controls: secondary antibody only e) donkey anti-sheep IgG, f) rabbit anti-horse IgG, and g) 
substrate only. 5µg of samples were loaded in the following order: 1) S. mansoni cercaria, 2) S. mansoni, 
schistosomula, 3) S. mansoni adult, 4) S. mansoni SEA, 5) F. hepatica adult, 6) E. ocellatus venom as positive 
control for the African antivenoms, *6) Acanthophis antarcticus as a positive control for the Australian 
antivenom CSL. The molecular weight markers (kDa) are shown on the left side of the image. 
 
 
 
Monospecific EchiTABG 
First of all, we used the monospecific EchiTAb G antivenom, raised against 
E. ocellatus venom, which is dominated by, Zn2+-metalloproteinases, and group II 
phospholipases A2 that disrupts. Immunoblotting analysis revealed differences in the 
reactivity of distinctt Schistosome life-cycle stages toward the antivenom. Starting 
with the S. mansoni infective stage, cercaria (lane 1, Figure 4.2a), which reacted with 
the MW 30kDa protein and three consecutive bands between MWs 50kDa and 
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55kDa, this was different from schistosomula, the stage following the cercaria, and 
the stage spent migrating through tissue compartments, like cercaria (lane 2, Figure 
4.2a), which showed cross-reactivity with protein at MW around 40kDa. Trying to 
link these molecular weights with proteomics studies done on schistosome proteins, 
several proteins were allocated between 40 and 55kDa. In those proteins, enzymes 
such as enolase (46.9kDa), putative cytosol aminopeptidase (56.4kDa), and one 
similar to citrate synthase (47.9kDa) were identified (Knudsen et al. 2005; Curwen et 
al. 2004). Similarly, many proteins were identified around MW 30kDa, such as 
triosephosphate isomerase (28.1kDa), pancreatic elastase precursor (elastase 1a) 
(28.5kDa), elastase (elastase 1b) (29.5kDa), and one similar to carbonyl reductase 
(30.6kDa) (Knudsen et al. 2005; Curwen et al. 2004). Cercarial elastase, which is a 
serine protease, has a molecular weight near the band that showed cross-reactivity 
with the antivenom in the cercaria sample.  
Moving to the adult stage (lane 3 Figure 4.2a), EchiTAb G antivenom 
showed cross-reactivity to more proteins compared with the cercaria and 
schistosomula stages. Six protein bands between MWs 28kDa and 50kDa, and one 
around 20kDa, displayed immune cross-reactivity. According to Losada et al. 
(2011), many proteins migrate to these molecular weights. Of those, enolase 
(47.4kDa), actin-2 (41.9kDa), triosephosphate isomerase, fructose-bisphosphate 
aldolase (39.96kDa), and thioredoxin peroxidase (21.9kDa), as well as Sm21.7 
antigen (21.7kDa), were around MW 20 kDa. According to the literature (Losada et 
al. 2011; Curwen et al. 2004; Knudsen et al. 2005; Delcroix et al. 2007), no serine 
protease or metalloprotease has been identified in the adult schistosome stage within 
these molecular weights. This caught our interest as this may imphasize on the 
presence of antibodies against non-enzymatic components and non-toxic proteins in 
antivenom. 
Two soluble egg antigen (SEA) (lane 4, Figure 4.2a) proteins reacted with 
EchiTAb G at MWs 30kDa and 50kDa. When locating these bands according to the 
SEA proteome, we found the following enzymes identified adjacent to cross-reacted 
bands we observed: enolase (46.9kDa), glutathione S-transferase (28kDa), and 
purine-nucleoside phosphorylase (31.1kDa) (Cass et al. 2007).  Finally, it was 
difficult to detect proteins immunoreactive to EchiTAb G antivenom in the F. 
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hepatica sample (lane 5, Figure 4.2a), as smearing in the background of the sample 
affected the result. 
Polyspecific EchiTAb-PLUS-ICP 
Parasite protein cross-reactivity to the polyspecific EchiTAb-Plus-ICP  
antivenom was substantially different from that to the monospecific EchiTAb G 
antivenom.. First of all, there was a complete loss of bands at the high MWs in the 
cercaria sample (lane 1, Figure 4.2b) and the appearance of new low MW proteins at 
approximately 20kDa and 22kDa - their size perhaps indicating they might be the 
Sm21.7 antigen 21.7kDa, thioredoxin peroxidase 21.9kDa or glutathione S-
transferase 23.8kDa (Losada et al. 2011)). In contrast, schistosomula proteins (lane 
2, Figure 4.2b) displayed more reactivity toward the antivenom, and many bands at 
both low and high molecular weights were detected, although there was some 
smearing. On the other hand, the adult stage (lane 3, Figure 4.2b) cross-reacted 
proteins appeared in the monospecific antivenom sustained in the polyspecific 
EchiTAb-Plus-ICP antivenom, in addition to the appearance of a new low MW band 
(~18kDa), while SEA (lane 4, Figure 4.2b) lost the bands that cross-reacted, and 
there was smearing in the background. The polyspecific antivenom, as stated in the 
Methods section, was prepared from a combination of venoms from B. arietans (puff 
adder) and N. nigricollis (spitting cobra), in addition to E. ocellatus, which added 
antibodies to other toxins more than that present in the monospecific antivenom, 
such as low molecular weight neurotoxins (from N. nigricollis venom) and therefore, 
might have a wider specificity. Even in the F. hepatica sample (lane 5, Figure 4.2b), 
when compared with the monospecific antivenom cross-reactivity, we noticed an 
intensification of the immunoreactivity of some proteins, such as that at MW 32kDa.  
 
Polyspecific SAIMR 
This antivenom was used in this study because it was developed against a 
wider number of snake species (vipers and elapids) (Table 4.1) than EchiTAB-
PLUS-ICP. The immunoblotting analysis revealed a different profile than found in 
the above results. New proteins lower than MW 25kDa appeared in cercaria, adult 
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Schistosoma worm, and SEA samples (lanes 1, 3, and 4, Figure 4.2c), in addition to 
a complete loss of schistosomula stage reactivity toward the antivenom. F. hepatica 
adult worm (lane 5, Figure 4.2c) had a single protein react, at a molecular weight of 
around 26kDa. This might correspond to the 25.7kDa glutathione S-transferase 
identified by proteomic studies on the F. hepatica adult worm. 
Australian polyspecific CSL antivenom 
Finally, we used CSL polyspecific antivenom as a control for the African 
antivenoms and to further investigate whether the immunoreactivity of parasite 
proteins to antivenoms was also evident in antivenoms  developed against non-
African snakes. The immunoblotting analysis revealed the existence of cross-
reactivity between parasite proteins and the polyspecific antivenom, with a broad 
range of molecular weights, from around 20kDa to around 50kDa (Figure 4.2c).    
All immunoreactivities tested in the above section were using reduced 
proteins. Thus the proteins have lost their secondary, tertiary, and quaternary levels 
of biomolecular structure, leaving only the primary structure to be analyzed. To 
investigate whether this immunoreactivity would be sustained when antivenoms 
reacted to the proteins in their native forms without any denaturing, we prepared 
non-reduced and native proteins from each sample and blotted against the 
antivenoms used in this study. For all of the above-mentioned samples, when the 
blotted proteins were changed from reduced to non-reduced and native, the cross-
reactivity faded or disappeared, as shown in the two examples in Figures 4.3 and 4.4.   
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Figure 0.3 Non-reduced immunoblotting of S. mansoni. 1) cercaria, 2) schistosomula, 3) adult, 4) SEA,  
and 5) F. hepatica adult; against EchiTABG antivenoms and controls; 7) normal sheep, 8) anti-sheep IgG; 9) 
substrate only (cercaria). The molecular weight markers (kDa) are shown on the left side of the image. 
 
 
Figure 0.4 Native protein immunoblotting against EchiTAB G antivenom. 1) S. mansoni cercaria, 2) S. 
mansoni schistosomula, 3) S. mansoni adult, 4) S. mansoni SEA, 5) F. hepatica adult; 6) An. gambiae salivary 
glands and controls; 7) normal sheep, 8) anti-sheep IgG; 9) Substrate only (cercaria). The molecular weight 
markers (kDa) are shown on the left side of the image. 
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1.13.3 LC-MS/MS analysis 
We conducted mass spectrometric identification to link the immune cross-
reactivity we observed in the previous experiment with the transcriptomic data 
available for the parasites and the results we demonstrated in Chapter 3. Protein 
bands with significant immunoreactivity to snake antivenom were excised from the 
Coomassie-stained gels (Figure 4.2).  The molecular weights of reactive proteins in 
the blots were measured and the exact protein band was excised (Table 4.2), in-gel 
trypsin digested then identified using bioinformatics.  The functional identities of the 
parasite proteins that expressed cross-reactivity to the antivenom were determined. 
The identified proteins and the number of peptides found in each sample are listed in 
Table 4.3. The molecular weight and LC-MS/MS derived protein sequences of the 
identified proteins are also included in the table. 
Among the recognised proteins, several known antigens for S. mansoni and 
F. hepatica were found. For example, major egg antigen p40 and fructose-
bisphosphate aldolase are from the identified bands in S. mansoni, and glutathione S-
transferase and Hsp 70 are in F. hepatica.  
In addition, in this analysis, we identified several structural proteins that are 
usually recognised as part of the cell cytoskeleton, such as actin and paramyosin. 
Notably, all the proteins that were identified were intracellular; no extracellular 
structural proteins were identified. 
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 Cercaria  Schistosomula  Adult worm (S. 
mansoni) 
SEA  Fasciola 
hepatica  
EchiTAb G® 30, 50kDa  40kDa    20,28,30,40,50kDa  30, 
50kDa  
-  
EchiTAb-Plus-ICP 
 
20,22 kDa  -  18kDa  -   32kDa  
SAIMR Polyvalent 
 
25kDa  -  50 kDa 25kDa 26kDa 
CSL Polyvalent 
snake antivenom  
35,75, 100 
kDa  
35, 50, 75kDa  75kDa  35, 50, 75 
kDa  
50,75kDa 
Table 0.2 Summary of positive cross-reacted protein bands from the different samples with a variety of 
snake antivenoms.
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1.13.4 Alignment with snake venom sequences 
The amino acid sequences of the identified proteins were examined for homology with 
those of snake venom proteins. The greatest homology was found among actin from CTF, SEA, 
and snake proteins. In addition, homologies were demonstrated with other proteins with varying 
degrees of similarity; for example, schistosoma adult worm calreticulin precursor and 
ECO00071_1 from snake venom, and enolase from schistosomula and alpha-enolase from snake 
venom. The snake venom protein EOP00474_1 sequence could also be aligned with fructose-
bisphosphate aldolase from cercaria, schistosomula, SEA, and F. hepatica adult worm proteins. 
Table 4.3 and Figure 4.6 illustrate some of the identified proteins, their band size, the antivenom 
they reacted to, and highlights of the identified peptides by mass spectrometry. 
 
 
Table 0.3 Identified proteins with high coverage rates in LC-MS/MS and high level of identity with venom proteins. 
Actual and excised band molecular weights linked to antivenom that showed reactivity to them. 
Protein Band 
MW Actual MW Anti-venom Organism 
Fructose-
bisphosphate aldolase 35 kDa 39.6 kDa CSL Cercaria 
Enolase 50 kDa 47 kDa SAIMR, CSL Schistosomula 
GAPDH 35 kDa 36.4 
kDa CSL   Schistosomula 
Calreticulin 
precursor 50 kDa 45.4 kDa EchiTAb G, CSL Schistosoma adult 
Heat shock 70 
 
50 kDa 69.8 
kDa 
EchiTAb-Plus-ICP, 
EchiTAb G, CSL  
Fasciola  
SEA 
 
14-3-3 28 kDa 28.4 
kDa EchiTAb G Schistosoma adult 
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Description Max 
score 
Total 
score 
Query 
cover 
E value Identity Accession 
Cercaria (CER) 
P53442 
190 190 43% 2e-63 60% 152199 
Schistosomula (SC) 
P46563 
171 188 46% 6e-56 58% 152199 
Fasciola adult 
(FAS) P53442 
190 190 43% 2e-63 60% 152199 
a) Sequence alignment of parasite fructose-bisphosphate aldolase identified by LC-MS/MS (CER = cercaria; SC = 
schistosomula; SEA = soluble egg antigen; FAS = Fasciola adult) with E. ocellatus matched protein. Comparative Clustal X 
sequence alignment of cercaria FBA (P53442), schistosomula FBA-2 (P46563), SEA FAB (P53442), and fasciola FAB (P53442) 
 with (EOP00474_1).  
Key: Yellow boxes indicate peptides identified by LC-MS/MS. Numbers and red arrows link the identified peptides with peptide 
column number in Table in Appendix II. The table shows identity % and E value of aligned sequences. 
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Description Max 
score 
Total 
score 
Query 
cover 
E value Identity Accession 
Cercarial 
transformation fluid 
(CTF) P10984 
747 747 100% 0.0 94% 27893 
Soluble egg 
antigen (SEA ) 
P53471 
739 739 100% 0.0 93% 27893 
 
b) Sequence alignment of parasite actin identified by LC-MS/MS (CTF = cercarial transformation fluid; SEA = soluble 
egg antigen) with Atractaspis microlepidota matched protein. (Note: This venom protein was used because no homologous 
sequence was found in E. ocellatus database.) Comparative Clustal X sequence alignment of CTF actin-2 (P53471) and SEA 
actin-2 (P10984) with Q90X971. Key: Yellow boxes indicate peptides identified by LC-MS/MS. Numbers and red arrows link 
the identified peptides with peptide column number in Table in Appendix II. The table shows identity % and E value of aligned 
sequences. 
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Description Max 
score 
Total 
score 
Query 
cover 
E value Identity Accession 
Schistosomula 
(SC) Q27877 
672 672 100% 0.0 72% 224277 
 
c) Sequence alignment of parasite enolase identified by LC-MS/MS (SC = schistosomula) with matched protein 
from Python regius snake venom. (Note: This venom protein was used because no homologous sequence was found in E. 
ocellatus database.) Comparative Clustal X sequence alignment of schistosomula enolase (Q27877) with Python regius 
alpha-enolase (Q9W7L0). Key: Yellow boxes indicate peptides identified by LC-MS/MS. Numbers and red arrows link the 
identified peptides with peptide column number in Table in Appendix II. The table shows identity % and E value of aligned 
sequences.  
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Description Max 
score 
Total 
score 
Query 
cover 
E value Identity Accession 
Schistosomula  
(SC) and Fasciola 
adult (FAS) P20287 
274 274 48% 2e-96 82% 42219 
 
d) Sequence alignment of parasite glyceraldehyde 3-phosphate dehydrogenase identified by LC-MS/MS (SC = 
schistosomula and FAS = Fasciola adult) with Laticauda semifasciata matched protein. (Note: This venom protein was used 
because no homologous sequence was found in E. ocellatus database.) Comparative Clustal X sequence alignment of 
schistosomula GAPDH (P20287) and fasciola GAPDH (P20287) with Laticauda semifasciata GAPDH (BAD04859). Key: 
Yellow boxes indicate peptides identified by LC-MS/MS. Numbers and red arrows link the identified peptides with peptide 
column number in Table in Appendix II. The table shows identity % and E value of aligned sequences.  
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Description Max 
score 
Total 
score 
Query 
cover 
E value Identity Accession 
Soluble egg 
antigen (SEA) 
P11147 
1065 1065 93% 0.0 83% 21627 
Fasciola adult 
(FAS) P08418 
1025 1025 95% 0.0 81% 171041 
 
e) Sequence alignment of parasite heat shock 70kDa identified by LC-MS/MS (SEA = soluble egg antigen; FAS; 
Fasciola adult) with Oxyuranus scutellatus matched protein. (Note: This venom protein was used because no homologous 
sequence was found in E. ocellatus database.) Comparative Clustal X sequence alignment of SEA HSP70 (P11147) and 
fasciola HSP70 (P08418) with Oxyuranus scutellatus HSP70 (Q4VRH8). Key: Yellow boxes indicate peptides identified by 
LC-MS/MS. Numbers and red arrows link the identified peptides with peptide column number in Table in Appendix II. The 
table shows identity % and E value of aligned MS/MS.  
Figure 0.5 a-e Alignment of some LC-MS/MS identified schistosome and fasciola proteins with significant 
immunoreactivity to snake antivenom and snake venom protein.  
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1.13.5 Immunoblotting with toxin-specific IgG 
Immunoblotting of parasite proteins with antivenoms revealed variations in parasite 
immunoreactivity towards the antivenom. However, mass spectrometric identification was 
surprising, as none of the identified proteins were of proteases we are interested in i.e. serine 
proteases, metalloprotease, cysteine proteases or toxin proteins known to be neutralize by 
antivenom and have parallels in parasites such as PLA2 and c-type lectin. Antivenom is produced 
by immunising adult horses or sheep with snake venom/s, and their immunoglobulin is purified 
for antivenom production. Taking into account that these animals have mature immune systems 
and are exposed to daily antigenic stimuli while grazing in open fields, it is not surprising that 
only 10% of the immunoglobulin in antivenom binds to snake venom proteins (Harrison et al. 
2011). Thus, to eliminate the possibility that the parasite-reactive antivenom  IgGs were 
stimulated by environmental antigens we tested antibodies from mice immunised with 
immunogens representing the following venom toxin proteins: snake venom metalloprotease 
SVMP (two types of IgGs—one raised against SVMP subclass P-I and the other against subclass 
P-II); serine protease SP; phospholipase A2 PLA2; and the non-enzymatic toxin proteins c-type 
lectin (CTL I, II—the numbers represent different domains of the protein) and cysteine-rich 
protein CRISP (IgGs designed and prepared at Alistair Reid Venom Research Unit, LSTM, as 
part of Camila Rinjifo’s PhD project) (Figure 4.7).  
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Figure 0.6 Reduced immunoblotting (15% SDS-PAGE gel) against various toxin-specific IgGs and controls: snake 
venom metalloprotease (SVMP PI, PII); serine protease SP; phospholipase A2 PLA2; c-type lectin (CTL I, II); cysteine-rich 
protein CRI. Samples are: 1) S. mansoni cercaria, 2) S. mansoni cercarial transformation fluid, 3) S. mansoni schistosomula, 4) S. 
mansoni adult, 5) S. mansoni soluble egg antigen, 6) F. hepatica adult. The molecular weight markers (kDa) are shown on the 
left side of the image. 
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 The results demonstrated in this section prove that antibodies produced against toxin-
specific proteases can specifically cross-react with parasite proteins.  
1.14 Discussion 
Shared molecules among organisms is an anticipated finding, as many molecules, such as 
enzymes, hormones, and receptors, have been found to be conserved during evolution (Losada et 
al. 2005). This has significance in the identification of molecules with potential for the 
development of drugs or vaccines effective against different species or genera of organisms. 
Comparing the cross-reactivity of parasite proteins to antivenoms known to inhibit the toxicity of 
proteinases in snakebite victims produced interesting findings. Different antivenoms developed 
to neutralize venom toxins, whether to single snake venom (monospecific) or to a group of snake 
venoms from different species and genera (polyspecific), showed an ability to react with parasite 
proteins. It was interesting to us to determine whether the presence of similar proteins in 
parasites and snake venom that exhibit similar functions in silico would reflect this in vitro. In 
migrating stages of Schistosome and Fasciola, it is known that proteases of serine protease and 
metalloprotease play a pivotal role in infection initiation and persistence. Therefore, we started 
the experiments by testing the ability of monospecific antivenom, EchiTAb G, developed against 
snake venom (E. ocellatus) known to cause major pathology using serine proteinases and 
metalloproteases. Comparing cross-reactivity of this antivenom toward venom with what we 
observed with parasites, we were expecting reactivity to proteins with molecular weights around 
30kDa (i.e. serine protease) or 55kDa (i.e. metalloprotease), or at a low molecular weight of 
around 14kDa (i.e. PLA2). Our observation was close to what we predicted, as we detected 
proteins with molecular weights around 30–50kDa in different stages of the Schistosoma 
parasite. We broadened the antivenom specificity, using polyspecific antivenom EchiTAb-
PLUS-ICP and SAIMR polyvalent, aiming to include more IgGs to different toxin proteins in 
our investigation with parasites. Using these antivenoms, we observed an increase in the number 
of reacted proteins in some parasite stages, the disappearance of others, and the occurrence of 
proteins at lower molecular weights than observed with the monospecific antivenom. This 
variation occurred when we were investigating immunoreactivity toward antivenom of non-
African snake venom. Some immunoreactive proteins appeared in more than one immunoblot, 
and what was interesting is that they were within the molecular weights of the proteins we are 
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looking for. As these antivenoms were capable of cross-reacting with parasite proteins in vitro, 
we wondered whether it would apply in vivo. However, before answering this question, it was 
necessary to identify these immunoreacted proteins and detect the specificity of the reaction. 
Mass-spectrometry was used to determine which proteins show cross-reactivity.  
The major proteinases released from invading and transforming schistosome cercariae are 
known to be serine proteinases (Ingram et al. 2012; Knudsen et al. 2005). Several of the parasite 
serine proteinases have been characterised, and a membrane-anchored enzyme has been reported 
(Coombs and Mottram, 1997). We were hoping that some of the antivenoms might cross-react 
with this crucial enzyme, as it showed some similarity when aligned with snake venom serine 
proteinase, as shown in Chapter 3 (Figure 3.2). We were also hoping to see antivenom cross-
reactions with the metalloproteinases involved in a variety of critical processes, including 
haemoglobin digestion, surface membrane re-modelling, host cell interactions, and degradation 
of the extracellular matrix. 
However, analysing the bands that showed reactivity to antivenom was surprising; none 
of the identified proteins were of the protease or protease inhibitor nature we expected based on 
our bioinformatics results. The LC-MS/MS-identified proteins included major egg antigen p40 
and fructose-bisphosphate aldolase from S. mansoni. Interestingly, one of the identified bands 
corresponded to protein 14-3-3 in the schistosome adult. In parasites, this protein could be 
involved in different processes, such as interaction between sexes and sexual maturation, 
interaction with the host, excretion, and movement (Schechtman et al. 2001; Liu et al. 2009; El 
Ridi and Tallima 2009). When regarding the same protein in snake venom, the literature 
describes a relation between 14-3-3 protein and snake venom PLA2s. The protein was found to 
act as an acceptor for the neurotoxic PLA2 (Šribar et al. 2003).  
In the MS analysis, we identified several structural proteins that are usually recognised as 
part of the cell cytoskeleton, such as actin and paramyosin. Notably, all the proteins that were 
identified were intracellular; no extracellular secreted proteins were identified. These finding 
emphasises that a similarity in transcription does not necessarily correlate with protein 
expression. It should also be kept in mind that the samples we used were from whole parasite 
stage homogenates and not secreted proteins only. In addition, it is important to remember that 
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we investigated cross-reactivity between very distinct organisms and using antivenom developed 
against whole venom that contained non-toxic components in addition to toxin proteins. 
To exclude any non-specific cross-reactivity that might result from the fact that the 
antivenom was developed against whole venom protein composed of a mixture of other proteins 
in addition to toxins, we tested the ability of toxin-specific IgGs to cross-react with parasite 
samples. We selected IgGs developed against several snake venom toxin proteases: anti-SVMP 
PI, produced to bind to the 25–30kDa metalloprotease PI in vipers; anti-SVMP PII 30–45kDa; 
anti-SP that binds to the 26–47kDa thrombin-like serine proteases in vipers; anti-PLA2 that 
immunoreacts with the low MW 13–18kDa snake venom PLA2; and two IgGs developed against 
non-enzymatic component c-type lectin 26–28kDa and cysteine-rich secretory proteins 21–
25kDa (venom toxin MWs according to Mackessy, 2010). Marked cross-reactivity was detected 
against several toxin-specific IgGs: e.g. anti-SVMP PI, PII; anti-SP; anti-PLA2; anti-CTL; and 
anti-CRI I. Interestingly, the different schistosome life-stages exhibited variable reactivity 
profiles to toxin-specific IgGs. For example, as Figure 4.7 illustrates, cercaria cross-reacted with 
anti-serine protease IgG (SP) in two different bands of MW 28 and 45 kDa, which, while 
necessarily speculative, may represent cercarial elastase and another serine protease from this 
parasite’s stage. In addition to that cross-reaction, the cercaria sample showed some reaction to 
SVMP PI, an IgG developed against a specific domain of snake venom metalloprotease, which 
again might represent a metalloprotease used at this stage to penetrate the skin or avoid the 
immune system. It is possible that this variation in immunoreactivity is related to the expression 
of these proteins in each stage and to the functions they perform during the journey from the site 
of infection to the site of pathogenesis. It would have been beneficial if we could have obtained 
LC-MS/MS identification to confirm the identities of the proteins. However, as mentioned 
previously, the parasite sample size and the time frame did not allow us to perform this 
experiment.  
Overall, although using samples of only parasite secretory proteins may provide more 
substantial identifications, the results observed in this chapter indicate the possibility of 
significant cross-reactivity of antivenom to parasite proteases. This directs our attention towards 
whether a similar immunoreactivity towards snake venom proteins exists in parasite-infected 
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patients, and if so, to what extent the immunoreactivity can be sustained. Investigation of this 
question will be addressed in the next chapter.  
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Chapter 5       Examining Immunoreactivity to Various African Snake 
Venoms of Sera from Parasite-Infected Humans in Africa 
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1.15 Introduction  
 Parasite infection is a constant immunological and clinical challenge to host 
immune systems, as parasites consume host resources and affect immune responses. Extensive 
evidence for the influence of parasites on various pathways of the immune system has been 
deliberated. Chronic helminth and trematode infections are characterised by the distortion of 
immune reactions towards the T helper 2 (Th2) type response, including the upregulation of IL-
4, IL-5 and IL-13 cytokine production, which induces B-lymphocytes to shift to IgE antibody 
production, as well as to regulatory responses (Riveau and Capron, 2005). Attenuation of the 
regulatory network that prevents augmented immune responses facilitates the long-term survival 
of parasites in the host. Presumably, modulation of the host immune system is beneficial to the 
parasite, as it might prevent their eradication and, at the same time, protect the host from extreme 
proinflammatory responses (El-Ansary, 2003). Hence, immune hyporesponsiveness is frequently 
apparent in chronic parasitic infections (Zandman-Goddard and Shoenfeld, 2009). During 
infection, the immune system is first triggered to try to eradicate the parasite; however, as the 
burden or time after infection increases, the parasite seems to be able to modify and 
downregulate these specific responses in order to survive (El-Ansary, 2003). 
These modifications not only change the immune system towards the parasites; they have 
more generalised effects towards even non-infectious diseases. Studies have demonstrated that 
the presence of parasitic infections might have a protective effect in murine models of particular 
autoimmune diseases (Zandman-Goddard and Shoenfeld, 2009). For example, the development 
of type 1 diabetes in non-obese diabetic (NOD) mice is inhibited by prior exposure to 
Schistosoma mansoni eggs or to soluble extracts from either the adult worms or eggs (Zandman-
Goddard and Shoenfeld, 2009). In addition, helminths have been shown to develop protection in 
several models of inflammatory bowel disease (IBD), where the disease and the parasites are co-
localised. A concurrent S. mansoni infection in a semi-permissive rat model decreased the course 
of colitis, and S. mansoni was shown to exhibit a protective effect in experimental autoimmune 
encephalitis (EAE), a murine model for multiple sclerosis (Zandman-Goddard and Shoenfeld, 
2009). 
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Taking into account that most African populations at risk of snakebite reside within 
parasite endemic areas, and adding in the above-mentioned factors and the turbulence in the 
immune system caused by parasitic infections towards even non-infectious diseases, raises the 
question of whether this situation can be applied to immunity towards snake venom.  
In examining this type of immunity, we found that human immunity against snake venom 
is a debatable topic (Isbister et al., 2010). There is limited verification supporting the 
development of human antibodies to snake toxins after repeated exposure. In some studies that 
have measured IgG levels after a second exposure of patients to the same snake venom, the 
patients had an elevated IgG titre against the venom, but it failed to protect them from local 
injuries and myocytosis (Isbister et al., 2010; Theakston et al., 1981). Ethical concerns have 
prevented any studies on the ability of venom-stimulated antibodies to protect against 
envenoming effects; however, there have been several anecdotal reports from snake handlers to 
suggest that self-immunisation with venom stimulates antibodies, and that some individuals 
exhibit a measure of protection against envenoming, although many do not. There is no 
immunological reason to suggest that humans could not develop the same level of venom-
specific IgG if they are subjected to the same venom-immunisation program as the horses or 
sheep involved in antivenom production. 
From a pathological point of view, the local and systemic effects of snakebite are often 
characterized by proinflammatory responses. The injection of the venom components into the 
victim’s tissues, and the direct pathological effects of the toxins provoking necrosis and 
haemorrhage, stimulate a prominent and complex inflammatory reaction associated with the 
synthesis and release of inflammatory mediators, followed by the recruitment of leucocytes 
(Gutiérrez et al., 2007; Farsky et al., 2005; Harrison et al., 2011). The anti-inflammatory effects 
of helminth infections might, through this immunological route, also impart a level of tolerance 
to the effects of snakebite.  
There are many ways to answer the broad question asked previously about whether the 
influence of a parasitic infection can favour the host immunity toward snake venom. However, 
by going through the progression of this study and correlating the findings in the literature with 
our findings, the objective of this chapter became to examine whether anti-helminth parasite 
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IgGs reacted with snake venom proteins, and if the presence of cross-reactive antibodies to snake 
venom in patients with parasitic infections imparts a level of protection to snakebite that has not 
before been recognized. In addition, investigate the ability of therapeutic IVIG to neutralize 
venom toxins and compare if these IVIG purified from malaria-infected patients will have a 
better affinity binding to snake venom toxin proteins. 
 
1.16 Materials and Methods 
The materials (parasite samples, venom, immunoglobulins and sera) described in this 
chapter were collected and prepared as described in Chapter 2. 
 
1.16.1 Human sera and immunoglobulins 
For the experimental investigations in this chapter, the following were used: 
• Serum collected from patients with schistosomiasis 
• Sera from patients with symptomatic and asymptomatic filariasis 
infections; 
•  Malawian malarial patients’ IgGs;  
• IgGs purified for therapeutic reasons; GAMMAGARD (IVIG) 
• IgM ; PENTAGARD. 
These human products were selected according to the following criteria: first, for the 
parasite infected sera and IgGs, they were all purified from African individuals living in areas at 
high risk for snakebite. All of them were tested in other studies for antibodies against parasites 
and all were positive.  
The Malawian IgGs were purified from malaria-infected patients, selected because the 
literature specified that Africans infected with parasitic diseases have a provoked 
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hypergammaglobulinemia, as a result of the persistent presence of antigens (Mekhaiel et al., 
2011). Thus, indications suggest that this IgG may be more effective at treating autoimmune 
diseases, rather than IVIG purified from European donors whose immune systems are not 
persistently being stimulated by parasites. Therefore, we wanted to examine if these IgGs are 
capable of neutralizing venom toxin proteins, and then compare them with GAMMAGARD and 
PENTAGARD purified from non-African donors.  
The non-infected normal human sera and purified IgGs were all from non-African 
populations, American or European, and were provided by the manufacturer and stored as 
specified by that manufacturer (Sigma, UK). A detailed description of the sera and 
immunoglobulin sources and collection are described in Chapter 2, Section 2.4. 
For the immunoblotting examinations, the primary antibodies (sera or immunoglobulin) 
were diluted in blocking buffer at a dilution of 1:100 and 1:200, and the blots were incubated 
overnight in the solution. The next day, the blots were incubated for 1 hour with a secondary 
antibody (goat anti-human IgG) (1:1000 dilution), coupled to horseradish peroxidase (HPR). 
Visualization of the results was performed using a 3,3’-diaminobenzidine peroxidase (DAB) 
substrate (Sigma, UK) after washing with TBST as described in Chapter 2, Section 2.6. 
For the ELISAs, the end-point titre started from the 1:10 diluted primary antibody, 
followed by 1:2 serial dilutions, and the method was repeated across the wells of the plate. 
Related to the avidity ELISA, the plates were coated with Echis pyramidum leakeyi venom and 
incubated overnight at 4°C, with a 1:10 dilution for the immunoglobulins and 1:50 for the sera 
(the avidity titres were optimized according to the end-point titres and amount of sera available), 
as described in Section 2.8 a-b, Chapter 2. 
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1.17 Results 
1.17.1 Reactivity of human IgG and sera to snake venom proteins  
The goal of this experiment was to investigate the possibility of the presence of 
antibodies that are able to immunoreact with venom toxin proteins in the sera of patients infected 
with parasites in African provinces known to be at high risk of snakebite. The following snake 
venoms were selected to cover most parts of the African continent, specifically areas at high risk 
of both parasitic infections and snakebite: Echis ocellatus (West Africa), Echis pyramidum 
leakeyi (East Africa), Bitis arietans (spread through most parts of Africa and the southern parts 
of the Arabian peninsula), Naja haje (North and West Africa), Naja nigricollis (Sub-Saharan 
Africa), Naja pallida (East Africa) and Dendroaspis angusticeps (east coast of southern Africa). 
Similar to why we selected a non-African antivenom in the previous chapter, Acanthophis 
antarcticus, found in Australia, was selected to test if the reactivity was exclusive to African 
snake venom. As a comparison, the following parasites samples were used: Schistosoma mansoni 
cercaria, S. mansoni adult and Fasciola hepatica adult (Figure 5.1).  
 
 
Figure 0.1 15% reduced SDS-PAGE profiles of eight venoms from the families’ elapids and vipers, 1) E. ocellatus, 2) 
E. p. leakeyi, 3) B. arietans, 4) N. haje, 5) N. nigricollis, 6) N. pallida, 7) D. angusticeps, 8) A. antarcticus; and 15% reduced 
LANE SAMPLE  
1 Echis ocellatus 
Viper 
(snakes) 2 Echis pyramidum leakeyi 
3 Bitis arietans 
4 Naja haje 
Elapid 
(snakes)  
5 Naja nigricollis 
6 Naja pallida 
7 Dendroaspis angusticeps 
8 Acanthophis antarcticus 
9 S. mansoni cercaria Trematode  
(parasites)  
10 S. mansoni adult 
11 F. hepatica adult 
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SDS-PAGE profile of parasites 9) S. mansoni cercaria, 10) S. mansoni adult, and 11) F. hepatica adult. 5µg of protein was loaded 
in each well. The molecular weight marker (kDa) is shown on the left of the image. 
i) Reactivity of sera collected from filariasis patients to snake venom 
In the immunoblotting profiles, several protein bands, ranging in molecular weight from 
10 to 125 kDa, were visible in the different antigen preparations. First, the immune-cross-
reactivity to the symptomatic filariasis patients’ sera was completely different when comparing 
the sera collected from the asymptomatic patients with that of the symptomatic individuals. By 
far, the viper snake venom cross-reactivity profile showed a reaction to various low and high 
molecular weight venom proteins, with a band of approximately 23 kDa present in all three 
vipers, which resembles the molecular weight of the venom toxin SVMP PI (MacKessy, 2009; 
Casewell et al., 2009).  
The dominant immunoreactive protein in each snake was different, as illustrated in 
Figure 5.2. The E. ocellatus dominant protein had a molecular weight of around 50 kDa, which 
again, might be linked to the SVMP, however to a different sub-class PIII, compared with 60 and 
16 kDa in E. p. leakeyi and B. arietans, which may correlate to L-amino acid oxidase (LAAO) 
and PLA2, respectively (MacKessy, 2009; Mitra and Bhattacharyya, 2013). In contrast, the most 
dominant proteins in the elapid snake venom had low molecular weights, with 10-15 kDa protein 
bands being highly represented, which share a molecular weight with PLA2 (14 kDa) and the 
three-finger neurotoxins (MacKessy, 2009; Fry et al., 2009; Gutiérrez & Lomonte, 2013; Bryan 
G Fry et al., 2003; B G Fry et al., 2003; Alape-Girón et al., 1999). However, an interesting 
observation is the disappearance of these highly cross-reacted, low molecular weight elapid 
proteins in blots probed with symptomatic filariasis patients (Figure 5.2), although these proteins 
were detected, even in sera collected from normal blood donors (Figure 5.4). 
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Figure 0.2 Immunoreactivity profile of filariasis patients’ sera to venom proteins: 15% reduced, non-reduced, and 
native gel immunoblotting against filariasis patients’ sera and controls at a dilution of 1:200 in the blocking buffer. Snake 
venoms: 1) E. ocellatus, 2) E. pyramidum leakeyi, 3) Bitis arietans, 4) Naja haje, 5) Naja nigricollis, 6) Naja pallida, 7) 
Dendroaspis angusticeps, and 8) Acanthophis antarcticus, and parasites: 9) S. mansoni cercaria, 10) S. mansoni adult, 11) F. 
hepatica adult homogenate. The molecular weight marker (kDa) is shown on the left of the image. 
 
ii) Reactivity of sera collected from Schistosomiasis patients to snake venom 
Sera collected from patients with schistosome infections showed cross-reactivity to 
various high and low molecular weight proteins in vipers, and mainly low molecular weight 
proteins in elapids, as these proteins are the dominant proteins in these venoms – therefore the 
reactivity observed may not be specific (Figure 5.3). The interesting finding, again, was the loss 
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of reactivity with the highly antigenic, low molecular weight elapid proteins when using sera 
collected from the same infected patients after one year of treatment, in patients living in a 
village with a low prevalence of schistosomiasis (Lwanika village) (Figure 5.3). As mentioned in 
Chapter 2, the schistosomiasis patients’ sera were collected from two villages, one with a high 
prevalence of infection (Bugoto), and the other with a low prevalence (Lwanika), on two 
separate occasions. The first was a baseline collection before treatment, and the second was one 
year after treatment.  
 
Figure 0.3 Immunoreactivity profile of schistosomiasis patients’ sera to venom proteins: 15% reduced, non-reduced 
and native gel immunoblotting against schistosomiasis patients’ sera and controls at a dilution of 1:200 in blocking buffer. Snake 
venoms: 1) E. ocellatus, 2) E. pyramidum leakeyi, 3) Bitis arietans, 4) Naja haje, 5) Naja nigricollis, 6) Naja pallida, 7) 
Dendroaspis angusticeps, and 8) Acanthophis antarcticus, and parasites: 9) S. mansoni cercaria, 10) S. mansoni adult, 11) F. 
hepatica adult homogenate. The molecular weight marker (kDa) is shown on the left of the image. 
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iii) Reactivity of sera collected from healthy individuals to snake venom 
Of note, the immunoblotting venom proteins to sera collected from healthy individuals, 
sterile-filtered from American males’ AB plasma (Sigma), showed reactivity to similar proteins 
reacted with patients samples, although with a weaker reaction (Figure 5.4). We were not 
expecting this reactivity in healthy humans (we selected it to be a negative control), presumably 
the IgG-donors had not been bitten by snakes. 
 
Figure 0.4 Immunoreactivity profile of normal human sera to venom proteins: 15% reduced, non-reduced and native 
gel immunoblotting against normal human sera, and controls at a dilution of 1:200 in blocking buffer. Snake venoms: 1) E. 
ocellatus, 2) E. pyramidum leakeyi, 3) Bitis arietans, 4) Naja haje, 5) Naja nigricollis, 6) Naja pallida, 7) Dendroaspis 
angusticeps, and 8) Acanthophis antarcticus, and parasites: 9) S. mansoni cercaria, 10) S. mansoni adult, 11) F. hepatica adult 
homogenate. The molecular weight marker (kDa) is shown on the left of the image. 
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iv) Reactivity of intravenous immunoglobulin IVIG to snake venom 
In this experiment we used purified immunoglobulins:  
• IgGs purified from Malawian malaria patients 
• as negative control, IgGs (IVIG) (gamma globulin) 
• IgMs (penta globulin) purified from healthy donors.  
Intravenous immunoglobulin (IVIG) has been used for the treatment of autoimmune 
inflammatory disorders (Ballow, 2011; Orange et al., 2006; Mekhaiel et al., 2011). Moreover, 
studies showed that IgGs collected from the African population have a mean concentration that is 
approximately twice that of the UK controls (Rowe et al., 1968; Mekhaiel et al., 2011). This 
significant increase in immunoglobulin levels appears to be the result of a notable polyclonal B 
and T cell activation associated with protozoal infections such as malaria and African 
trypanosomiasis (Mibei and Orago, 2005). Similar to IVIG, IgM showed the ability to stimulate 
autoantibody activity through idiotypic interactions (Hurez et al., 1997).  Therefore, we wanted 
to test in vitro the capability of Malawian IgGs to cross-react with snake venom, and probably to 
prevent the immunopathology caused by snake venom; then compare that with the reactivity of 
commercially-available IVIGs prepared as IgG and IgM formulations. 
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Figure 0.5 Immunoreactivity profile of purified immunoglobulins IVIG to venom proteins: 15% reduced, non-reduced 
and native gel immunoblotting against purified immunoglobulins IVIG and controls at a dilution of 1:200 in blocking buffer. 
Snake venoms: 1) E. ocellatus, 2) E. pyramidum leakeyi, 3) Bitis arietans, 4) Naja haje, 5) Naja nigricollis, 6) Naja pallida, 7) 
Dendroaspis angusticeps, and 8) Acanthophis antarcticus, and parasites: 9) S. mansoni cercaria, 10) S. mansoni adult, 11) F. 
hepatica adult homogenate. The molecular weight marker (kDa) is shown on the left of the image. 
 
   
IgGs purified from the malaria patients in Malawi exhibited intense and reactivity to the 
low molecular weight elapid venom antigen, compared with a more comprehensive and broad 
reactivity to viper venom (Figure 5.5). On the other hand, GAMMAGUARD (IVIG), filtered 
from normal individuals, expressed less reactivity than that showed in the Malawian IgG, with 
high cross-reactivity to low molecular weight elapid proteins only, and limited immunoreactivity 
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to proteins of approximately 21 kDa in vipers in general. In contrast, the IgMs failed to show any 
cross-reactivity to any of the used antigens, whether venom or parasites (Figure 5.5).  
To complete the cross-reactivity profile, and to investigate whether this immunoreactivity 
would be continued when the sera and IVIG reacted to the proteins in their native forms: non-
reduced and native proteins were processed and probed against the above-mentioned primary 
antibodies (Figures 5.2- 5.5). When non-reduced proteins are used, the cross-reactivity profiles 
change. An intense reaction occurred, with low molecular weight elapid venom antigens 
disappearing and a few high molecular weight proteins reappearing. However, the viper non-
reduced proteins showed cross-reactivity to proteins with high and low molecular weights, 
similar to that which it showed in the reduced blots. On the other hand, blots probed with 
immunoglobulin showed very week or no reaction at all. Likewise, the native proteins failed to 
cross-react with any of the antibodies and sera, except for sera collected from patients living in 
the high schistosomiasis prevalence village (Figures 5.2-5.5). 
 
1.17.2 Reactivity of human IgG and sera to deglycosylated snake venom 
proteins 
In order to determine if the immunoreactivity of snake venom toward human sera and 
immunoglobulin is affected by post-translational glycosylation of some venom proteins, a 
deglycosylation experiment was done for the proteins prior to immunoblotting.  
Although the PNGase F enzyme will release glycans from many glycoproteins in their 
native forms, the denaturation step is still required to guarantee complete hydrolysis of all 
subject bonds. Proteins that were run on SDS-PAGE in this experiment were in a fully denatured 
state.  
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Figure 0.6 SDS-PAGE profile of deglycosylated venom proteins: 15% reduced SDS-PAGE profiles of eight venoms 
from the elapids: N. haje, N. nigricollis, N. pallida, D. angusticeps and A. antarcticus, and vipers: E. ocellatus, E. p. leakeyi, B. 
arietans, after in vitro enzymatic deglycosylation was achieved by the addition of PNGase F (10 units/mL) to 140 µg of venom 
proteins, with incubation for 1 hour at 37°C. An equal amount of PNGase F treated (*lane) and non-treated (next lane) lysate (10 
µg) was loaded. The molecular weight marker (kDa) is shown on the left of the image. Red arrows indicate the molecular weight 
of PNGase F at around 36 kDa.  
 
As expected, only a minor shift in electrophoretic mobility was observed in the elapid 
venom when compared to the non-digested venom, and there was no difference between the 
deglycosylated and non-deglycosylated low molecular weight proteins (Figure 5.6). However, in 
the viper venom, deglycosylation resulted in the appearance of new protein bands in addition to 
the slight shift in the other proteins, indicating how glycosylation contributes to the total protein 
molecular mass and antigenicity. A comparison of the digested proteins (lanes with *) and the 
non-digested ones (lanes without *) revealed that the deglycosylated proteins in both elapid and 
viper venom migrated at a slightly lower molecular weight than the glycosylated material, 
suggesting that deglycosylation was complete. The molecular weight of PNGase F was 36 kD 
(arrows in Figures 5.6 and 5.7). 
Comparing the immunoreactivity profile of the deglycosylated and non-deglycosylated 
proteins showed a very minor difference between the two lanes. This may indicate that the 
reactivity was not affected by the sugars attached to the proteins in the post-translational 
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modification (Figure 5.7).  
 
Figure 0.7 Immunoreactivity profile of deglycosylated venom proteins: Immunoblotting profile of eight venoms from 
the elapids: N. haje, N. nigricollis, N. pallida, D. angusticeps, and A. antarcticus, and vipers: E. ocellatus, E. p. leakeyi, B. 
arietans, reactivity toward human sera and immunoglobulin after in vitro enzymatic deglycosylation was achieved by the 
addition of PNGase F (10 units/mL) to 140 µg of venom proteins with an incubation for 1 hour at 37°C. An equal amount of 
PNGase F treated (*lane) and non-treated (next lane) lysate (10 µg) was loaded and the blots were probed with sera collected 
from schistosomiasis patients and sera collected from healthy individuals. The molecular weight marker (kDa) is shown on the 
left of the image. Red arrows indicate the molecular weight of PNGase F at 36 kDa.  
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1.17.3 The titre and avidity of helminth-infected human sera and IVIG 
preparations to snake venom proteins 
To determine the titres of the sera of the helminth-infected human and IVIG interacting 
with snake venom, and the antigen-binding strength (relative avidity ELISA), an end-point 
enzyme-linked immunosorbent assay and avidity ELISA were performed. The end-point titre 
comparisons of the three immunoglobulins and three human sera end-point titres revealed some 
variation between them. 
First, by comparing the results of the IVIG, the IgGs collected from African malaria 
patients and that collected from normal humans (Malawian and GAMMAGARD), end-point 
titres were 1:30 and 1:15, respectively (Table 5.1). On the other hand, the IgM (PENTAGARD) 
showed a higher titre (1:80) than the IgG titres, although it had lower relative avidity (2.05 M) 
compared with 2.53 and 4.25 M for Malawian IgG and GAMMAGARD (IVIG), respectively. 
This result might be related to the nature of each immunoglobulin, as IgMs represent the first 
antibodies to appear in response to the initial exposure to an antigen, and they are not as versatile 
as IgGs and decline after a short period of infection. The relative avidity shown in the 
GAMMAGARD (IVIG) (4.25 M) might be explained by the ability of the IgG to bind 
and neutralise toxins. However, immunoglobulin avidity to venom was not as strong as we were 
hoping it would be. 
Serum samples collected from the patients with filariasis (symptomatic and 
asymptomatic) exhibited titres against E. p. leakeyi venom that varied by about two dilution 
factors. Interestingly, the schistosomiasis patients’ sera collected from non-treated patients 
demonstrated similar titres to asymptomatic filariasis patients’ sera, which were not treated, 
either. This result agrees with the immunoblotting, as the profiles of the schistosomiasis and 
asymptomatic filariasis patients showed similar reactivities to snake venom, which might be 
related to the immune response exhibited by the two parasites. This will be discussed in detail in 
the Discussion section. The results of the relative avidity ELISA performed on the samples 
collected from the patients with filariasis and schistosomiasis showed that the relative avidity of 
the filariasis samples was consistently (but not markedly) more robust than that of the 
schistosomiasis samples (Table 5.1). This finding did not support our expectations regarding the 
probability of the presence of natural immunity to venom toxin in patients with parasitic 
115 
infections. 
 
Figure 0.8 End-point titre of helminth-infected human sera and IVIG preparations to snake venom proteins: Bar charts 
demonstrating the ELISA titres of IVIG preparations (IgGs collected from malaria patients in Malawi and IgGs and IgMs 
purified from healthy individuals for therapeutic purposes) and sera (collected from symptomatic and asymptomatic filariasis 
patients, schistosomiasis patients and healthy individuals (Sigma)) were tested against E. p. leakeyi venoms. The end-point titre 
was described as the dilution at which absorbance was greater than that of the negative control (venom only) plus 2 standard 
deviations (represented by the linear trend line in the graph). 
Human serum/ IgG ELISA Chaotropic ELISA 
 End-point titre Relative avidity (M) 
Malawian IgG (malaria patients) ≈ 3 x 10⁸¹ 2.53 
GAMMAGARD (human IgG) ≈ 1.5 x 10⁸¹ 4.25 
PENTAGARD (human IgM) 8 x 10⁸¹ 2.05 
Filariasis (symptomatic) serum ≈ 6 x 10⁸¹ 3.02 
Filariasis (asymptomatic) serum 8 x 10⁸¹ 3.93 
Schistosomiasis serum 8 x 10⁸¹ 0.57 
Normal human serum 2 x 10⁸¹ 0.68 
Table 0.1 The end point-titres and relative avidity of immunoglobulins and human sera: three different 
immunoglobulins (IgGs collected from malaria patients in Malawi, and IgGs and IgMs purified from healthy individuals for 
therapeutic purposes) and four sera (collected from symptomatic and asymptomatic filariasis patients, schistosomiasis patients 
and healthy individuals (Sigma)) were tested against E. p. leakeyi venoms. Relative avidity is expressed as the amount of 
ammonium thiocyanate required to reduce the antibody binding to the venom by 50%. 
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1.18 Discussion 
The examination of the presence of immunologic reactivity against snake venom proteins 
in patients infected with parasitic diseases elicited some interesting observations. First were the 
obvious differences between asymptomatic and symptomatic filariasis patients. The 
asymptomatic patients’ sera showed higher cross-reactivity ability toward venom proteins in 
comparison with the symptomatic ones. Interestingly, this immunoreactivity included both high 
and low molecular weight proteins in viper venom, which represents major toxin proteins in 
venom like SVMP, LAAO and PLA2 that play a major role in the pathology caused by viper 
venom.  
When these sera were probed to test elapid venom reactivity, low molecular weight 
proteins, including PLA2 and the extremely toxic low immunogenic 3-finger toxins, were the 
main reacted proteins, the assumption of the proteins were based on Mackessy, 2009. Although 
this immunoreactivity might be a result of triggering the immune system of the host by parasite 
proteins similar in function and sharing some homology in the protein sequence with venom 
proteins, it is interesting to observe such a difference between the two patient groups. This 
remarkable difference between the two groups might be explained by understanding the role and 
the effects of filarial nematodes in disturbing and regulating the immune systems of infected 
patients.   
Filariasis patients’ immune responses towards the parasite are of the T helper-2 type, 
which is involved in the production of cytokines IL-4, IL-5, IL-9, IL-10 and IL-13 and the 
antibody isotypes IgG1, IgG4 and IgE (Babu and Nutman, 2012). It also harbours an expanded 
population of eosinophils, basophils, mast cells and alternatively activated macrophages. Over 
time, when patients reach chronic infection, prototypical type-2 responses are modulated by both 
adaptive and natural regulatory T cells, alternatively activated macrophages, and eosinophils. 
Filarial infections usually exhibit elevated levels of IgE, which are detected soon after exposure. 
These IgEs are mostly not antigen-specific, and they persist for many years after treatment for 
the infection (Mitre and Nutman, 2006). Filarial parasites exert intense immunoregulatory effects 
on the immune system of the infected host; these effects exhibit both parasite antigen-specific 
and more generalised levels of immunosuppression (van Riet et al., 2007). Patients with 
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lymphatic filariasis have shown markedly diminished responses to parasite antigens, as well as 
some considerable attenuation in response to bystander antigens and routine vaccinations (van 
Riet et al., 2007). Treating symptomatic patients with the anti-filarial drug ivermectin might also 
play a role in diverging the immune response of treated patients, and therefore, induce the loss of 
immunoreactivity to snake venom proteins (Bergquist and Lustigman, 2010). This may explain 
the differences we observed between blots probed with sera collected from symptomatic patients 
and asymptomatic ones. 
The ELISA results support the previous assumption that the alteration in the immune 
system caused by the infection triggered the reactivity. In addition, the elevation of the antigen 
non-specific IgE levels, along with the changes in the immune responses, clarifies the observed 
low-affinity binding of the human sera to snake venom proteins, which lost their stability with 
the addition of a low concentration of chaotropes.  
The results of the schistosome-infected patients did not show a diverse picture from that 
of the filarial patients; instead, the reaction sequences showed similar progression. The immunity 
to the schistosomes resembles the filariasis response in many ways. It is associated with the T 
helper cell type-2 immune response, which is characterised by elevated levels of IgE, a high 
production of IL-4, and eosinophilia (Riveau and Capron, 2005). Similar to filariasis, the T 
regulatory cells and suppressive macrophage populations of schistosome-infected patients might 
be crucial for down-modulating immune inflammatory responses through infection (Capron et 
al., 2005). More importantly, schistosomiasis might also have potent systemic 
immunomodulatory and immunoregulatory effects on the host system towards other infectious 
and non-infectious antigens (Maizels & Yazdanbakhsh, 2003; Wickelgren, 2004).  
The interesting observation in the experiments conducted on the schistosomiasis patients’ 
sera was the difference between results obtained from patients living in low prevalence villages 
compared with high prevalence villages. The complete loss of immunoreactivity to the high 
antigenic, low molecular weight elapid venom proteins from blots performed with sera collected 
from the low prevalence village one year after treatment was surprising. Reactivity toward these 
venom proteins appeared even in sera collected from healthy individuals. This finding might 
correlate with the potent systemic immunomodulatory and immunoregulatory effects on the host 
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system described above (Capron et al., 2005). 
Besides the substitutive treatment of patients with primary and secondary antibody 
deficiencies, therapeutic preparations of normal polyspecific IgG (IVIG) are used in treating a 
large number of immune-mediated conditions, such as acute and chronic/relapsing autoimmune 
diseases and systemic inflammatory disorders (Prasad et al., 1998). Furthermore, studies showed 
that IgGs purified from African populations may have better efficacy when used for treatment 
than those purified from Europeans, as they have not been persistently stimulated by parasites 
(Mekhaiel et al., 2011; Rowe et al., 1968). In the present study, we were hoping to discover 
positive outcomes by immunoreacting snake venom proteins with purified human 
immunoglobulins.  
Malawian IgG showed an interesting pattern of cross-reactivity towards venom proteins 
similar to that obtained by the sera collected from asymptomatic filariasis patients and non-
treated schistosomiasis patients. We were looking for this pattern of immunoreactivity in the 
Malawian IgG, proposing that these antibodies might have the ability to neutralise some of the 
venom toxin proteins, similar to those from parasites. This agreed with what the literature was 
describing about the greater capability of IVIG purified from malaria-infected Africans to 
neutralise antigens in comparison with IVIGs from European and American donors. Although 
not expected, the presence of reactivity between low immunogenic proteins in snake venom and 
the non-specific purified IgGs (GAMMAGARD) may support the above. In contrast, purified 
IgM (PENTAGARD) showed the expected results, and failed to cross-react with the venom 
proteins.  
Although the IgGs (IVIG and Malawian IgG) showed cross-reactivity towards venom 
proteins, this reactivity was not robust when tested by ELISA, as the end point titre did not reach 
higher than 3 x 10-¹ in Malawian IgG and 1.5 x 10-¹ and 8 x 10-¹ in GAMMAGARD and 
PENTAGARD, respectively. This was supported by the loss of connectivity between the 
antibodies and the venom when a low concentration of chaotrope was added in the avidity 
ELISA.   
To further investigate if the post-translational modification of the proteins affected the 
way the venom reacted to human sera and immunoglobulin, a venom protein deglycosylation 
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experiment was done. The evidence confirms that the immunoreactivity we observed and 
described in this chapter did not show a significant difference between the deglycosylated 
proteins and non-deglycosylated ones. Thus, the post-translational modification and the addition 
of glycan did not affect the reactivity of the venom.  
Overall, in going through the information derived from the results described in this 
chapter, we can conclude that pre-existing parasitic infections generate IgG responses that cross-
react, with weak affinity, to snake venom proteins. The low titre and weak affinity of this IgG 
cross-reactivity precludes us from concluding that parasite-induced IgGs offer any protection to 
the effects of snake envenoming. Nevertheless, it would be interesting to study sera collected 
from envenomed patients who are infected or have been infected with parasites, and compare it 
with non-infected envenomed patients. It would be fascinating to study the differences in 
pathology and immune reactivity between them.  
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1.19 Introduction 
 
Despite the effectiveness of antivenom, the mortality and morbidity rates of snakebite 
remain high in countries (particularly African countries, with 32,000 deaths annually) with the 
lowest GDP/capita and governmental expenditures on health (Harrison et al. 2009; Kasturiratne 
et al. 2008; Harrison et al. 2011). The high cost (>$100/vial) and logistical difficulties of delivery 
explain the poor demand for antivenom in these countries (Harrison et al. 2009). Research 
encouragement to broaden the geographic efficacy and improve the commercial viability of 
antivenom therapy is compelled by several factors. There are promising developments in 
experimental tests in this area, involving ‘antivenomics’(Wagstaff et al. 2009; Lomonte et al. 
2008; Calvete et al. 2010; Calvete et al. 2009) and ‘epitope-string immunogen’ (Harrison 2004; 
Wagstaff et al. 2006) approaches, that aim to amplify the clinical and snake-species efficacy of 
snakebite serotherapy and to reduce manufacturing costs. On the other hand, several studies in 
the early 50s have tested the efficiency of vaccination against snakebite (Sawai et al. 1969; 
Someya et al. 1972). They represented a promising neutralization of toxic effects of snake 
venom. However, the developed immunity did not persist for long periods as envenomation 
occurred in immunized individuals when bitten 2-years post immunization (Flowers 1963).  
The study of epidemiological maps indicates that populations residing in geographic 
zones with a high risk of snakebite also suffer from the medical burden of vector-transmitted 
diseases and neglected tropical diseases (NTD) (Harrison et al. 2009; Harrison et al. 2011). 
Disease vectors, such as mosquitoes, coincide with snakebites during rainfall season. The 
probability of high snakebite incidence is increased at the beginning of the rainy season 
(Kasturiratne et al. 2008). Rainfall facilitates the growth of mosquito populations, resulting in an 
overlapping period during the rainy season where both snakebite incidence and the number of 
mosquitoes increase (Chaves and Kitron 2011; Chaves et al. 2011).  
All of the aforementioned factors, in addition to, the fact that some mosquitoes salivary 
proteins are of the same protein types as some of the most pathogenic venom proteins – 
metalloproteinases (Francischetti 2010; Arcà et al. 2005) led to the development of the Natural 
Immunogen Boosting of Vaccination (NIBOVAC) vaccine concept by Harrison of the Alistair 
Reid Venom Research Unit. NIBOVAC offers an alternative, mass-treatment, and thus cost-
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effective approach using natural boosting through mosquito bites to generate high titres of 
circulating anti-toxin IgG to neutralise envenoming.  
NIBOVAC was conceptualised as a potential prophylactic therapy for snakebite on the 
basis that: (i) immunity to the lethal effects of snakebite has developed in horses hyper-
immunised with venom during antivenom production, (ii) the capability of IgGs specific to 
discrete venom toxin motifs to neutralise venom-induced lethality (Wagstaff et al. 2006; Iddon et 
al. 1988) and (iii) the coincidence between West Africa E. ocellatus viper bites and mosquito 
bites during the rainy season (Molesworth et al. 2003). Concerning NIBOVAC feasibility, the 
most critical challenge is determining whether a primary immunogen can be designed such that 
the seasonal surge in mosquito bites (which provoke immunogenic responses in both endemic 
and temporal human populations (Fontaine et al. 2011; Orlandi-Pradines et al. 2007; Titus et al. 
2006) can be manipulated to boost circulating anti-toxin IgGs naturally at the time of peak 
snakebite risk. Conventional vaccination against snakebite is impractical because the lethal 
effects occur rapidly (6–24 hours post-bite) and well before protection could be mounted by a 
recalled immunological response (Müller et al. 2012). 
NIBOVAC is completely a novel vaccine perception designed to exploit natural 
immunogens to stimulate sustained levels of protective immunity against snakebite. The success 
of NIBOVAC will (i) preclude the current requirement for conventional boosting vaccination, 
which is considered one of the obstacles in vaccination against snakebite and constitutes a 
financial and logistic impediment to the uptake and effectiveness of many vaccine programs and 
(ii) establish pre-existing protective immunity for the rapid onset of snakebite pathology. One of 
the barriers to vaccination against snakebite is that conventional vaccination establishes dormant 
immune memory, which is activated into protective immunity by antigens from venom. 
Therefore, there is a several-day delay before the ‘vaccinee’ is protected from pathology/death 
by the immune response, which prevents the implementation of vaccine for snakebite, as 
pathological manifestations are very rapid (Chippaux and Goyffon 1998). 
To attain our goal, we selected mosquito bites (day and night biters; natural booster) and 
haemorrhagic venom from West Africa, E. ocellatus, as test models. We utilised a ‘reverse 
vaccinology’ approach (Donati and Rappuoli 2013) to detect multiple epitopes for each 
toxin/mosquito salivary protein (MSP; sialome) family that is predicted to be immunologically 
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cross-reactive. Multiple linear B-cell and T-cell epitopes, designed to direct IgG to the native 
epitope, identified by the computational selection of short, conserved peptide sequences 
predicted to be surface-exposed in toxin/MSP macromolecular structures. The identified epitopes 
subjected to an amino acid sequence manipulation technique used at the Alistair Reid venom 
research unit, to devise 6–12 overlapping AA peptides, a set of chimeric epitope candidate 
immunogens best representing the conformation of the native epitopes (Wagstaff et al. 2006). 
The designed epitopes will be conjugated to carbon nanotubes (phase 1). In phase 2, with local 
Ethics Committee approval, three groups of 10 mice vaccinated once in week 0, 4 or 8 with 
NIBOVAC-carbon nanotube immunogen. Then, in week 12, the mice are subjected to two weeks 
(three times/week) of mosquito feeding. In week 16, the mouse groups subjected to assays 
approved by the WHO to determine the IgG neutralisation of venom-induced haemorrhage 
whereby the mice intradermally injected with venom followed by examination of the 
haemorrhagic lesion size 24 hours post-injection. Throughout the experiment, sera samples 
collected and examined for the temporal induction of IgG specific to venom toxin epitopes 
predicted from heir sequences. Control groups included: mice receiving (i) only mosquito bites 
and (ii) only the NIBOVAC immunogen. The measurement of hypersensitivity induction to MSP 
in all groups is undertaken by measuring MSP-specific IgE. This chapter will discuss the 
methods and the results of phase one of this study that include epitope selection, design and 
construction, as the time elected for this PhD restricted this study to phase one. Phase two that 
will examine the feasibility of NIBOVAC concept by vaccinating mice with the peptide 
immunogens conjugated to carbon nanotubes followed by assessing specificity, titre, avidity and 
venom-neutralising efficacy of IgG from vaccinated mice. And finally validate the NIBOVAC 
concept in vaccinated mice subjected to mosquito-feeding and then challenged with snake venom 
will be conducted in an alternative study. 
  
1.20 Materials and Methods 
1.20.1 Snake venom and mosquito sialome database construction 
After searching mosquito sialome databases and studying related literature, databases 
were constructed for each protein group from mosquito sialomes (day and night biters) that have 
a parallel in snake venom toxin proteins (Holt et al. 2002; Valenzuela et al. 2002; Francischetti et 
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al. 2002; Valenzuela et al. 2003; Ribeiro et al. 2004; Kalume et al. 2005). Of these, databases 
populated with sequences, of publicly available mosquito sialome database or a published paper, 
representing each protein group: mosquito sialome metalloprotease database (db-MSPMP), 
serine protease (db-MSPSP), phospholipase A2 (db-MSPPLA2) and c-type lectin (db-MSPCLP) 
were constructed. The sequences from each database were organised according to mosquito 
species represented by the sequence An. gambiae, Ae. aegypti and Cu. quinquefasciatus. Parallel 
databases for snake venom toxin (E. ocellatus) (Wagstaff and Harrison 2006) proteins were 
constructed: db-SVMP, db-SVSP, db-SVPLA2 and db-SVCLP.  
1.20.2 Bioinformatics 
A homology search between snake venom databases and MSP was undertaken using an 
Intel, dual 2.8GHz RedHat Enterprise Linux 9.0 workstation running Biolinux 6.0 (available at 
http://envgen.nox.ac.uk). Sequences were analysed using blastp (protein-protein BLAST) protein 
sequences searching program, and the top five hit sequences were selected from each database. 
The MSP databases were aligned to parallels from snake venom databases using the CLUSTAL 
alignment tool in Jalview a free program for multiple sequence alignment editing, visualization 
and analysis (available at; http://www.jalview.org )(Waterhouse et al. 2009). 
1.20.3 Electrophoresis analysis and immunoblotting    
The source and preparation of the samples are described in detail in Chapter 2, Section 
2.2. The blotting protocol and the antivenom/toxin-specific IgGs were used as described in 
Chapter 2, Section 2.5 and Chapter 4, Section 4.3.1. 
1.20.4 Chimeric epitope construction 
To predict epitopes of homologous snake venom (E. ocellatus) and MSP as primary 
vaccines that are immunologically cross-reactive, a reverse vaccinology approach utilised. After 
identifying MSP sequences that are homologous to snake venom toxins from each protein group, 
the FASTA format files containing homologous MSP and snake venom sequences, divided into 
groups according to protein type, similar to the databases used previously, were loaded on 
BepiPred to predict multiple linear B-cell epitopes designed to direct IgG to the native epitope 
(available at http://www.cbs.dtu.dk/services/BepiPred/) (Larsen et al. 2006). In parallel, CD4+ T-
cell epitopes predicted to bind with high affinity to the human MHC class II cell surface 
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receptors of HLA-DR1 alleles were simultaneously identified through a similar approach using 
NetMHCIIpan-2.0 (available at http://www.cbs.dtu.dk/services/NetMHCIIpan-2.0/) (Nielsen et 
al. 2010). This specific allele was selected for this model system because of its wide expression 
in human populations, including West African populations, and the availability of HLA-DR1 
transgenic mice (Hill et al. 1992; Richards et al. 2009) that will permit testing of the concept. 
The linearity of the predicted epitopes was tested using ElliPro (available at 
http://tools.immuneepitope.org/tools/ElliPro/iedb_input) (Ponomarenko et al. 2008). The protein 
sequences in FASTA file format were loaded to the server and the default parameters were used 
in the search. The parameters used in the application predicted the structural templates from PDB 
that used to model a 3D structure of the submitted sequence. 
1.20.5 Prediction of antigenicity and surface exposure of predicted epitopes 
The Protean Software (Lasergene software, DNASTAR, Madison, Wisconsin, USA) was 
used for protein structure analysis and prediction to locate the most antigenic domains and 
surface probability for each previously predicted epitope sequence. Following the identification 
of the most antigenic epitopes, their surface exposure was confirmed by overlay using YASARA 
program (Yet Another Scientific Artificial Reality Application) (http://www.yasara.org) on 
available models of snake venom protein (3DSL; Bothropasin a PIII snake venom 
metalloprotease, 2AIP; serine protease protein C activator, 1OZ7; Echicetin c-type lectin from E. 
carinatus) (Muniz et al. 2008; Jasti et al. 2004; Murakami & Arni 2005). These crystallographic 
data were selected using the ConSurf server (http://consurf.tau.ac.il) (Landau et al. 2005). The 
alignments of the snake venom and MSP protein sequences were loaded on the server, and the 
closest 3D structure was selected. 
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1.21 Results  
1.21.1 Identification of pathogenic venom toxin group homologues in 
mosquito sialomes 
Preliminary to the epitope design, I identified homologues of each pathogenic venom 
toxin group (metalloproteinases, phospholipase A2s, serine proteases and C-type lectins) in 
mosquito sialome datasets. The databases were populated by assembled contigs of E. ocellatus 
venom toxin proteins and blasted with the MSP databases populated with selected mosquito 
sialomes protein sequences belonging to proteases found in both mosquitoes and snake venom in 
available literature.  
Databases BLAST search was undertaken on an Intel, dual 2.8GHz RedHat Enterprise 
Linux 9.0 workstation running Biolinux 6.0 (available at http://envgen.nox.ac.uk). The inferred 
homology of the full-length comparative sequence analysis of the snake venom protein and 
mosquito sialomes, though of low identity percentage (around 30%, provided in Figure 6.1), 
illustrates the degree of sequence and domain conservation. First, metalloproteases from 
mosquito sialomes exhibited the conserved α2β1 ECD motif known to be part of the disintegrin-
like domain in SVMP (Fox and Serrano, 2005; Wagstaff and Harrison, 2006). Additionally, the 
alignment of metalloproteases identified the DLPEY motif in mosquitoes and SVMP transcripts, 
which have been found to be conserved in ADAM family members that bind α9β1 integrin (Eto et 
al., 2002; Wagstaff and Harrison, 2006). The sequences of SVMP and mosquito sialomes not 
only showed conservation in only these two motifs; several other motifs were identified as well 
(Figure 6.1-a). 
Serine proteases also showed homology in both SVSP and sialomes. Conservation 
surrounding some serine proteinase evolutionary markers and active site residues for the S1 
family of clan SA were detected. These motifs are TAAHC, surrounding the catalytic His, and 
GDSGGP around Ser (Figure 6.1-b) (Serrano and Maroun, 2005). 
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Figure 6.1 Snake venom proteins and MSP alignment: sequence alignment using Jalview of venom and mosquito a) 
metalloprotease, b) serine protease and c) c-type lectin. Blue and red boxes indicate preliminary T- & B-cell epitopes identified 
by bioinformatics analysis. 
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Similarly, c-type lectin homology was found to be within the carbohydrate recognition 
domain (CRD). C-type lectin proteins containing this domain bind to γ-carboxyglutamic acid 
(Gla)-containing domains of coagulation factors IX and X in the presence of calcium ions 
(Figure 6.1-c) (Morita 2004; Arlinghaus and Eble 2012; Ogawa et al. 2005).  
1.21.2 Reactivity of snake antivenoms and toxin-specific IgGs to mosquito 
salivary gland proteins (MSP) 
i) Antivenoms (monospecific and polyspecific) 
The goal of this study was to corroborate the above bioinformatics predictions by 
investigating whether antivenom IgGs bind to proteins in mosquito saliva (MSP) and, if so, 
determine whether the MSPs were indeed similar to pathogenic venom proteins. The antivenoms 
used in these experiments were selected according to the same criteria used in Chapter 4, as they 
are all active against African snakes. 
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Figure 6.2 Protein profiling and immunoblotting: reduced 15% SDS-PAGE gel Coomassie blue stained and 
immunoblotts against various antivenoms: African a) monospecific EchiTAb G, b) polyspecific EchiTAb-Plus-ICP and c) 
SAIMR polyvalent. As controls: secondary antibody d) donkey anti-sheep IgG, e) rabbit anti-horse IgG and f) substrate only. 5µg 
of, non-blood fed, female An. gambiae salivary gland homogenate (lane 1) and E. ocellatus venom (lane 2) were loaded. The 
molecular weight markers (kDa) are shown on the left side of the image. 
 
Antivenoms provide immunological cross-reactivity to MSP. As Figure 6.2 illustrates, 
several proteins exhibited reactivity to EchiTAbG, the E. ocellatus monospecific antivenom. The 
reaction showed specificity to proteins mainly in the high molecular mass range of 30 to around 
130 
200 kDa molecular mass. This range correlates with the following MSP proteins: the D7 related 
protein 33.4kDa, the salivary gland 5 protein 35.8kDa, the serine protease 40kDa, the salivary 
gland 1-like2 protein 41.4kDa, the salivary gland 1 44.2kDa, calerticulin 44.6kDa, 
metalloprotease 50.2kDa and 5’-nucleotidase 61.1kDa (Ribeiro et al. 2004; Francischetti et al. 
2002; Gorman et al. 2000; Valenzuela et al. 2002; Alvarez et al. 2012). Moving from the 
monospecific to the polyspecific, the number of reacted proteins decreases. However, the 
opposite was expected, we used monospecific and polyspecific antivenoms as polyspecific 
antivenoms have antibodies to venom toxin from more than one single species or even more than 
one family (vipers and elapids). However, the interesting result is that, in the correlation between 
the blotting results and molecular weights from studies done on MSP includes proteins, we 
detected homology in their protein sequences and venom toxin proteins (i.e. metalloprotease and 
serine protease). 
ii) Toxin-specific IgGs 
To be more specific and to eliminate any cross-reactivity to proteins other than those that 
are homologous to venom toxin, toxin-specific IgGs immunoblotting was done (Figure 6.3). 
Blots were probed with IgGs raised by the Alistair Reid Venom Research Unit to  SVMP, SVSP 
and c-type lectins. For SVMP, IgGs developed against different subclasses were used: the anti-
SVMP PI, anti-SVMP PII and anti-disentigrin domains. Figure 6.3 illustrates that probing MSP 
to SVMPI (Figure 6.3-1) showed restricted specificity to proteins, mainly in the 75 to 100 kDa 
molecular mass range, although weaker cross-reactivity was also detected at lower molecular 
weights. In contrast, anti-SVMP PII showed weak cross-reactivity to all proteins ranging 
between the molecular weights of 35 and 100 kDa (Figure 6.3-2). Anti-disintegrin, an IgG 
developed against the disintegrin domain, a polypeptide that interacts with integrins in cell 
membranes and is known to be present in snake venoms, showed intense, restricted specificity to 
MSP at a molecular weight of ~90 kDa (Figure 6.3-3). Comparing these results with the 
molecular weights of toxin proteins that these IgGs were prepared to neutralise, we can observe 
that some are in accord with those of venom protein and MSP, while others have a very distinct 
molecular weight. For example, despite the intense reactivity to SVMP PI, all the proteins that 
reacted appeared in the high molecular weight range, while the molecular weight of SVMP, that 
this specific IgG was prepared to, have a lower molecular weight (~21 kDa) (MacKessy 2009). 
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Similarly, anti-disintegrin and anti-c-type lectin IgGs showed reactivity to high molecular weight 
MSP proteins, while they are of a low molecular weight (disintegrin in snake venom around 10 
kDa and c-type lectin in both snake venom and MSP of around 14 kDa) (Valenzuela et al. 2002; 
MacKessy 2009). Another factor that can be noted here is the presence of cross-reactivity 
between MSP and snake venom disintegrin. Anti-disintegrin IgG was developed against snake 
venom disintegrin and anti-integrin molecules found in viper venom (Marcinkiewicz 2005; 
Juárez et al. 2008). This detection of anti-disintegrin IgG to an MSP protein with high specificity 
despite the fact that the molecular weight is different from that of snake venom disintegrin, is 
interesting. Furthermore, the close molecular weight of the protein detected by anti-c-type lectin 
to that detected by anti-disintigrin is of questioning whether this mosquito protein has the ability 
to bind to host integrin similar to snake venom disintegrin and c-type lectin (Marcinkiewicz 
2005; Ogawa et al. 2005).  
 
 
 
Figure 6.3 Toxin specific-IgG reactivity: reduced immunoblotting (15% SDS-PAGE gel) against various toxin-
specific IgGs and controls: snake venom metalloprotease (1) ANTI-SVMP- P I IgG, 2) ANTI-SVMP-PII IgG and 3) ANTI-DIS); 
serine protease SP (4) ANTI-SP); c-type lectin (5) ANTI_CTL I). Controls; 1) normal mouse serum, 2) goat anti-mouse IgG 
tested against 5µg of An. gambiae salivary gland homogenate. The molecular weight markers (kDa) are shown on the left side of 
the image.  
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On the other hand, anti-SVMP PII and anti-SP cross-reacted to diverse MSPs in wide 
molecular mass ranges of 35–150 kDa, which includes the weights of these proteins in both 
snake venom and MSP (Figures 6.3-2, 4). This might reflect the observed homology in protein 
sequences and the present conserved sites between snake venom and MSP metalloproteases and 
serine proteases. 
1.21.3 Epitope construction 
The preliminary data obtained from bioinformatics and immunoblotting indicates that 
there exist domains within some proteins groups that are shared between MSPs and pathogenic 
snake venom proteins. Our intent is to manipulate these domains to produce chimeric 
immunising peptides representing both venom toxin and MSP. For this purpose, a in silico 
vaccine predection approach to identify multiple epitopes for each toxin/MSP family that is 
predicted to be immunologically cross-reactive was performed (Wagstaff et al. 2006). Multiple 
linear B-cell epitopes, designed to direct IgG to the native epitope, were identified by 
computational selection. These epitopes are of short, conserved peptide sequences (5–7aa) 
predicted to be surface-exposed in toxin/MSP macromolecular structures. In addition, CD4+ T-
cell epitopes (12–15aa), predicted to bind with high affinity to the human MHC class II cell 
surface receptors of HLA-DR1 alleles, were identified in a similar manner. 
After the alignment of protein sequences from E. ocellatus venom proteins and MSP, the 
prediction of B-cell and T-cell epitopes was done according to the criteria described above. The 
prediction was done using BepiPred, a Web tool that predicts B-cell epitopes (available at 
http://www.cbs.dtu.dk/services/BepiPred/) (Larsen et al. 2006) in accordance with 
NetMHCIIpan-2.0 (available at http://www.cbs.dtu.dk/services/NetMHCIIpan-2.0/) (Nielsen et 
al. 2010) to predict the relative binding strengths of all possible nonapeptides to MHC class II 
molecule HLA-DR1 (available at http://www-bimas.cit.nih.gov/molbio/hla_bind/) (Parker et al. 
1994). Additionally, to detect the linearity of these epitopes, the ElliPro Web tool was used 
(http://tools.immuneepitope.org/tools/ElliPro/iedb_input) (Ponomarenko et al. 2008).  
Peptide prediction was conducted through an analysis of MSP and snake venom protein 
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databases in addition to the available related 3D structure of the protein using the aforementioned 
Web tools. This analysis identified seven domains whose antigenic profiles are similarly 
conserved across SVMP isoforms and homologues from MSP, two domains from serine protease 
and three from c-type lectin (Figures 6.4-5–7). These antigenic domains were aligned and 
colour-identified.   
Following epitope prediction, the selected epitopes were scored for the degree of 
antigenicity and surface exposure probability using the Protean software (DNASTAR, Madison, 
Wisconsin, United States). In addition, surface exposure was confirmed by overlay using 
YSARA (http://www.yasara.org) on available models of snake venom protein (3DSL; 
Bothropasin a PIII snake venom metalloprotease, 2AIP; serine protease protein C activator, 
1OZ7; Echicetin c-type lectin from E. carinatus) (Muniz et al. 2008; Jasti et al. 2004; Murakami 
& Arni 2005). These crystallographic data was selected using the ConSurf server 
(http://consurf.tau.ac.il) (Landau et al. 2005). The alignments of snake venom and MSP protein 
sequences were loaded on the server, and the closest 3D structure was selected. 
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Figure 6.4 Metalloprotease T- & B-cell epitope prediction: metalloprotease venom toxin and mosquito protein 
homologues. Percentage identity sequence alignments display identified T (a) and B (b) cell epitopes identified by bioinformatics 
analysis and the prediction of antigenicity and surface exposure (c, d). Mapping of B- & T-cell epitopes to the macromolecular 
structure (PDB: 3DSL) (e, f) with the greatest similarity to mosquito and venom metalloprotease, rotated 180°. Note that the 
metalloprotease alignment is not full-length; the displayed alignment represents the T- & B-cell epitope with high antigenicity. 
Additional epitopes (not displayed) were identified in other regions of the protein but showed lower antigenicity. 
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Figure 6.5 Serine protease B- & T-cell epitope prediction: serine protease venom toxin and mosquito protein 
homologues. Percentage identity sequence alignments display identified T (a) and B (b) cell epitopes identified by bioinformatics 
analysis and prediction of antigenicity and surface exposure (c, d). Mapping of B- & T-cell epitopes to the macromolecular 
structure (PDB: 2AIP) (e, f) with the greatest similarity to mosquito and venom serine protease, rotated 180°. Note that the serine 
protease alignment is not full-length; the displayed alignment represents the T- & B-cell epitope with high antigenicity. 
Additional epitopes (not displayed) were identified in other regions of the protein but showed lower antigenicity.  
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Figure 6.6 C-type lectin T- & B-cell epitope prediction: c-type lectin venom toxin and mosquito protein 
homologues. Percentage identity sequence alignments display identified T (a) and B (b) cell epitopes identified by bioinformatics 
analysis and prediction of antigenicity and surface exposure (c, d). Mapping of T- & B-cell epitopes to the macromolecular 
structure (PDB: 1OZ7) (e, f) with the greatest similarity to mosquito and venom c-type lectin, rotated 180°. Note that the c-type 
lectin alignment is not full-length; the displayed alignment represents the T- & B-cell epitope with high antigenicity. Additional 
epitopes (not displayed) were identified in other regions of the protein but showed lower antigenicity. 
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Following extraction, antigenic profiling and alignment of selected peptides, a second, 
custom-designed data mining solution (db-2) (a database created at the Alistair Reid venom 
research unit) scored epitopes for cross-reactivity against all available Echis ESTs and identified 
small antigenic peptides with broad predicted toxin-neutralising potential. In addition, the length 
of each antigenic peptide was incrementally reduced and the peptide composition refined into 6-
12 amino acids that represented the maximum number of matches to venom proteins clusters and 
ESTs.  
Table 6.1 Total number of individual venom ESTs matched to each venom part of the chimeric peptide predicted using 
db-2. 
 
Peptide  # of hits in 
venom 
Anopheles Culex 
IWSNGD 59 WNTRDNIWSNGD - 
IWSNGDK 22 WNTRDIWSNGDK - 
SNRDL 16 - DRYDSNRDL 
NQRDL 13 - DRYDNQRDL 
TQGDL 9 - DRYDTQGDL 
FWNQRDL 8 WNTRDFWNQRD
L 
- 
FWNQR 8 WNTRDNFWNQR - 
    
HDGNQ 87 TEECSHDGNQ HDTPDCKHDGNQ 
HDVDGECHDGNQ 
HDGNQC 87 - HDTPDCHDGNQC 
HDVDGHDGNQC 
CGANS 39 HDTEECSCGANS HDTPDCKCKCGANS 
CGAKS 23 HDTEECSCGAKS HDTPDCKCKCGAKS 
CGADS 15 HDTEECSCGADS HDTPDCKCKCGADS 
HDVDGECQCGADS 
HDVPS 14 TEECSHDVPS - 
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Then, the epitope regions selected in silico were synthesised into chimeric epitopes by 
constructing overlapping peptide libraries; each peptide contains part of a snake venom protein 
and MSP. The length of each peptide was 12 amino acids. Following peptide library 
construction, the new peptides were again tested for antigenicity. This analysis identified 13 
potential epitopes that represented the maximum number of matches to SVMP clusters and ESTs 
and showed a high antigenicity profile (Table 6.1). Peptides identified from SP and c-type lectin 
had weaker antigenicity or were buried within the protein in comparison with those from SVMP 
and therefore were excluded.  
 
 
Figure 6.7 Epitopes predicted from metalloprotease: red box (SVMP II), yellow box (SVMP III), first column 
represent individual metalloprotease epitopes identified from conserved domains between venom and MSP. The number of 
venom ESTs matched against each peptide is shown in column 2. Columns 3 and 4 represent the designed chimeric epitope, 
amino acids in black represent the MSP amino acids identifed in the conserved domain between MSP and snake venom 
metalloprotease (from An. gambiae and Cu. Quinquefasciatus) followed by venom amino acids from the consarved domain (red 
represent (SVMP II), yellow represent (SVMP III). Upper right graphs: Jameson-Wolf antigenic profiling of the constructed 
chimeric epitopes. Lower left graphs: Jameson-Wolf antigenic profiling of the selected controls only from MSP peptides. Lower 
right: percentage identity alignment of target domains for individual MP epitopes.  
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The metalloprotease peptides represented two domains, SVMP PII and SVMP PIII 
(Figure 6.7). Therefore, the epitopes with the highest number of hits in the Echis venom EST 
data (db-2) was selected from each group. In addition, two control epitopes was constructed each 
one selected from predicted epitopes representing snake venom only, from each SVMP (II and 
III) domain, as a positive control. Another two controls were constructed as scrambled epitopes 
with no antigenicity as a negative control using the MIMOTOPES  Web tool 
(http://www.mimotopes.com/peptidelibraryscreening.asp?id=97). The selected epitopes were 
then sent to Dr Steven L. Cobb’s lab at Durham University for epitope manufacturing and 
conjugation to carbon nanotubes (Figure 6.8).  
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Figure 6.8 Epitopes sent for manufacturing and conjugation to carbon nanotubes: a) immunogens represent 
chimeric epitopes (red represents SVMP II; yellow represents SVMP III), b) Jameson-Wolf antigenic profiling of the conserved 
domain representing each immunogen group (venom and MSP). c) Controls sent along with the epitopes; the first two MSPs 
were selected from the conserved domain; the following two venom only 3-SVMPII 4- SVMP III represent the same conserved 
domains the MSP controls selected from, and known to induce immunological cross-reactivity to E. ocellatus venom 
(unpublished work by Camila Renjifo at the Alistair Reid venom research unit) as a positive control. 5 and 6 are scrambled 
epitopes as negative controls. 
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1.22 Discussion 
The genomic/transcriptomic/proteomic data available for snake venom proteins and MSP 
provides wealthy resources for comparative protein composition. This establishes a critical 
supply for bioinformatically designed cross-conserved chimeric epitope immunogens. Thus, 
homology between many protein groups in MSP and snake venom main toxin proteins was 
observed. SVMP alignment with MSP metalloprotease indicated conservation in domains known 
in SVMP to be vital for toxicity: the metalloproteinase, disintegrin and cysteine-rich domains 
(Wagstaff et al. 2009). In addition, these domains have been previously identified as a part of the 
EoSVMP string, a multiepitope DNA immunogen, showing an intense and extensive 
immunoreactivity to SVMP (Wagstaff et al. 2006).  
Similarly, serine proteases from MSP exhibited conservation with SVSP in domains that 
characterized by a catalytic mechanism that includes a highly reactive serine residue that plays a 
fundamental role in the formation of a transient acyl-enzyme complex. This complex is stabilized 
by the existence of histidine and aspartic acid residues within the active site (Serrano and 
Maroun 2005). C-type lectin demonstrated homology between MSP and snake venom c-type 
lectin in the CRD domain that plays an important role in pathology stimulated by this protein 
(binding to γ-carboxyglutamic acid (Gla)-containing domains of coagulation factors). These data 
represent a promising result for the identification of chimeric epitopes. 
Immunoblotting results with snake antivenom (mono- and polyspecific) or toxin-specific 
IgGs supported the bioinformatics prediction of the presence of homology between these 
proteins that could be considered as experimental vaccine candidates in both organisms 
(Wagstaff et al. 2006; Harrison 2004). The cross-reactivity observed between MSP homogenate 
and antivenom/toxin-specific IgGs included the molecular weights of some of the proteins of 
interest in this study. Critically, these preliminary data suggest that epitopes can be identified and 
manipulated to produce chimeric immunising peptides representing both venom toxin and MSP.  
An examination protein sequences from both MSP and venom reveals the cross-
conserved expression of immunogenic domains that are naturally occurring B- and T-cell 
epitopes, as Figures 6.3–6.5 indicate. Using a bioinformatics approach, we constructed a 
chimeric epitope immunogen that may be able to generate antibody responses that neutralised 
142 
venom haemorrhagic toxins. NIBOVAC is a novel concept designed to exploit natural 
immunogens to stimulate sustained levels of protective immunity after initial vaccination against 
lethal toxin proteins. This, if successful, will overcome the decline of antibody concentrations 
after immunisation over time.  
In this study, we designed chimeric epitopes that represented both MSP and snake venom 
toxins. These epitopes were of short, conserved peptide sequences predicted to be surface-
exposed in toxin/MSP macromolecular structures, linked together to generate immunogens of 
12aa length that can be conjugated to carbon nanotubes or linked to nanoparticles. All the 
selected epitopes were selected to stimulate Th1-associated immune responses preferentially, 
avoiding Th2-mediated hypersensitivity induction. In addition, all were selected with avoidance 
to human analogues. This was taken into account to avoid the development of an undesirable 
hypersensitivity reaction to natural mosquito bites and the induction of autoimmunity. These 
designed epitopes were sent to Dr Steven L. Cobb’s lab at Durham University for epitope 
manufacturing and conjugation to carbon nanotubes. This vaccine delivery was selected because 
carbon nanotubes could serve as an excellent vehicle to administer vaccines (Pantarotto et al. 
2003; Yang et al. 2007). Antigen conjugated to carbon nanotube vaccination may allow the 
effective utilisation of antigens that have previously been unable to induce adequate or 
appropriate responses, in addition to providing significant means of enhancing and modulating 
immune responses (Pantarotto et al. 2003). 
Unfortunately, the time limitation of this PhD, as mentioned in the introduction section, 
restricted this study to designing the epitopes, as the end of the PhD period arrived before the 
delivery of the synthetic epitopes that had been conjugated to carbon nanotubes. Therefore, 
phase 2 of this study, which will validate the efficacy of NIBOVAC and test the protective 
efficacy of immune responses stimulated by mosquito saliva via challenging models of 
immunotherapy to mosquito bites, will be performed in a complementary study. 
Overall, the work done at the Alistair Reid venom research laboratory has 
comprehensively defined the venom composition of medically important African Echis vipers 
and tested their immunological reactivity to venom toxin-specific antibodies using various 
approaches (Harrison 2004; Harrison et al. 2000; Wagstaff et al. 2006). In this study, I identified 
homologues of each pathogenic venom toxin group (metalloproteinases, phospholipase A2s, 
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serine proteases and C-type lectins) in mosquito sialome datasets. It was determined that this 
cross-taxa sequence similarity extends to immunological cross-reactivity (immunoblotting) of 
mosquito salivary proteins (MSP) with snake antivenom and toxin-specific IgGs. I constructed in 
silico chimeric peptide immunogens from both organisms that showed antigenicity potential to 
stimulate immunity that, it is hoped, will be able to induce protective immunity by the 
completion of all phases of the study. 
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Chapter 7   General discussion 
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Epidemiological maps of neglected tropical diseases (NTDs) illustrated geographical 
overlap between the different diseases. The maps revealed that most of the diseases were 
concentrated in sub-Saharan Africa where the majority of the at-risk population, mortality, 
morbidity, and burden associated with the diseases reside. Furthermore, these populations are 
under great risk for snakebite that exert daily occupational hazard (Harrison et al. 2009). 
Emergent emphasis on integrated control of NTDs has created new awareness regarding the 
prospect and challenges of this approach (Utzinger et al. 2009). Co-endemicity of these diseases, 
as well as comorbidity, is of considerable public health relevance and offers opportunities for 
integrated control. Molyneaux et al. (2005) speculates that the administration of just four drugs 
may control seven NTDs in a cost-effective manner. These facts encouraged us to examine 
molecular parallels of the mechanisms used by a variety of tropical disease pathogens including 
parasites, snake venom toxins and hematophagous parasite vectors to access blood stream. 
In accordance, biological studies of these diseases show that several of them may use 
similar mechanisms to complete their pathology. These mechanisms may include disturbing 
coagulation, disguising the immune system, or penetrating tissue compartments. Additionally, 
next-generation sequencing and integrated bioinformatic analyses have offered detailed and 
biologically relevant perceptions into the transcriptome of the different life stages of 
Schistosome, adult Fasciola, and venom composition. The bioinformatics analysis in this study 
illustrated that proteases utilized by venom and parasites belong to the same molecular function 
in terms of gene ontology (GO). In addition, the analysis also detected homology between 
proteases from venom and proteases from parasites.  
Proteases play a major role in the pathology caused by parasites Schistosome and 
Fasciola, as well as venom. For example, parasite matrix metalloproteinases facilitates 
metalloprotease in the parasites’ degradation of host collagen (Singh et al. 2006; Gomez et al. 
1999). In the case of venom, metalloproteinases play an important role in inhibition of platelet 
aggregation and the degradation of blood clotting factors, which constitute systemic alterations, 
and thus cause systemic bleeding (Markland and Swenson 2013). Additionally, the 
metalloproteinases in venom also contribute to local tissue damage, probably by potentiating the 
hemorrhagic effect, which results from metalloproteinase in the local microvasculature and 
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degradation caused by matrix metalloproteinase (Gutiérrez and Rucavado 2000). Serine protease 
is also critical for both parasites and venom. Cercarial elastase, a serine proteinase secreted from 
the acetabular gland in the infective state of the parasite, is believed to initiate infection in 
schistosomes (Ingram et al. 2003; Ingram et al. 2012; Curwen et al. 2006). Other major 
mechanisms of initial infection include digestion, blood coagulation, immune response, and 
complement cascade. In the case of snake venom, serine proteases act on a variety of 
components of the coagulation cascade, the fibrinolytic and kallikrein–kinin systems, and cells, 
which triggers an imbalance of the prey’s haemostatic system (Serrano and Maroun 2005; 
Mackessy 2009).  
It is conceivable that transcriptomic representation of proteins in parasites or venom does 
not accurately represent true protein expression. A combination of transcriptomic and proteomic 
techniques is ideal. Therefore, we applied immunological cross-reactivity of parasites’ proteins 
with antivenoms—known to have the ability to neutralize lethal toxins in snake venom—to 
measure the similarity between parasites and venom proteases based at the protein level. We 
demonstrated a presence of cross-reactivity toward parasite proteins in antivenoms. While 
immunological reaction did not prove to be specific to proteases from parasites, taking into 
account the fact that antivenoms are intended to attack the venom rather than only the toxins may 
clarify this discrepancy. Snake venom is a complex mixture with biologically active proteins, the 
vast majority consisting of peptides. Antivenoms, therefore, comprise antibodies to the majority 
of venom components, regardless of their toxicity or immunogenicity (Harrison 2004).  
Interestingly, the analysis revealed that the majority of the identified parasites’ proteins 
are important for the success of parasitism, or they were previously identified as vaccine or as 
potential therapy target. Of these, fructose 1,6 bisphosphate aldolase, and glutathione S-
transferase proved to not only stimulate human immune responses against Schistosome, but can 
also mediate protection against a challenging infection, as well as decrease granuloma size in 
experimental schistosomiasis (Marques et al. 2008; Wright et al. 1991). Similarly, the analysis 
showed the identified enolase—a multi-functional protein localized on the cell surface and the 
tegument of helminthes—may bind to plasminogen, and may also have the ability to stimulate 
fibrinolytic activity for parasitic invasion and migration within the host (Liu et al. 2009). 
Manneck et al. (2012) demonstrated enolase as a potential drug target. They illustrated that the 
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antimalarial drug mefloquine has encouraging antischistosomal properties, killing 
haematophagous adult schistosomes and schistosomula by inhibiting enolase activity in the 
parasite (Manneck et al. 2012). In the same vein, studies identified Sm37-GAPDH as a vaccine 
candidate, showing mice and rats immunized with epitopes identified from Sm37-GAPDH were 
partially protected against a challenging infection (Argiro et al. 2000; Argiro and Doerig 2000). 
Other identified proteins from this study, such as Heat shock 70 (HSP70), calreticulin precursor, 
and 14-3-3 protein, are considered essential proteins in the pathology caused by Schistosome or 
Fasciola, and may be potential targets for therapy production (Schechtman et al. 2001; Kusel et 
al. 2007; Hedstrom et al. 1987; Ferreira et al. 2004). 
Given the complexity of venom and comprehensive immune-binding nature of 
antivenom, the study revealed the identification of proteins rather than proteases cross-reacted 
with antivenom. To better define the specificity of the cross-reactive venom and parasite proteins 
we tested the ability of toxin-specific IgGs (raised against pathogenic venom proteins), to 
immunoreact with parasite proteases. Reactions of several IgGs raised against proteases from 
venom vary from parasite proteins. These IgGs represent proteases we are interested to compare 
between parasites and snake venom. The presence of immunological reaction in this experiment 
may provide insight into the effects of treating parasite stages with these toxin-specific IgGs. 
Toxin-specific IgGs proved to neutralize toxic effects of the specific toxin protease they raised 
against (Harrison et al. 2003; Harrison 2004; Wagstaff et al. 2006). If these IgGs were able to 
cross react with parallel proteases from parasites will they be able to prevent their effects in host?  
This may also set the foundations for testing the migratory or pathological ability of parasite 
stages, and perhaps for preparing affinity columns coupled with toxin-specific IgGs and identify 
bound proteins. Unfortunately, this was outside the scope of this study, as the sample size, 
presence of life stages of the parasites, and time limitation restricted this investigation. 
The possibility of significant cross-reactivity of antivenom to parasite proteases, as 
illustrated in our experiments, led to investigating whether a similar immunoreactivity towards 
snake venom proteins exists in parasite-infected patients, and if so, to what extent the 
immunoreactivity can be sustained. The two parasites, Schistosome and Filaria, are characterized 
by a Th-2 type immune response in infected patients (Pearce and MacDonald 2002; Babu and 
Nutman 2012). This type of immune response is associated with elevated levels of IgE, high 
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production of IL-4, and eosinophilia (Paul and Zhu 2010; Riveau and Capron 2005; Babu and 
Nutman 2012). Both parasites are known to exert intense immunoregulatory effects on the 
immune system of the infected host. These include systemic immune-modulatory and immune-
regulatory effects on the host system, against other infectious and non-infectious antigens (van 
Riet et al. 2007; Maizels and Yazdanbakhsh 2003; Wickelgren 2004). This disturbance in the 
immune system, caused by the presence of parasitic infection, represented a degree of difference 
between the immunoreactivity of human sera of infected and non-infected individuals. This 
observation may merit more relevance if we could investigate the immunoreactivity toward 
venom toxins in snakebite victims infected with parasitic diseases compared to those are not. It 
would be interesting to determine whether treatment with anti-parasitic drugs like ivermectin 
may exert down-regulatory effects on the patients’ immune systems. It would also be relevant to 
determine if exposing individuals treated against parasitic diseases to snake venom might 
increase the risk of devastating effects (morbidity and mortality) resulted from snakebite on these 
populations. The result we demonstrated in Chapter 5 showed a complete loss of 
immunoreactivity toward the low molecular weight venom proteins, when probed with sera 
collected from treated filariasis patients and schistosomiasis patients living in villages with low 
prevalence of schistosomiasis.  
The effects of the parasite infection on the immune system extend to the efficacy of 
therapeutic IgGs purified from infected patients. Studies demonstrated that IgGs purified from 
African patients infected with the malaria parasite exhibited a higher efficacy rate, compared to 
those purified from Americans or European donors for treatment purposes (Mekhaiel, Daniel-
Ribeiro, et al. 2011; Rowe et al. 1968). We examined the reactivity of the IgGs toward 
antivenom, and although it showed immune cross-reactivity, it did not show a titre or robustness 
comparable with that from antivenom or toxin-specific IgGs neutralization. 
In this study, we investigated possibilities of using homologous proteins in parasitic 
vector and snake venom as therapeutic applications. Molecules secreted and produced by these 
different pathogens exert complex effects on human physiological mechanisms, and thus may 
serve as the basis for novel therapeutic strategy. We constructed chimeric epitopes of 
homologous snake venom (Echis ocellatus) and mosquito salivary proteins as the primary 
vaccine. These designed chimeras when tested in silico exhibited promising antigenicity profiles. 
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This encouraging antigenicity, associated with that the domains from which these chimeric 
epitopes were designed, have been identified previously as potential vaccine candidates 
(Wagstaff et al. 2006; Harrison et al. 2003) (unpublished work done by Camila Renjifo in 
Alistair Reid venom research unit). If these epitope immunogens succeed in inducing and 
stimulating sustained levels of protective immunity against snakebites—when boosted with 
proteins delivered by mosquito bites—they will overcome the impracticality of conventional 
vaccination against snakebite. Vaccination against envenoming caused by snake venom is 
unfeasible, given the unlikelihood that a recalled immunological response could defend against 
the venom before the toxins’ rapid lethal effects occurred (Müller et al. 2012).  The presence of 
natural, seasonal boosting of immunological memory against venom toxins would hopefully 
protect a population at risk of snakebite against the lethal effects of venom. Ideally, this method 
would prevent, or at least reduce, the devastating pathology and death caused by snake venom at 
a low cost, with limited logistical complications. 
Generally, this study demonstrated a presence of similarity between shared molecular 
molecules (proteases and other proteins) causing pathology in parasites, parasitic vectors and 
snake venom. These findings could become more relevant if field-based studies were to 
investigate the relation between parasitic infections and envenoming caused by snakebite. And 
test the effects of pre-existing parasite infections that cause minor bleeding in the infected host 
such as Schistosomes and hook worms may become a great deal worse subsequent to the 
haemorrhagic effects that follows systemic envenoming by some vipers – Echis. Other relevant 
experiments on living parasites include examining the effects resulting from treating these 
parasite stages with antivenom or toxin-specific IgGs on parasite migration and tissue 
destruction.  Additional tests may consist of using secretory/excretory products of parasites to 
examine their similarity and cross-reactivity to antivenom and antitoxins, as well as using 
affinity purification to examine parasite proteins with binding ability to antitoxin IgGs. The area 
of NTD/snakebite biomedicine requires more research for the same factors demonstrated in the 
study, as pathogens causing NTDs affect the same population use molecules that may related to 
the same family or function in parallel way and they may cause pathologies that affect the same 
tissue or organ. 
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APPENDICES 
1.23 Appendix I: General stock solutions and buffers 
1.24 Preparation of SDS-PAGE gel, electrophoresis and Western Blotting buffer 
1. Resolving gel.  
 
 
*APS and TEMED are activators so they need to be added last. 
# APS should prepare freshly each time 50 mg to 500 µl dHⁿO. 
 
2. Staking gel. 
 2 gels 4 gels 
H20 2.5ml  5ml 
Tris pH 6.8 1ml  2ml 
40% Bis Acrylamide 350µl  700µl  
10% APS 30µl  60µl 
TEMED 5µl  10µl 
 15% 12.5% 10% 
 4 gels 2 gels 4 gels 2 gels 4 gels 2 gels 
H20 7.5ml 3.75ml 8.75ml 4.4ml 10ml 5ml 
Tris pH 8.8 5ml 2.5ml 5ml 2.5ml 5ml 2.5ml 
40% Bis 
Acrylamide 
7.5ml 3.75ml 6.25ml 3.1ml 5ml 2.5ml 
10% SDS 200µl 100 µl 200µl 100 µl 200µl 100 µl 
10% APS*# 120µl 60 µl 120µl 60 µl 120µl 60 µl 
TEMED* 14µl 7 µl 14µl 7 µl 14µl 7 µl 
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3. 10x SDS running buffer. 
 
Glycine  720 g 
SDS 50 g 
Tris-base 151 g 
dHⁿO Up to 10 L 
 
 
 
 
4. Coomassie blue stain. 
Coomassie brilliant R 250 4 mg 
Destain solution 2 L 
 
5. Coomassie destain solution. 
Methanol  4.5 L 
Acetic acid 1 L 
dHⁿO Up to 10 L 
6. 10x PBS 
Dissolve the following in 800ml distilled H2O. 
i. 80g of NaCl 
ii. 2.0g of KCl 
iii. 14.4g of Na2HPO4 
iv. 2.4g of KH2PO4 
Adjust pH to 7.4. 
Adjust volume to 1L with additional distilled H2O. Sterilize by autoclaving. 
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7. Native PAGE gel. 
 
 
 
 
 
 
 
 
 
 
 
8. Native PAGE electrophoresis buffer.  
 
 
  
 
9. Transfer buffer. 
Tris 2.03g  
glycine 14.26g  
H2O 800ml  
Methanol 200ml 
 
Resolving gel 2 gels Stacking gel 2 gels 
H20 3.71ml H20 2.5ml  
Tris pH 8.8 1.87ml Tris pH 6.8 1ml  
40% Bis 
Acrylamide 
1.87ml 40% Bis 
Acrylamide 
350µl  
10% APS 37.5µl 10% APS 30µl  
TEMED 3.75µl TEMED 5µl  
Electrophoresis buffer pH 8.3 
dH20 1.0 L  
Tris base 3.0  g 
Glycine 14.4 g 
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Preparation of sample homogenates  
10. 2X protein loading buffer 
dHⁿO 2.65 ml 
0.5 M Tris-HCl pH 6.8 1.25 
Glycerol  2.5 ml 
10 % SDS 3 ml 
Saturated Bromo-blue solution (1mg in 1ml) 0.1 ml 
5 % β-mercaptoethanol 0.5 ml 
 
11. Non-reduced protein loading buffer 
dHⁿO Up to 20 ml 
0.5 M Tris-HCl pH 6.8 4 ml 
Glycerol  5 ml 
SDS 1.5 g 
Saturated Bromo-blue solution (1mg in 
1ml) 
0.3 ml 
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12. Native protein loading buffer.         
 
 
 
 
 
 
 
13. Fasciola hepatica homogenate buffer. 
20 mM KHPO₁ pH 7.4 0.802 ml of 1M KⁿHPO₁ + 
0.198ml of 1M KHⁿPO₁ 
50 mM NaCl 0.5 ml of 1 M stock 
10% glycerol 1ml 
1% triton x 100 10 µl 
1 mM DTT 100 µl of 100mM stock (154 mg 
in 10 ml dHⁿO) 
dHⁿO Up to 10 ml (~7.39 ml) 
 
 
 
 
 
 
 
 
Sample buffer  
 H20 1.375 ml  
Tris pH 6.8 0.625 ml  
20% Glycerol 0.5 ml  
0.02% Bromophenol Blue 40 µl of 5% Bromophenol 
Blue 
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ELISA buffers 
 
1. TBST buffer 
Tris-HCl, pH 8.5 10mM  
NaCl 150mM  
Tween 20 1%  
 
 
 
 
 
 
 
 
2. Citrate buffer 
Citric acid 525mg 
H2O 50ml  
 
 
 
 
      3.Coating buffer 
 
 
 
 
 
 
 
 
Na2CO3 1.59g  
NaHCO3 2.93g 
NaN3 0.2g  
H2O 1L  
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1.25 Appendix II: LC-MS/MS identification of cross-reacted parasites proteins 
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Antiveno
m 
Band  Organism  Protein Accessio
n no. 
m/z 
(Da) 
Z 
(+) 
Peptide 
numbe
r  
MS/MS derived sequence Mascot Sequest 
          Ion 
score 
Exp 
value 
Probabilit
y 
Xcor
r 
1 35 -
50 
kDa 
Cercaria  Fructose-
bisphosphate 
aldolase (EC 
4.1.2.13) 
(P53442) 760.79 2 1 GILAADESTATMGKR 83 1.07432
E-05 
61.59 4.91 
     683.06 2 1 GILAADESTATMGK 73 1.21E-
04 
65.71 3.65 
     635.13 2 2 FEGNMGTTLGDK 67 5.22E-
04 
21.91 3.39 
     717.61 2 3 AYTPQENALATVR 66 5.64E-
04 
6.89 3.27 
     514.56 2 4 IAQAICAPGK 53 1.35E-
02 
1.00 3.25 
     691.20 2 5 ENVHAAQEELLK   10.13 3.19 
     781.74 2 6 KAYTPQENALATVR     
1,4 50 
kDa 
SEA 
 
 Actin-2 (P53471) 977.87 2 1 VAPEEHPVLLTEAPLNPK 61 
 
5.29E-
04 
 
  
     1056.1 3 2 TTGIVLDSGDGVTHTVPIYEGY
ALPHAILR 
  27.71 3.49 
     977.87 2 1 VAPEEHPVLLTEAPLNPK   1.00 3.27 
     566.94 2 3 GYSFTTTAER   54.16 3.06 
     586.63 2 4 HQGVMVGMGQK   1.00 2.95 
     599.73 2 5 AVFPSIVGRPR   34.33 2.72 
     581.58 2 6 EITALAPSTMK   7.49 2.64 
     489.01 2 7 AGFAGDDAPR   11.26 2.51 
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Antiveno
m 
Band  Organism  Protein Accessio
n no. 
m/z 
(Da) 
Z 
(+) 
Peptide 
number  
MS/MS derived sequence Mascot Sequest 
          Ion 
score 
Exp 
value 
Probabilit
y 
Xcor
r 
4 50 
kDa 
Schistosomu
la 
Enolase (EC 
4.2.1.11) (2-
phosphoglyce
rate 
dehydratase) 
(2-phospho-
D-glycerate 
hydro-lyase) 
(Q27877)  530.54 2 1 IEEELGTAAK 62 2.18E-
03 
  
     551.53 2 2 GVLTAVSNVNK   30.89 3.41 
     595.11 2 3 AGAAEAGLPLYR   11.68 3.16 
     530.54 2 1 IEEELGTAAK   7.53 2.95 
     694.72 2 4 GNPTVEVDLKTSK   1.00 2.16 
4 35 
kDa 
Schistosomu
la 
Glyceraldehy
de-3-
phosphate 
dehydrogena
se (EC 
1.2.1.12) 
(GAPDH) 
(Major larval 
surface 
antigen) (P-
37) 
(P20287) 894.53 3 1 KVIISAPSADAPMFVVGVNENS
YEK 
77 2.27E-
05 
 2.57 
     724.08 2 2 GAMQNIIPASTGAAK 64 1.02E-
03 
 2.55 
     715.61 2 2 GAMQNIIPASTGAAK 63 1.03E-
03 
 2.55 
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     889.19 3 1 KVIISAPSADAPMFVVGVNENS
YEK 
57 2.07E-
03 
 2.55 
Antiveno
m 
Band  Organism  Protein Accessio
n no. 
m/z 
(Da) 
Z 
(+) 
Peptide 
number  
MS/MS derived sequence Mascot Sequest 
          Ion 
score 
Exp 
value 
Probabilit
y 
Xcor
r 
     911.35 3 3 VIHDKFEIVEGLMTTVHSFTAT
QK 
55 3.84E-
03 
 2.49 
     1064.7
6 
2 4 SMSVVSNASCTTNCLAPLAK 53 8.14E-
03 
 2.44 
     778.87 3 5 LTGMAFRVPTPDVSVVDLTCR 52 8.94E-
03 
 2.40 
     911.35 3 3 VIHDKFEIVEGLMTTVHSFTAT
QK 
  33.60 2.34 
     894.53 3 1 KVIISAPSADAPMFVVGVNENS
YEK 
  6.29 2.33 
     778.87 3 5 LTGMAFRVPTPDVSVVDLTCR   62.50 2.29 
     889.19 3 1 KVIISAPSADAPMFVVGVNENS
YEK 
  11.56 2.28 
     899.12 2 6 LVSWYDNEFGYSCR   75.40 2.24 
     668.84 3 7 DSTHGTFPGEVSTENGKLK   27.95 2.23 
     1269.4
6 
2 1 VIISAPSADAPMFVVGVNENSY
EK 
  24.46 2.17 
     815.82 2 8 VVDLITHMHKVDHA   13.61 2.00 
     640.72 3 7 RDSTHGTFPGEVSTENGK   1.00 1.86 
     588.35 3 7 DSTHGTFPGEVSTENGK   1.12 1.84 
     916.70 3 3 VIHDKFEIVEGLMTTVHSFTAT   1.86 1.80 
175 
QK 
     808.29 2 8 VVDLITHMHKVDHA   30.85 1.74 
     779.70 2 5 VPTPDVSVVDLTCR   53.40 1.32 
     715.61 2 2 GAMQNIIPASTGAAK   17.51  
Antiveno
m 
Band  Organism  Protein Accessio
n no. 
m/z 
(Da) 
Z 
(+) 
Peptide 
number  
MS/MS derived sequence Mascot Sequest 
          Ion 
score 
Exp 
value 
Probabilit
y 
Xcor
r 
     724.08 2 2 GAMQNIIPASTGAAK   10.22 3.41 
     539.15 3 8 VVDLITHMHKVDHA   18.11 3.16 
     669.11 3 7 DSTHGTFPGEVSTENGKLK   5.84 2.95 
     633.65 2 9 GASYEEIKAAVK   27.78 2.16 
     598.13 2 9 LGKGASYEEIK   17.02  
     669.13 3 7 DSTHGTFPGEVSTENGKLK   1.00  
     589.08 2 10 AGISLNNNFVK   1.00  
     715.61 2 2 GAMQNIIPASTGAAK   1.00  
     591.96 3 2 DGRGAMQNIIPASTGAAK   1.00  
     715.11 2 2 GAMQNIIPASTGAAK   1.00  
     605.14 2 8 VVDLITHMHK   7.15  
     715.56 2 2 GAMQNIIPASTGAAK   1.56  
     879.79 2 2 DGRGAMQNIIPASTGAAK   1.00  
     715.69 2 2 GAMQNIIPASTGAAK   1.00  
     1265.5
1 
1 9 GASYEEIKAAVK   1.00  
176 
     715.62 2 2 GAMQNIIPASTGAAK   1.00  
     715.28 2 2 GAMQNIIPASTGAAK   1.00  
     1063.2
6 
2 4 SMSVVSNASCTTNCLAPLAK 
 
  1.00  
Antiveno
m 
Band  Organism  Protein Accessio
n no. 
m/z 
(Da) 
Z 
(+) 
Peptide 
number  
MS/MS derived sequence Mascot Sequest 
          Ion 
score 
Exp 
value 
Probabilit
y 
Xcor
r 
     1429.5
9 
1 2 GAMQNIIPASTGAAK   1.00  
     410.01 2 11 VGINGFGR   8.90  
     715.85 2 2 GAMQNIIPASTGAAK   1.00  
     510.09 2 11 AKVGINGFGR   2.12  
     589.56 2 10 AGISLNNNFVK   16.82  
     1430.5
6 
1 2 GAMQNIIPASTGAAK   1.00  
     715.62 2 2 GAMQNIIPASTGAAK   1.00  
     812.29 1 12 VIPALNGK   1.00  
     1177.4
7 
1 10 AGISLNNNFVK   1.00  
     1176.5
1 
1 10 AGISLNNNFVK   1.00  
     811.32 1 12 VIPALNGK   1.00  
     812.29 1 12 VIPALNGK   1.00  
1,3 50 
kDa 
Schistosoma 
adult 
 Calreticulin 
precursor 
(SM4 
(Q06814) 746.18 2 2 DNPEYKGEWTPR 55 7.22E-
03 
  
177 
protein) 
     721.06 2 2 IMFGPDICGMATK   54.86 3.14 
     642.05 2 2 SPVDPIEDLGLK   10.79 2.82 
     746.18 2 2 DNPEYKGEWTPR   12.22 2.60 
     726.24 1 1 FYGIAR   1.00 1.42 
Antiveno
m 
Band  Organism  Protein Accessio
n no. 
m/z 
(Da) 
Z 
(+) 
Peptide 
number  
MS/MS derived sequence Mascot Sequest 
          Ion 
score 
Exp 
value 
Probabilit
y 
Xcor
r 
     890.20 1 1 TIPDMDAK   1.00 1.12 
2 15 
kDa 
Schistosoma 
adult 
 Peptidyl-
prolyl cis-
trans 
isomerase 
(EC 5.2.1.8) 
(PPIase) 
(Rotamase) 
(Cyclophilin) 
(Cyclosporin 
A-binding 
protein) 
(p17.7) 
(Smp17.7) 
(Q26565) 840.65 2 2 IIFELFNDVPDTTR 73 9.16E-
05 
  
     1065.2
3 
2 2 IIPGFMCQGGDFTNGDGTGGK 55 5.00E-
03 
  
     1065.2
9 
2 2 IIPGFMCQGGDFTNGDGTGGK 54 6.71E-
03 
  
     840.64
5 
2 2 IIFELFNDVPDTTR   49.40 3.83 
     555.40
5 
2 2 IIIEDCGEC   11.91 3.01 
178 
     635.06
0 
2 2 AFFDIKAGDER   7.37 2.98 
     1065.2
2 
2 2 IIPGFMCQGGDFTNGDGTGGK   63.39 2.90 
Antiveno
m 
Band  Organism  Protein Accessio
n no. 
m/z 
(Da) 
Z 
(+) 
Peptide 
number  
MS/MS derived sequence Mascot Sequest 
          Ion 
score 
Exp 
value 
Probabilit
y 
Xcor
r 
     713.17
0 
2 2 NNFGYKGSVFHR   12.95 2.62 
     840.15
5 
2 2 IIFELFNDVPDTTR   36.01 2.61 
     1065.2
9 
2 2 IIPGFMCQGGDFTNGDGTGGK   11.75 2.41 
     458.45
0 
2 2 VVSGIDVVK   1.00 2.29 
     916.36
5 
1 1 VVSGIDVVK   1.00 2.01 
     740.23
0 
1 1 AFFDIK   1.00 1.86 
     915.39
5 
1 1 VVSGIDVVK   1.00 1.83 
     1109.1
9 
1 1 IIIEDCGEC   7.15 1.78 
     1108.1
8 
1 1 IIIEDCGEC   4.91 1.76 
     740.26 1 1 AFFDIK   1.00 1.47 
179 
0 
 59 
kDa 
FAS 
 
Heat shock 
70 kDa 
homolog 
protein 
(HSP70) 
(Major 
surface 
antigen) 
 
(P08418) 
 
585.56
0 
2 1 DAGAIAGLNVLR 85 7.88837
E-06 
  
     1040.2
6 
2 2 VYQAGGMPGGMHEASGAGGG
SGK 
76 3.7231E
-05 
  
     826.09
5 
2 3 NQVAMNPTNTVFDAK 67 4.26E-
04 
  
Antiveno
m 
Band  Organism  Protein Accessio
n no. 
m/z 
(Da) 
Z 
(+) 
Peptide 
number  
MS/MS derived sequence Mascot Sequest 
          Ion 
score 
Exp 
value 
Probabilit
y 
Xcor
r 
     846.74
5 
2 4 STAGDTHLGGEDFDNR 64 7.93E-
04 
  
     676.04
0 
2 5 NSLESYVYTMK 63 1.18E-
03 
  
     642.15
0 
2 6 MKEVAESYLGR 58 3.76E-
03 
  
     936.81
0 
2 7 MDKSQIHDIVLVGGSTR 56 5.14E-
03 
  
     585.56
0 
2 1 DAGAIAGLNVLR   23.83 4.23 
     642.15
0 
2 6 MKEVAESYLGR   48.69 4.09 
180 
     676.04
0 
2 5 NSLESYVYTMK   9.04 4.06 
     846.74
5 
2 4 STAGDTHLGGEDFDNR   53.19 3.85 
     1032.2
3 
2 2 VYQAGGMPGGMHEASGAGGG
SGK 
  48.70 3.60 
     624.81
5 
3 7 MDKSQIHDIVLVGGSTR   1.00 3.40 
     615.06
0 
2 8 VEIIANDQGNR   1.00 3.32 
     911.50
0 
2 3 NQVAMNPTNTVFDAKR   33.53 2.94 
     737.08
5 
2 9 TTPSYVAFTDSER   3.67 2.82 
     692.76
0 
2 10 IPESDRQVIISK   12.87 2.74 
     563.14
5 
2 11 ICVEYKGEK   10.67 2.52 
     992.20
5 
2 12 TVSDAVITVPAYFNDSQR   6.89 2.50 
     720.65
5 
2 13 RFDDPSVQSDMK   5.04 2.09 
     860.12
0 
1 14 GPTIEEVD   1.00 1.45 
Antiveno
m 
Band  Organism  Protein Accessio
n no. 
m/z 
(Da) 
Z 
(+) 
Peptide 
number  
MS/MS derived sequence Mascot Sequest 
          Ion 
score 
Exp 
value 
Probabilit
y 
Xcor
r 
     858.23
0 
1 15 GTLDPVEK   1.00 1.43 
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Table 0.1 LC-MS/MS identification of cross-reacted parasites proteins: Proteins with immunological cross-reactivity with snake venom were excised and trypsin-digested from 
individual parasite samples. The table includes; a list of peptide sequences derived by mass spectrometry for each protein of interest, numbered to link it to the alignment in the 
following section, and the accession number of the protein, which corresponds to the closest protein match identified by BLAST search. The numbers in the first column refer to 
the antivenom the corresponding protein reacted with: 1) EchiTAb G, 2) EchiTAb-Plus-ICP, 3) SAIMR polyvalent, 4) CSL polyspecific. Ion score and E value indicate protein 
identified by Mascot algorithm, and Probability and XCorr correspond to protein identification by Sequest algorithm.  
1 25 
kDa 
Schistosoma 
adult 
 14-3-3 
protein 
homolog 1 
(Q26540) 612.55
5 
2 2 YLAEVATDDAR 95 7.40E-
07 
  
     797.22
0 
2 2 ATTAAENLPTTHPIR 65 6.72E-
04 
  
     636.77
5 
3 3 YLAEVATDDARTEVVQK 43 9.78E-
02 
  
     612.55
5 
2 2 YLAEVATDDAR   21.07 3.71 
     797.22
0 
2 2 ATTAAENLPTTHPIR   54.58 3.32 
     636.77
5 
3 3 YLAEVATDDARTEVVQK   17.62 3.06 
